---
document_datetime: 2023-09-21 19:54:59
document_pages: 123
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/xiapex-h-c-2048-ii-0044-epar-assessment-report-variation_en.pdf
document_name: xiapex-h-c-2048-ii-0044-epar-assessment-report-variation_en.pdf
version: success
processing_time: 105.6834797
conversion_datetime: 2025-12-28 15:23:27.221822
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

18 December 2014 EMA/CHMP/349968/2015 Committee for Medicinal Products for Human Use (CHMP)

Assessment report Xiapex International non-proprietary name: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Procedure No. EMEA/H/C/002048/II/0044 Note Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised

Telephone

+44 (0)20 3660 6000

Send a question via our website

Facsimile

+44 (0)20 3660 5555

www.ema.europa.eu/contact

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| International non-proprietary name: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM............1                                        |                                                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Procedure No. EMEA/H/C/002048/II/0044 .....................................................................1                 |                                                                                                                     |
| Note                                                                                                                         | ............................................................................................................1       |
| 1. Background information on the procedure                                                                                   | ..............................................5                                                                     |
| 1.1. Type II variation                                                                                                       | ..................................................................................................5                 |
| 1.2. Steps taken for the assessment of the product.........................................................6                 |                                                                                                                     |
| 2. Scientific discussion ................................................................................7                   |                                                                                                                     |
| 2.1. Introduction.........................................................................................................7  |                                                                                                                     |
| 2.2. Non-clinical aspects                                                                                                    | ..............................................................................................8                     |
| 2.2.1. Introduction......................................................................................................8   |                                                                                                                     |
| 2.2.2. Pharmacology                                                                                                          | ...................................................................................................9                |
| 2.2.3. Pharmacokinetics.............................................................................................11       |                                                                                                                     |
| 2.2.4. Toxicology                                                                                                            | ......................................................................................................12 authorised |
| 2.2.5. Ecotoxicity/environmental risk assessment                                                                             | .........................................................18                                                         |
| 2.2.6. Discussion on non-clinical aspects......................................................................18 longer     |                                                                                                                     |
| 2.2.7. Conclusion on the non-clinical aspects................................................................19              |                                                                                                                     |
| 2.3. Clinical aspects                                                                                                        | ..................................................................................................20                |
| 2.3.1. Introduction....................................................................................................20    |                                                                                                                     |
| 2.3.2. Pharmacokinetics.............................................................................................24       |                                                                                                                     |
| Exposure relevant for safety evaluation .......................................................................28 no         |                                                                                                                     |
| 2.3.3. Pharmacodynamics..........................................................................................28 product  |                                                                                                                     |
| 2.3.4. PK/PD modelling..............................................................................................29       |                                                                                                                     |
| 2.3.5. Discussion on clinical pharmacology...................................................................29              |                                                                                                                     |
| 2.3.6. Conclusions on clinical pharmacology.................................................................29               |                                                                                                                     |
| 2.4. Clinical efficacy                                                                                                       | ..................................................................................................30                |
| 2.4.1. Dose response study(ies)                                                                                              | .................................................................................30                                 |
| 2.4.2. Main studies ...................................................................................................40    |                                                                                                                     |
| 2.4.3. Discussion on clinical efficacy............................................................................82         |                                                                                                                     |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................84 Medicinal |                                                                                                                     |
| 2.5. Clinical safety                                                                                                         | ....................................................................................................85              |
| 2.5.1. Discussion on clinical safety ............................................................................            | 101                                                                                                                 |
| 2.5.2. Conclusions on clinical safety ..........................................................................             | 103                                                                                                                 |
| 2.5.3. PSUR cycle                                                                                                            | ................................................................................................... 103             |
| 2.6. Risk management plan......................................................................................              | 103                                                                                                                 |
| 2.7. Update of the Product information ......................................................................                | 106                                                                                                                 |
| 2.7.1. User consultation...........................................................................................          | 106                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| 3. Benefit-Risk Balance............................................................................106                |
|-----------------------------------------------------------------------------------------------------------------------|
| 4. Recommendations...............................................................................108                  |
| 5. EPAR changes......................................................................................110              |
| 6. Introduction ........................................................................................112           |
| 7. Justification of significant clinical benefit as presented by the MAH....112                                       |
| 7.1. Demonstration of new therapeutic indication ....................................................... 112          |
| 7.2. Details of existing therapies............................................................................... 113 |
| 7.3. Significant clinical benefit based on improved efficacy........................................... 114           |
| 7.4. Significant clinical benefit based on improved safety............................................. 115           |
| 7.5. Significant clinical benefit based on major contribution to patient care .................... 116                |
| 8. Assessment of the MAH's justification of significant clinical benefit....117                                       |
| 8.1. Demonstration of new therapeutic indication ....................................................... 117          |
| 8.2. Details of existing therapies............................................................................... 118 |
| 8.3. Significant clinical benefit based on improved efficacy........................................... 119           |
| 8.4. Significant clinical benefit based on improved safety............................................. 121           |
| 8.5. Significant clinical benefit based on major contribution to patient care .................... 122 authorised     |
| 9. Conclusion...........................................................................................122           |
| 10. Recommendation...............................................................................123                  |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                          |
|----------------|-----------------------------------------------------|
| ADAs           | antidrug antibodies                                 |
| AE             | adverse event                                       |
| A2M            | alpha-2-macroglobulin                               |
| AUX-I          | clostridial type I collagenase                      |
| AUX-II         | clostridial type II collagenase                     |
| BTC            | Biologics Technologies Corp.                        |
| ED             | erectile dysfunction                                |
| ESWT           | extracorporeal shock wave therapy                   |
| IIEF           | International Index of Erectile Function authorised |
| ISE            | integrated summary of efficacy                      |
| ISS            | integrated summary of safety                        |
| ITT            | intent-to-treat                                     |
| LOCF           | last observation carried forward longer             |
| mITT           | modified intent-to-treat                            |
| MMPs           | matrix metalloproteinases no                        |
| NS             | not significant                                     |
| PBO            | placebo                                             |
| PD             | Peyronie's disease product                          |
| PDQ            | Peyronie's Disease Questionnaire                    |
| PRO            | Patient Reported Outcome Medicinal                  |
| RCT            | randomized controlled trials                        |
| SAE            | serious adverse event                               |
| TEAE           | treatment-emergent adverse event                    |
| TIMPs          | tissue inhibitors of metalloproteinases             |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Swedish Orphan Biovitrum AB (publ) submitted to the European Medicines Agency on 12 June 2014 an application for a variation.

This application concerns the following medicinal product:

| Centrally authorised Medicinal product:   | Common name:                         |
|-------------------------------------------|--------------------------------------|
| For presentations: See Annex A            |                                      |
| Xiapex                                    | COLLAGENASE CLOSTRIDIUM HISTOLYTICUM |

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

The Marketing authorisation holder (MAH) applied for a new indication for the treatment of Peyronie's disease in adult men with a palpable plaque and curvature deformity. Consequently, the MAH proposed the update of sections 2, 3, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC.

The Package Leaflet was proposed to be updated in accordance.

Furthermore, the MAH proposed this opportunity to bring the PI in line with the latest QRD template version 9.0.

The variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet

Medicinal product no longer authorised

## Information on paediatric requirements

Pursuant to Article 13 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/139/2009 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition

<div style=\"page-break-after: always\"></div>

related to the proposed indication.

## Applicant's request(s) for consideration

## Additional data protection/marketing exclusivity

The applicant requested consideration of its application in accordance with Article 14(11) of Regulation (EC) No 726/2004 - one year of market protection for a new indication which provides a significant clinical benefit in comparison with existing therapies.

## Scientific advice

The applicant received Scientific Advice from the CHMP on 1 December 2010. The Scientific Advice pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Martina Weise

| Timetable                                                                                                                                           | Dates             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Submission date longer                                                                                                                              | 12 June 2014      |
| Start of procedure:                                                                                                                                 | 27 June 2014      |
| CHMP Rapporteur Assessment Report no                                                                                                                | 18 August 2014    |
| CHMP Co-Rapporteur Assessment Report                                                                                                                | 18 August 2014    |
| PRAC Rapporteur Assessment Report                                                                                                                   | 26 August 2014    |
| PRAC Meeting, adoption of PRAC Assessment Overview and Advice product                                                                               | 11 September 2014 |
| Rapporteur Revised Assessment Report                                                                                                                | 19 September 2014 |
| Request for supplementary information (RSI) Medicinal                                                                                               | 25 September 2014 |
| CHMP Rapporteur Assessment Report                                                                                                                   | 17 November 2014  |
| PRAC Rapporteur Assessment Report                                                                                                                   | 17 November 2014  |
| PRAC Rapporteur Updated Assessment Report                                                                                                           | 25 November 2014  |
| Rapporteur Revised Assessment Report                                                                                                                | 12 December 2014  |
| PRAC Meeting, adoption of PRAC Assessment Overview and Advice                                                                                       | 4 December 2014   |
| CHMP adoption of report on the novelty of the indication/significant clinical benefit for Xiapex in comparison with existing therapies (Appendix 1) | 18 December 2014  |
| CHMP Opinion                                                                                                                                        | 18 December 2014  |

Co-Rapporteur: Pierre Demolis Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Xiapex  (collagenase  clostridium  histolyticum  also  referred  to  as  AA4500)  is  a  parenteral  lyophilized product comprised of two collagenases AUX-I and AUX-II. These collagenases bind and selectively digest fibrillar collagen or collagen-derived peptides by hydrolyzing the triple helical region of collagen under physiological  conditions.  Xiapex  was  granted  marketing  authorisation  in  the  European  Union  for  the treatment of Dupuytren's contracture on 28 February 2011. The purpose of this application is to extend the indication of Xiapex for the treatment of Peyronie's disease (PD) in adult men.

Peyronie's disease (PD, also known as Induratio penis plastica, IPP) is an idiopathic, connective tissue disorder of the penis and is characterized by the pathological deposition of collagen (types I and III) in the tunica albuginea of the corpus cavernosum. This collagenous plaque replaces the normal elastic fibers of the tunica albuginea and causes penile curvature, which is most evident during erection. The curvature deformity can cause pain during erection and often leads to significant patient bother, distress, and sexual dysfunction.  The  etiology  of  PD  is  not  well  understood;  however,  recent  research  has  identified microvascular trauma, abnormal wound healing, and genetic predispositions as potential contributors to development of the condition.

PD is a progressive disorder with up to 48% of men having disease progression if left untreated. In most cases, PD may be divided into an acute inflammatory phase and a chronic phase. The early, acute phase lasts  for  approximately  6  -  12  months  after  disease  onset  and  is  typically  characterized  by  painful erections and progression in plaque size and deformity. In the chronic phase (12-18 months after onset), erections are no longer painful and the deformity has stabilized. Most men present during the acute phase, but approximately 33% of men do not seek medical care until the stable phase of the disease. In most men with PD, symptoms gradually worsen during the first year after disease onset; however, one retrospective review of medical records in 307 men with PD reported that a small percentage of patients experienced complete resolution of PD symptoms after 8 months of follow-up. With regard to long-term prognosis,  the  medical  literature  offers  few  additional  insights.  However,  because  the  morbidity associated with PD often relates to chronic impairments in sexual functioning and psychological status, further long-term studies are warranted to obtain a better understanding of prognostic factors that may contribute to the deterioration, improvement, or resolution of PD symptoms. The incidence and prevalence of PD has not been studied extensively. In Europe, the latest prevalence estimates  were  published  in  2001  and  2002.  In  three  cross-sectional,  population-based  studies,  PD prevalence estimates were in 3% of men aged 30-80 years in Germany (Schwarzer et al., 2001, Sommer et al., 2002) and in 7% of men aged 50-69 years in Italy (La Pera et al., 2001). Disease onset commonly occurs  in  older  men  (mean  age,  53  years;  range,  19-83  years)  (Hellstrom,  2009)  and  has  been associated with a history of penile trauma (Brant et al., 2007, Casabe et al., 2011, Zargooshi, 2004) and genetic  predisposition  (Qian  et  al.,  2004,  Dolmans  et  al.,  2012).  Associated  comorbidities  include diabetes, vascular disease, erectile dysfunction (ED), depression, and Dupuytren's contracture (Ralph et al., 2010). Medicinal product no longer authorised

As a result of the lack of a clear understanding of the etiopathophysiology, a cure has not been found. Several factors should be considered for the therapeutic management of patients with PD, including the duration of disease, presence or absence of pain with erection, the severity of penile deformity, and the adequacy of erectile function (Hellstrom, 2009). A variety of treatment options have been used.

Conservative  treatment  options  are  multiple  and  diverse  and  include  oral  (colchicine,  tamoxifen, pentoxyphylline, vitamin E, potassium para-aminobenzoate) and topical (verapamil) agents, intralesional  injections  (corticosteroids,  iloprost,  interferon,  verapamil),  extracorporeal  shock  wave therapy (ESWT), iontophoresis, and others.

The value of many published reports has been questioned as most were not well controlled, often had a small number of subjects in various phases of stability and with limited reports on objective measures of deformity change. Studies focus on reduction of pain that appears to resolve with time untreated, and reduction of plaque size, which has never been found to correlate with curvature improvement.

<div style=\"page-break-after: always\"></div>

Following a consensus statement of leading experts (Ralph et al. 2010, The Management of Peyronie's disease: Evidence-based 2010 Guidelines) reduction of erect penile deformity (i.e. curve, narrowing, shortening) is the most critical outcome measure.

Surgical interventions are indicated when PD has reached the chronic phase and penile morphology, including plaque size and curvature, has been stable for ≥3 months. The goals of surgery are to correct penile deformity and improve erectile and sexual function. Therefore, surgery is typically only appropriate for patients who cannot achieve intercourse owing to the severity of their deformity and/or those with refractory ED that fails to respond to medical treatment. In addition, patients who have extensive plaque calcification are typically best treated with surgery, as nonsurgical approaches have not been shown to be beneficial in this circumstance. Surgery is typically not indicated for patients whose penile deformity does not prevent intercourse, because of the risk of postoperative ED (Ralph et al., 2010).

In the expert statement (Ralph et al. 2010) it is summarised that surgery remains the gold standard for correcting  erect  penile  deformity  in  the  man  with  stable  disease.  However,  potential  postoperative complications include excessive penile shortening, reduced penile sensitivity, palpable nodules, and ED.

Since AA4500 is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, AA4500 may have the potential to be effective in lysing collagen deposits such as those in the plaque that cause the curvature deformity and subsequent bother and distress in patients with Peyronie's disease.

Plaque disruption enables correction of the offending curvature deformity and may preclude the resultant morbidity and extensive recovery time associated with invasive surgical procedures. The  proposed  dose  of  AA4500  is  0.58  mg  to  be  administered  as  an  intralesional  injection  into  the Peyronie's plaque that causes curvature deformity. A treatment cycle consists of two AA4500 injection procedures and a penile modeling procedure. Each injection is administered 1 to 3 days apart. The penile modeling procedure is performed 1 to 3 days after the second injection of each treatment cycle. The treatment cycle may be repeated at approximately 6-week intervals. Up to four treatment cycles (for a total of eight injection procedures and four modeling procedures) may be administered to the plaque that causes the curvature deformity. One treatment course is defined to consist of a maximum of four treatment cycles. In the two pivotal phase III studies covering a 1-year double-blind treatment duration patients were given the option to receive up to four treatment cycles. The safety of more than one treatment course of Xiapex for PD is not known. 2.2. Non-clinical aspects Medicinal product no longer authorised

## 2.2.1. Introduction

In below non-clinical assessment emphasis is given to newly submitted data in support of the new indication. Relevant data previously submitted for the indication Dupuytren contracture is mentioned for completeness.

Throughout this section, AA4500 doses are expressed in units of enzyme activity to allow comparison between studies and the peer-reviewed literature. The activity of AA4500 (BTC Process 1 and AA4500 Process 3) = 17,241 U/mg protein, ie, 10,000 units for a clinical dose of 0.58 mg protein. This provides a more accurate basis for the comparison of results across studies, as doses are thus compared on a pharmacologically similar basis.

For ease of comparison across studies and species, standard body weights and body surface area formulae were used to convert the mg of AA4500 administered/animal to the equivalent dose in U/kg and U/m 2 ).  A standard human body weight of 70 kg (with a body surface area of 1.797 m 2 ) has been

<div style=\"page-break-after: always\"></div>

employed to derive the Human Equivalent Dose (HED) on a body weight and surface area basis (143 U/kg and 5565 U/m 2  respectively).

## 2.2.2. Pharmacology

## Primary pharmacodynamic studies

Two additional primary pharmacodynamics studies were conducted to support the use of AA4500 for treatment of Peyronie's disease: an in vitro study of the effect of AA4500 injected into Peyronie's plaque tissue explants (Study RU-001) and an in vivo study of the collagenolytic effect of AA4500 injected subcutaneously in Göttingen minipigs (Study WIL-696007).

An overview of the pharmacodynamics studies is presented in the Table below.

Table: Tissue Explant Culture Studies and in vivo Collagenolytic Study Performed with Commercial Manufactured AA4500 (or early BTC process material, Purified Research-Grade Collagenase)

| Study Type                                                       | Collagenase and Dose/Concentration Used                                     | Route of Administration                                                  | Study Endpoints                                                                                                                                                       | Reference                |
|------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Collagenolysis on type I collagen                                | AUX-I, AUX-II, and AA4500                                                   | In vitro incubation                                                      | SDS-PAGE analyses of collagen digestion pattern                                                                                                                       | H-ADTR-2008-01. 00       |
| Peyronie's plaque Dupuytren's cord                               | AA4500                                                                      | Intralesional injection no longer                                        | Hydroxyproline release (collagen lysis rate) Light microscopy (histomorphology, collagen lysis) Immunostaining (type I, II, IV collagen)                              | RU-001                   |
| Peyronie's plaque Tunica albuginea Corpus cavernosum Pericardium | Purified research-grade collagenase (Worthington, CLSPA) 10-400 U Medicinal | Incubation (collagen digestion rate) Injection (histomorphology) product | Amino acid release by ninhydrin reaction (collagen digestion rate) and tissue weight Light microscopy (histomorphology)                                               | Gelbard et al, 1982      |
| Dupuytren's cord                                                 | AA4500 (early BTC process) 150-3600 U                                       | Injection                                                                | Mechanical loading (tensile modulus and breaking force determination) Light microscopy (histomorphology) Picrosirius red staining (collagen subtype characterization) | Starkweather et al, 1996 |
| In vivo Göttingen minipig                                        | AA4500 5-259 U/injection                                                    | Subcutaneous injection                                                   | Light Microscopy (histopathology, trichrome and picrosirius red stain)                                                                                                | WIL-696007               |

<div style=\"page-break-after: always\"></div>

The results from these studies can be summarized as follows:

- AUX-I and AUX-II directly lysed type I collagen in vitro and, when mixed at an approximate 1:1 ratio as in AA4500, demonstrated a synergistic effect, ie, the lysis of collagen generated by AA4500 was greater (more fragments and at a faster rate) than the summation of the fragmentation pattern generated by the individual AA4500 intermediate components.
- The rate of collagen digestion was greatest at early timepoints (first four hours of incubation of Peyronie's plaques or tunica albuginea), with no differences in digestion rate noted between different tissues.  Digestion was essentially complete in 12 to 24 hours following injection or incubation of tissues (evidenced by loss of up to 99% of tissue dry weight and/or loss of trichrome staining).
- Lysis following injection into tissues was focal, well circumscribed and primarily confined to tissue directly adjacent to the injection site (more focal in Dupuytren's cord than Peyronie's plaque).
- Immunostaining of AA4500 treated explant tissues demonstrated that AA4500 selectively lyses type I and III, while sparing type IV collagen.
- No damage to non-collagenous tissue elements (elastic fibers, arteries, arterioles, nerve fibers, and fibroblasts) are detected following exposure to AA4500 (early BTC process) or purified research-grade collagenase, with the exception that disruption of small venules and the perineurium do occur in injected tissues. This is consistent and supports the selectivity demonstrated by immunostaining.
- Collagen digestion resulting from injection of the early BTC process material into fibroproliferative collagen (Dupuytren's cords) increases the elasticity of the remaining tissue (93% decrease in the mean tensile modulus 24 hours following injection with 3600 U) and decreases the amount of force needed to rupture the tissue to physiologically achievable levels (~ 2.7 to 4.1 megapascals, estimated normal extensor forces in the human finger, in cords treated with ≥300 U).

## Secondary Pharmacodynamics

Local secondary pharmacodynamic effects have been described, including inflammatory responses and regenerative changes reflecting enhanced wound healing, probably resulting from the release of small, pharmacologically active collagen fragments. The relevance of these effects has been discussed during the original MAA for XIAPEX. No additional studies on secondary pharmacodynamics were conducted to support the use of AA4500 in treatment of Peyronie's disease. This is considered acceptable.

## Safety Pharmacology

Medicinal product no longer authorised

No studies were conducted to support of the use of AA4500 in treatment of Peyronie's disease. Given that systemic exposure was limited or not quantifiable following local administration by a clinically relevant route of exposure in nonclinical species this is acceptable.

## Pharmacodynamic Drug Interactions

Literature on drug interactions indicates that some antibiotics may have limited inhibitory activity of clostridial collagenase in vitro. Given the therapeutic use of these antibiotics, clinical concomitant treatment with AA4500 is unlikely to occur. Studies have not been conducted with AA4500. This is considered acceptable.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Pharmacokinetics

## Methods of Analysis

No additional studies were conducted to support of the use of AA4500 in treatment of Peyronie's disease.

## Absorption

Systemic exposure was evaluated following single and repeated intrapenile administration in dogs to support the use of AA4500 in the treatment of Peyronie's disease (Study TRL 520, this study had already been submitted as supportive information during the original MAA).

In Study TRL 520, dogs received injections ranging from approximately 140 to 1430 U/animal into the tunica albuginea three times weekly every four weeks for a total of three cycles (nine doses).  Plasma level profiles were evaluated on the first day of dosing of the first treatment cycle (Day 1) and following the last dose in the third cycle (Day 61).  To evaluate effects on sites of inadvertent administration, additional groups of dogs received single doses of approximately 1430 or 2570 U/animal of AA4500 injected into the tunica albuginea, corpus cavernosum, urethra, or subcutaneous tissue adjacent to the main vein, artery, and nerve of the penis (referred to as the VAN complex).

In the repeat-dose phase of the study almost all plasma samples were below the limit of quantification for both AUX-I (12.5 ng/mL) and AUX-II (37.5 ng/mL) following the first dose on Day 1.  No animals had quantifiable plasma levels on Day 61.  In the single dose phase of the study, sporadic low levels of AUX-I and AUX-II were only quantifiable five minutes postdose from four animals injected into highly vascular sites (the corpus cavernosum or urethra).  Overall, the results of the plasma analysis of AUX-I and AUX-II indicate that there were no consistently quantifiable systemic levels of the AA4500 in plasma.  No toxicokinetic analysis could be performed on these data due to lack of sufficient AA4500 levels over time in the plasma in any of the treatment groups. Distribution New data were not provided. No distribution studies have been performed with AA4500 for original marketing authorisation. Metabolism New data were not provided. No metabolism studies have been performed with AA4500 for original marketing authorisation. Medicinal product no longer authorised

## Excretion

New data were not provided. No studies on excretion of AA4500 have been performed with AA4500 for original marketing authorisation.

## Pharmacokinetic Drug Interactions

New data were not provided. No pharmacokinetic drug interaction studies have been performed with AA4500 for original marketing authorisation.

## Other Pharmacokinetic Studies

Antibody Responses

<div style=\"page-break-after: always\"></div>

As an exogenous protein administered by local injection, antibody responses to AA4500 are anticipated to occur in the majority of treated animals or human subjects. Because these antibodies have the potential to alter the pharmacokinetic profiles of AA4500 components (AUX-I and AUX-II), the formation of antibodies were usually evaluated in the repeat dose studies in which toxicokinetic assessment was also performed.

Following repeated intrapenile injection in dogs (TRL 520), both anti-AUX-I and anti-AUX-II antibody titers were apparent and detected in all animals at all dose levels following the last dose and at the end of the recovery period.

## 2.2.4. Toxicology

To support the use of AA4500 in Peyronie's disease, three new non-GLP toxicology study reports are submitted with this variation application.

## Table: Additional Nonclinical Toxicology Studies, submitted with this MA Variation

| Study Type and Duration/ GLP Status   | Route of Administratio n   | Species/ Cell Line         | Study Number               | Lot Numbe r                | Collagenas e (Process)     | Source                     |
|---------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Non pivotal                           | Non pivotal                | Non pivotal                | Non pivotal                | Non pivotal                | Non pivotal                | Non pivotal                |
| Single Dose / Acute longer            | Single Dose / Acute longer | Single Dose / Acute longer | Single Dose / Acute longer | Single Dose / Acute longer | Single Dose / Acute longer | Single Dose / Acute longer |
| non-GLP                               | Intrapenile                | Dog                        | TRL 507                    | 7280                       | AA4500 (Process 3)         | Horsha m                   |
| non-GLP                               | Intrapenile                | Dog                        | TRL 510                    | 7280                       | AA4500 (Process 3)         | Horsha m                   |
| non-GLP                               | SC Injection               | Minipig/ Göttingen         | WIL-696007 no              | 7280                       | AA4500 (Process 3)         | Horsha m                   |

In addition to these new toxicological study reports, a supplemental toxicokinetic analysis report (PKPD-005-2012-01) is provided.

As already submitted in the original MAA for Dupuytren's contracture, a study evaluating the toxicity following intrapenile injection into the dog penis is provided.

Table: Nonclinical Study already submitted with the XIAFLEX MAA for Dupuytren's Contracture

| Study Type and Duration/ GLP Status                                  | Route of Administratio n                                             | Species/ Cell Line                                                   | Study Number                                                         | Lot Number                                                           | Collagenase (Process)                                                | Source                                                               |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Pivotal Studies                                                      | Pivotal Studies                                                      | Pivotal Studies                                                      | Pivotal Studies                                                      | Pivotal Studies                                                      | Pivotal Studies                                                      | Pivotal Studies                                                      |
| Repeat-Dose Toxicity                                                 | Repeat-Dose Toxicity                                                 | Repeat-Dose Toxicity                                                 | Repeat-Dose Toxicity                                                 | Repeat-Dose Toxicity                                                 | Repeat-Dose Toxicity                                                 | Repeat-Dose Toxicity                                                 |
| Single/Rep eat Dose GLP                                              | Intrapenile Injection                                                | Dog                                                                  | TRL 520                                                              | NFF-0035                                                             | AA4500 (Process 3)                                                   | Cobra                                                                |
| GLP = Good Laboratory Practice; Cobra = Cobra Biomanufacturing, Plc; | GLP = Good Laboratory Practice; Cobra = Cobra Biomanufacturing, Plc; | GLP = Good Laboratory Practice; Cobra = Cobra Biomanufacturing, Plc; | GLP = Good Laboratory Practice; Cobra = Cobra Biomanufacturing, Plc; | GLP = Good Laboratory Practice; Cobra = Cobra Biomanufacturing, Plc; | GLP = Good Laboratory Practice; Cobra = Cobra Biomanufacturing, Plc; | GLP = Good Laboratory Practice; Cobra = Cobra Biomanufacturing, Plc; |

Medicinal product no longer authorised

These studies (two of which were conducted with the drug product manufactured according to the final commercial process, AA4500-Process 3 Horsham) are designed to characterize the local and systemic toxicity after single and repeated administration as a surrogate for extravasation from the Peyronie's plaque or misapplication into surrounding penile structures adjacent to the clinically intended site of administration.

<div style=\"page-break-after: always\"></div>

## Single dose toxicity

Single-dose and acute (5 day) intrapenile administration toxicity studies (TRL 507 and TRL 510) in dogs were conducted in support of the use of AA4500 for treatment of Peyronie's disease. Relevant findings are summarized in the table below.

Table: Non-GLP  Single/Repeat-Dose studies with intrapenile application in dogs

<!-- image -->

In non-GLP study TRL 507 AA4500 was injected into four specific locations of the dog's penis [tunica albuginea (TA), corpus cavernosum (CC), vein-artery-nerve complex (VAN), and urethra (UR)].  The study was conducted in three phases. Phase 1 of Study TRL 507 consisted of methods development and evaluated the effects of injection of AA4500 in three of the targeted sites, the tunica albuginea (TA), corpus cavernosum (CC), and vein-artery-nerve complex (VAN). A volume of 0.10 mL/site was determined to be the maximum volume that could be consistently confined within the injection site of interest. Groups of three dogs received total doses of 0 (0.125 mL/site), 1621 (0.040 mL/site), 3276 (0.08 mL/site), and 5000 (0.125 mL/site) U/injection site (corresponding to approximate doses of 0, 4863, 9828 and 15,000 U/animal, approximate doses of 0, 607.9, 1228.5 and 1875 U/kg based on the mean dog weight of ~8 kg, or approximate doses of 0, 12,158, 24,570 and 37,500 U/m2) were selected for initial evaluation. Medicinal product no longer authorised Dogs/ Beagle ND=not determined

| no longer   | authorised   |
|-------------|--------------|

The subsequent dose escalation study (Phase 2 of Study TRL 507) was conducted in three of the sites [tunica albuginea (TA), corpus cavernosum (CC), and VAN complex (VAN)] in order to determine the optimum dose for a subsequent GLP study (TRL 520). Three dogs were assigned to each of the sites (one dog/site) and received single escalating doses of AA4500. The initial dose chosen was ~138 U/animal (13.8 U/kg, or 276 U/m2) and the dose was elevated after a period of at least 48 hours if the dose was tolerated (ie, the degree of local reaction (swelling and/or bruising) was not severe enough to preclude accurate placement of the next dose).

A separate dose escalation study (phase 3 of Study TRL 507) was performed to determine the optimum dose for the subsequent GLP study for injections into the urethra.  The dose escalation study was carried out in the same fashion as for the previous three sites. The dose level of ~431 U/dose was considered the highest dose that would permit accurately placed repeated injections every 48 hours.

<div style=\"page-break-after: always\"></div>

A dose-range finding non-GLP study (TRL 510), was conducted in order to determine the maximal tolerated dose for repeated administration at approximately every 48 hours over a period of a week for a subsequent subchronic GLP study (TRL 520). In study TRL 510, AA4500 was administered to 25 male Beagle dogs either as single dose or approximately every 48 hours over a period of a week into or adjacent to one of four anatomic sites [tunica albuginea (TA), corpus cavernosum (CC), vein-artery-nerve complex (VAN), or urethra (UR)] in the penis and to evaluate the local changes resulting from these injections and their reversibility following a 14-day recovery period. For the repeat dose portion, twenty-four dogs were assigned to one of eight groups (3/group/dose level/injection site) and were scheduled to receive AA4500 administered by local injection into their assigned sites at either ~138 or ~431 U/dose q48 h X 3 doses.

Study TRL 520 consisted of a single-dose phase and a repeat-dose phase. The single dose phase was conducted in order to evaluate potential effects of misapplication of AA4500 on penile structures surrounding the target injection site in Peyronie's disease. The repeat-dose phase was intended to evaluate the potential effects following repeat administration into the target injection site in Peyronie's disease. In the single dose phase of Study TRL 520 dogs (3 or 5/group) received single doses of 0, ~1430 or ~2570 U/dose of AA4500 (0, 143 or 257 U/kg; and 0, 3473, or 6235 U/m2; respectively) via injection into the tunica albuginea, corpus cavernosum, urethra, or VAN complex.

Table: GLP Single/Repeat-Dose study TRL 520 with intrapenile application in dogs

<!-- image -->

Single-dose local toxicity studies by intrapenile injection or (as submitted during the original MAA) subcutaneous injection into the hindlimb of rats or subcutaneous and intratendon injection into the forelimb of dogs, demonstrated that AA4500-induced adverse effects are localized to the site of injection and the draining lymph node and are qualitatively similar across both species and sex.

Medicinal product no longer authorised

## Repeat dose toxicity

The repeated dose toxicity of AA4500 has been investigated by a clinically relevant route (intrapenile in dog). Dose levels selected for this study were based on the results of single or acute toxicity studies with local administration (see studies TRL 507 and 510).

In the repeat-dose phase of Study TRL 520, dogs received injections of 0, 140, 430, or 1430 U/animal (0, 14, 43, or 143 U/kg; and 0, 336, 1032, or 3432 U/m 2 ) into the tunica albuginea 3x weekly every four weeks for a total of three cycles (nine doses).  The high dose was lowered to approximately 1050 U/animal (105 U/kg; 2520 U/m 2 ) for the second and third cycles due to excessive local reactions.

<div style=\"page-break-after: always\"></div>

Anti-AA4500 antibodies were detected in all repeat-dose dogs following the last dose on Day 61 and persisted or increased in most dogs 28 days after the last dose.  However, no adverse systemic effects were reported and the clinical signs related to AA4500 administration occurred with approximately equal frequency and severity during all dosing weeks in the study.

After single- or repeat-dose intrapenile injections into dogs, clinical signs and gross necropsy observations related to AA4500 treatment were confined to the injection site and consisted of discoloration/bruising of the penis and/or adjacent skin and swelling of the penis.  Both findings were seen at all dose levels, with the incidence and persistence of the findings in general reflecting the dose level (although dose responses were not robust or consistently noted across the different injection sites). Corresponding histologic findings consisted of hemorrhage and inflammation (affecting both the adventitial tissue of the penis and the surrounding subcutaneous tissue of the prepuce or inguinal skin), and neovascular proliferation in the penile adventitial tissue. With the exception of subcutaneous hemorrhage and inflammation in the inguinal/preputial skin, all findings were present in the 0 U/dose animals but in general were more severe or extensive in animals receiving AA4500, however, with no clear dose response. Non-collagenous structures (in particular, arteries, nerves and large veins) were unaffected by AA4500 administration although lysis (necrosis) was seen in smaller veins comprised mostly of collagen and minimal smooth muscle. Collagen lysis of the tunica albuginea was detected in some animals after single administration but was not detected in any animals following repeated administration of AA4500. Partial to complete reversal was noted following a 30-day recovery period.

Genotoxicity No additional studies on genotoxicity were conducted to support the use of AA4500 in treatment of Peyronie's disease. This is considered acceptable. AA4500 was neither mutagenic nor clastogenic in the available studies conducted in vivo or in vitro. Furthermore, according to ICH S6, genotoxicity studies for proteins are usually not necessary. Carcinogenicity In accordance with relevant regulatory guidance (ICH S1A and ICH S6), carcinogenicity studies with AA4500 were not conducted. This is accetaple, based on the intermittent and limited clinical dosing regimen, the very limited systemic exposure in animal studies, and minimal and brief or nonquantifiable exposure in humans, and the negative results in genetic toxicity tests in vitro and in vivo.  In view of these factors there is little potential for carcinogenicity and no special advice on carcinogenic risk is included in the SmPC. Medicinal product no longer authorised

## Reproduction toxicity

No additional reproductive and developmental toxicity studies were conducted in support of the use of AA4500 for the treatment of Peyronie's disease this is considered acceptable.

## Toxicokinetic data

As Peyronie's disease is extremely rare in patients less than 18 years of age, use of AA4500 in neonates, infants, and children is extremely unlikely.  Therefore, studies in juvenile animals are of no clinical relevance and hence have not been conducted with AA4500.

<div style=\"page-break-after: always\"></div>

## Local tolerance

An additional non-GLP local tolerance study in Göttingen minipigs was performed:

<!-- image -->

| Species/Stra in     | Methodof Administration   | Doses(mg/kg)                                                                                                                | Gender and No.Per Group   | NoteivorthyFindings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | StudyNunber   |
|---------------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Minipigs/ Gottingen | Subcutaneous injection    | 844 U/animal, dividedinto12 different injections at concentrations rangingfiom26 to2586U/mL dosevolumesof 0.05.0.1or0.2 mL) | M&F 3/group               | Nodeaths,unscheduled euthanasia orevidenceofsystemic toxicity Swellingnoted atinjectionsitestreatedwithconcentrations ≥259U/mL Darkred discolorationofthesubcutaneoustissuenoted at necropsyatall doselevels Histologyfindings:collagen lysis,hemomhageand/or acute inflammation at all doselevels,skeletalmusclenecrosis (panniculuscalnosis)at252U/mL;sporadicperivascularand intramuraledema,neovascularization/fibrosis,vascularnecrosis and/orthrombosisat≥155U/mL;sporadicarterialintrammual hemorrhageat≥517U/mL Collagen lysiswas dose dependent at<259U/mL,butwas generallyproportional to thedosevolume injected asopposed to | WIL-696007    |

## Other toxicity studies

## Key Toxicologic Responses in Relation to Human Equivalent Dose (HED)/human clinical exposure

The cited animal studies had already been submitted with the original MAA for AA4500, however, as a new aspect, the current calculation of safety margins is based on the clinical dose of AA4500 used for treatment of peyronie´s disease and/or the clinical exposure to AA4500 determined in peyronie´s disease patients.

As systemic exposure was minimal and brief in clinical trials with AA4500, margins are usually expressed in relation to the HED on a body weight and body surface area basis.

## Safety margins in case of potential misapplication

## Safety margins based on HED

Systemic toxicity is not anticipated under conditions of clinical use, but for the unlikely event that a complete 0.58 mg dose of AA4500 is misapplied during treatment of Peyronie's disease, systemic toxicity has been evaluated and characterized following IV bolus administration in rats.

Following single or repeated IV dosing in rats, at approximately 50x and 25x the HED on a surface area basis (280x or 140x on a body weight basis), death was observed associated with evidence of hemorrhage into the peritoneal cavity and friable livers (in some cases).  The liver was the primary target organ following repeated bolus IV administration.  The NOEL for systemic toxicity by the IV route was 500 U/animal and provides an adequate margin of safety to account for inadvertent injection of the whole clinical dose into the systemic circulation (2.5x and 14x the HED surface area and body weight basis).  The injection site findings noted after IV dosing were consistent with the rat and dog paw studies and demonstrated recovery following the cessation of treatment.

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table: Estimated Safety Margins for Inadvertent IV Exposure in Humans Based on Rat Data and Based on Human Equivalent Dose

| Effect           | Rat Dose Level/Exposure a   | Rat Dose Level/Exposure a   | Rat Dose Level/Exposure a   | X HED/ Predicted Human Exposure based on b   | X HED/ Predicted Human Exposure based on b   |
|------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------------------------|----------------------------------------------|
|                  | U/dose                      | U/kg                        | U/m 2                       | U/kg                                         | U/m 2                                        |
| Min. Lethal dose | 10,000                      | 40,000                      | 280,000                     | 280X                                         | 50X                                          |
| Systemic NOEL    | 500                         | 2000                        | 14,000                      | 14.0X                                        | 2.5X                                         |
| Systemic LOEL b  | 2240                        | 8960                        | 62,222                      | 62.7X                                        | 11.2X                                        |

HED=human equivalent dose; NOEL=no observed effect level; LOEL= lowest observed effect level

a  U/kg and U/m 2  estimated based on 0.25 kg body weight.

b  HED = human equivalent dose, based on a total human dose of 10,000 U correlating to 143 U/kg and 5565 U/m 2  respectively based on a body weight of 70 kg and surface area of 1.797 m 2 .

## Safety margins based on human clinical exposure

The safety margins based on human exposure after penile plaque injection of 0.58 mg AA4500 compared to rat exposure were large (13X - 564X).

Table: AUX-I - Mean PK Parameters and Safety Margins

| AA4500 Dose (mg)                | Cmax (ng/mL)                    | AUCtlast (ng∙h/mL)              | X Human Cmax a                  | X Human AUCtlast a              |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Human (penile plaque) Medicinal | Human (penile plaque) Medicinal | Human (penile plaque) Medicinal | Human (penile plaque) Medicinal | Human (penile plaque) Medicinal |
| 0.58 - Day1                     | 12.6                            | 3.1 b,c                         |                                 |                                 |
| 0.58 - Day2                     | 12.2                            | 2.4 b,c                         |                                 |                                 |
| Rat (IV) - Day 1                | Rat (IV) - Day 1                | Rat (IV) - Day 1                | Rat (IV) - Day 1                | Rat (IV) - Day 1                |
| 0.029                           | 164                             | 42.3                            | 13X                             | 14X                             |
| 0.13                            | 1454                            | 373                             | 115X                            | 120X                            |
| 0.29                            | 8250                            | 2081                            | 654X                            | 671X                            |

Medicinal product no longer authorised

a  Safety margins (X Human Cmax or X Human AUCtlast ) were based on Day 1 values.

b Subject 1100-8716 was excluded due to insufficient quantities of samples for bioanalysis

c  Subjects 1100-8704 and 1100-8722 were excluded for bioanalytical reasons (ELISA interference).

<div style=\"page-break-after: always\"></div>

Table: AUX-II - Mean PK parameters and Safety Margins

| AA4500 Dose (mg)      | Cmax (ng/mL)          | AUCtlast (ng∙h/mL)    | X Human Cmax a        | X Human AUCtlast a    |
|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Human (penile plaque) | Human (penile plaque) | Human (penile plaque) | Human (penile plaque) | Human (penile plaque) |
| 0.58 - Day1           | 15.1                  | 2.2 b                 |                       |                       |
| 0.58 - Day2           | 16.1                  | 2.3 b                 |                       |                       |
| Rat (IV) - Day 1      | Rat (IV) - Day 1      | Rat (IV) - Day 1      | Rat (IV) - Day 1      | Rat (IV) - Day 1      |
| 0.029                 | 613                   | 169                   | 40X                   | 77X                   |
| 0.13                  | 4532                  | 1241                  | 300X                  | 564X                  |
| 0.29                  | 11665                 | 4166                  | 772X                  | 1894X                 |

a  Safety margins (X Human Cmax or X Human AUCtlast ) were based on Day 1 values. b Subject 1100-8716 was excluded due to insufficient quantities of samples for bioanalysis c  Subjects 1100-8704 and 1100-8722 were excluded for bioanalytical reasons (ELISA interference). Safety margins in case of local application The key treatment related findings with AA4500 were consistent with the primary and secondary pharmacology and were localized at the site of injection and qualitatively similar across animal species and sexes. Systemic toxicity was not observed following local administration by any route. 2.2.5. Ecotoxicity/environmental risk assessment In accordance with the CHMP guidance EMEA/CHMP/SWP/4447/00 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' proteins are exempted from the requirement of an environmental risk assessment (ERA) because they are unlikely to result in significant risk to the environment. As the active ingredient collagenase clostridium histolyticum is composed of two proteins, an environmental risk assessment is not required. Medicinal product no longer authorised

## 2.2.6. Discussion on non-clinical aspects

The nonclinical pharmacology, pharmacokinetics and toxicology of Xiapex had been characterized during the original MAA. The present discussion focuses on the additionally submitted nonclinical data in support of the current extension application.

Pharmacology : Clostridium collagenases have been well characterized and extensively studied since they were first isolated and purified. Microscopic assessment of tissues exposed to AA4500 confirms that when clostridial collagenase is injected into collagenous tissues the only structures that are affected are those containing fibrillar collagen; elastic fibers, blood vessels with smooth muscle-containing walls, the urethral mucosa and nerve fibers are unaffected. Evaluation of immunostained tissues that have been treated with commercial manufactured AA4500 shows that AA4500 selectively lyses collagen types I and III in pathological collagen tissues and spares non-fibrillar collagen type IV.  Additionally, collagen lysis in these structures is limited to a circumscribed area adjacent to the injection site, with little or no evidence of diffusion to distant structures.  In contrast, injection in looser fibrous connective tissue structures (subcutis or dermis in multiple species, canine VAN complex, corpus cavernosum or corpus spongiosum,

<div style=\"page-break-after: always\"></div>

Peyronie's plaque) results in somewhat greater diffusion of clostridial collagenase and more widespread collagen lysis but the affected area is still localized to the injection site.

Collectively, the available primary pharmacology data support the view that AA4500 administration into localized deposits of pathological (fibrillar) collagen, like that present in Peyronie's disease, will result in therapeutically meaningful lysis and removal of the collagen.

Pharmacokinetics : Absorption: No systemic toxicity and limited to no quantifiable systemic exposure was observed following repeated local administration of AA4500 by clinically relevant routes of exposure into rats and dogs as documented in the original MAA. Further support for the lack of systemic toxicity and limited systemic exposure following local application was provided by the results of the single/repeat dose intrapenile toxicity study in dogs.

Toxicology : Local adverse effects : Adverse effects observed in nonclinical studies after administration by the clinically relevant route of injection in the penis or (original MAA) after administration to other structures (e.g. paw/tendons/subcutaneous) were local in nature, and were reversible or showed evidence of ongoing resolution and healing during the recovery period. No evidence of systemic toxicity was reported. This is consistent with the spectrum of adverse effects observed in clinical studies.

Findings in the repeat-dose studies in rats and dogs were consistent with those reported in the single dose studies.  In general, the clinical observations were less severe and resolved more rapidly following repeated administration in dogs.  Ongoing healing processes were reported at the end of the 28-day recovery period in both species.  Similar findings were reported following intrapenile injection into dogs. Treatment related findings following direct injection into superficial digital flexor tendon of the paw or other dense collagenous structures (tunica albuginea) resulted in less severe/extensive findings and more complete recovery than subcutaneous injection into the rat and dog paw or application into the looser fibrous connective tissue structures (corpus cavernosum, urethra, and VAN complex) of the dog penis. Safety margins in case of local application : No systemic toxicity and limited to no quantifiable systemic exposure was observed following repeated local administration of AA4500 by clinically relevant routes of exposure into rats and dogs (original MAA). Further support for the lack of systemic toxicity and limited systemic exposure was provided by the results of the single/repeat dose intrapenile toxicity study. Safety margins in case of potential misapplication: Clinically, the worst scenario following misapplication of AA4500 into the local vasculature would be injection of the full clinical dose of AA4500 into the local vein or artery or both surrounding the collagen cord.  The misapplication would be expected to trigger similar systemic effects as induced by an IV injection. As documented in the orginal MAA, in repeat-dose IV studies in rats, following misapplication of partial or full clinical dose into the local vasculature, no systemic toxicity is to be expected.  At ≥11x HED, the systemic toxicity would likely be related to hepatic findings. 2.2.7. Conclusion on the non-clinical aspects Medicinal product no longer authorised

Collectively, the available primary pharmacology data support the view that AA4500 administration into localized deposits of pathological (fibrillar) collagen, like that present in Peyronie's disease, will result in therapeutically meaningful lysis and removal of the collagen.

AA4500 has limited or no quantifiable systemic exposure with no systemic toxicity following local administration, including intrapenile application in dogs. Local findings were restricted to the site of injection and the draining lymph node, with (almost) complete recovery of the gross findings following the cessation of treatment, with ongoing healing processes at the end of the recovery period.

As documented in the original MAA, following IV bolus administration of the commercial drug product, the primary target organ was the liver and a clear systemic NOEL and adequate safety margins were established to account for inadvertent administration of the whole clinical dose into the systemic circulation.

Anti-AA4500 antibodies were generated in almost all animals after local or IV administration; however, no evidence for antibody mediated adverse effects was observed.

<div style=\"page-break-after: always\"></div>

Overall, the results of the non-clinical studies with AA4500 support its proposed use in the treatment of Peyronie's disease.

Furthermore, proteins are exempted from the requirement of an environmental risk assessment (ERA) because they are unlikely to result in significant risk to the environment. Xiapex is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the Union were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

The clinical program for AA4500 in the treatment Peyronie's disease (PD) in adults consists of 11 clinical studies: two Phase 1, six Phase 2, and three Phase 3.

Biospecifics Technologies Corp. (BTC) sponsored the first six studies (open-label pilot study, double-blind pilot study, 1001-PEY, 1025-PEY, 1030-PEY, and 1035-PEY) using study drug produced from an earlier comparable manufacturing processes (ie, early BTC process). Each of these early studies was led by a single investigator.

Auxilium has sponsored five studies using the commercial process

| AUX-CC-801             | phase IIb                                                  |
|------------------------|------------------------------------------------------------|
| AUX-CC-802             | open-label safety and efficacy                             |
| AUX-CC-803, AUX-CC-804 | two identical pivotal placebo-controlled phase III studies |
| AUX-CC-805             | pharmacokinetic study                                      |

In the early BTC studies (using the early BTC process) doses were expressed in 'Units of AA4500 activity'. In the latter studies (using Auxilium's optimized commercial process) doses were expressed in 'mg of protein'. AA4500 produced by Auxilium's optimized process has been shown to be comparable to the AA4500 produced by the early BTC process (ie, AA4500 activity ≈ 17,241 U/mg protein).

Medicinal product no longer authorised

Thus, the commercial 0.58 mg dose of AA4500 is equivalent to 10,000 U of AA4500.

<div style=\"page-break-after: always\"></div>

Table 1: Overview of the AA4500 Clinical Program for the Treatment of Adults With Peyronie's Disease

| Study Country                                                                                                                                                                                                                          | Number Treated         | Design                                                                   | Dosing Regimen                                                                                                                                                                                                                                                                                                                                                                                                           | MAA                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Phase 1                                                                                                                                                                                                                                | Phase 1                | Phase 1                                                                  | Phase 1                                                                                                                                                                                                                                                                                                                                                                                                                  | Phase 1                                                                     |
| Pilot open-label study (USA)                                                                                                                                                                                                           | AA4500: 31             | Design: Phase 1 open-label pilot study                                   | Dosing: Single intralesional injections on 3 consecutive days as follows: 1st 6 subjects: AA4500 total dose: 270 - 1595 units Remaining 25 subjects: AA4500 total dose: 1739 - 4850 units Topical ß-aminopropionitrile fumarate was applied as an adjuvant in Subjects 7-13 on Days 7-28 Oral ß-aminopropionitrile fumarate 250 mg QID was administered as an adjuvant in the remaining subjects on Days 7-28 authorised | No formal database; results based on publication (Gelbard MK et al, 1985).  |
| Pilot double-blind, randomized, placebo-controlled study with an open- label placebo crossover arm Subjects stratified within treatment group by penile deviation angle: Category 1: <30˚ Category 2: 30 - 60˚ Category 3: > 60˚ (USA) | AA4500: 22 Placebo: 27 | Phase 1, double-blind, placebo-controlled pilot study                    | Double-blind: AA4500: 2000 U in 0.5 mL of NaCl containing 2 mM of CaCL Placebo: 0.5 mL of NaCl containing 2 mM of CaCL Total dose categories: Category 1: 3 aliquots AA4500 total dose: 6000 U Placebo: 1.5 mL Category 2: 5 aliquots AA4500 total dose: 10,000 units Placebo: 2.5 mL Category 3: 7 aliquots AA4500 total dose: 14,000 units Placebo: 3.5 mL Open-label: 23 subjects product no longer                   | No formal database; results based on publication (Gelbard MK et al., 1993). |
| Phase 2 Medicinal                                                                                                                                                                                                                      | Phase 2 Medicinal      | Phase 2 Medicinal                                                        | Phase 2 Medicinal                                                                                                                                                                                                                                                                                                                                                                                                        | Phase 2 Medicinal                                                           |
| 1001-PEY (USA)                                                                                                                                                                                                                         | AA4500: 15 Placebo: 15 | Phase 2 double-blind, placebo-controlled study - investigator initiated. | AA4500: 10,200 units (divided into 6 syringes; each containing 1700 units in a volume of 0.5 mL 0.9% NaCl containing 2mM CaCl) Placebo: Six 0.5 mL syringes of 0.9% NaCl containing 2mM CaCl Same treatment repeated 3 months later for a total dose of 20,400 units of AA4500.                                                                                                                                          | No formal database; study specific safety summary will be included in ISS   |

<div style=\"page-break-after: always\"></div>

| Study Country                         | Number Treated          | Design                                                                                  | Dosing Regimen                                                                                                                                                                                                                                                                                                                                                                                                                 | MAA                                                                |
|---------------------------------------|-------------------------|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| 1025-PEY (USA)                        | AA4500: 5               | Phase 2 open-label, investigator-initiated                                              | Up to 5 single injections of AA4500 10,000 units in a volume of 0.5 mL, each separated by 1 week for a total dose of 50,000 units of AA4500.                                                                                                                                                                                                                                                                                   | No formal database; study specific safety summary will be included |
| 1030-PEY (USA)                        | AA4500: 25              | Phase 2 open-label, investigator-initiated                                              | Single injections of AA4500 10,000 units in a volume of 0.25mL on 3 separate days within a period of 3 to 10 days. The same treatment was repeated 3 months later, at the discretion of the investigator for a total dose of 60,000 units of AA4500.                                                                                                                                                                           | in ISS                                                             |
| 1035-PEY (USA)                        | AA4500: 10              | Phase 2 open-label, investigator-initiated                                              | Single injections of AA4500 10,000 units in a volume of 0.25mL every other day, or every 3 days (if the subject developed ecchymosis). Subjects could receive up to three doses per treatment cycle. The same treatment cycle could be repeated 2 more times (6 weeks and 3 months after the first injection) at the discretion of the investigator for a total dose of 90,000 units of AA4500. longer authorised              | ISS                                                                |
| AUX-CC-801 (USA)                      | AA4500: 111 Placebo: 36 | Phase 2 double-blind, placebo-controlled                                                | Treatment Cycle: 2 single Intralesional injections of AA4500 0.58 mg or placebo separated by 24-72 hours and followed 24-72 hours later by penile plaque modeling (subjects were randomized in a 1:1 ratio at baseline to receive penile plaque modeling or not to receive penile plaque modeling). Up to 3 treatment cycles each separated by 6 weeks with a total dose of up to 3.48 mg (60,000 units) of AA4500. product no | ISS                                                                |
| AUX-CC-805 a (USA)                    | AA4500: 20              | Phase 2, open label, single treatment cycle, pharmacokinetic and safety study Medicinal | Single Treatment Cycle: Two single intralesional injections of AA4500 0.58 mg separated by 24 hours and followed 24 hours later by penile plaque modeling with a total dose of 1.16 mg (20,000 units) of AA4500.                                                                                                                                                                                                               | PK and ISS                                                         |
| Phase 3                               | Phase 3                 | Phase 3                                                                                 | Phase 3                                                                                                                                                                                                                                                                                                                                                                                                                        | Phase 3                                                            |
| AUX-CC-802 (USA, New Zealand, Europe) | AA4500: 348             | Phase 3 open-label study                                                                | Treatment Cycle: 2 single intralesional injections of AA4500 0.58 mg separated by 24-72 hours and followed 24-72 hours after the second injection of each treatment cycle by penile plaque modeling. Up to 4 treatment cycles each separated by 6 weeks with a total dose of up to 4.64 mg (80,000 units) of AA4500.                                                                                                           | ISS                                                                |

<div style=\"page-break-after: always\"></div>

| Study Country                  | Number Treated           | Design                                   | Dosing Regimen                                                                                                                                                                                                                                                                                                                             | MAA         |
|--------------------------------|--------------------------|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| AUX-CC-803 (USA and Australia) | AA4500: 277 Placebo 140  | Phase 3 double-blind, placebo-controlled | Treatment Cycle: 2 single intralesional injections of AA4500 0.58 mg or placebo separated by 24-72 hours and followed 24-72 hours after the second injection of each treatment cycle by penile plaque modeling. Up to 4 treatment cycles each separated by 6 weeks with a total dose of up to 4.64 mg (80,000 units) of AA4500.            | ISE and ISS |
| AUX-CC-804 (USA and Australia) | AA4500: 274 Placebo: 141 | Phase 3 double-blind, placebo-controlled | Treatment Cycle: 2 single intralesional injections of AA4500 0.58 mg or placebo separated by 24-72 hours and followed 24-72 hours after the second injection of each treatment cycle by penile plaque modeling. Up to 4 treatment cycles each separated by 6 weeks with a total dose of up to 4.64 mg (80,000 units) of AA4500. authorised | ISE and ISS |

a Subjects who complete Study AUX-CC-805 rolled into the Phase 3 open-label study AUX-CC-802 to complete Treatment Cycles 2 through 4 and follow-up

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

In subjects with Dupuytren's contracture there were no quantifiable levels of AUX-I and AUX-II after single and concurrent injections of AA4500 into Dupuytren's cords within the hand. The Dupuytren's cord is essentially avascular. In contrast, the site of injection in Peyronie's disease is the Peyronie's plaque, which is contiguous with the tunica albuginea and the highly vascular corpora cavernosa. Therefore, a separate pharmacokinetic study, AUX-CC-805, was performed in subjects with Peyronie's disease.

## Absorption

The objectives of study AUX-CC-805 were to determine if there was systemic exposure following two injections (one treatment cycle) of AA4500 0.58 mg (separated by 24 hours) into the primary penile plaque of men with Peyronie's disease, and to evaluate the safety of AA4500 in these subjects.

## · Methodology

Subjects were screened for study eligibility within 21 days before the initial injection of study drug. Each subject  received  a  single  treatment  cycle,  which  included  two  single  injections  of  AA4500  0.58  mg administered 24 hours apart and followed by a penile plaque modeling procedure 24 hours after the second injection. Subjects were admitted to the study unit the day before the first injection of AA4500 (Day -1) and remained in the study unit until the PK sample was collected after investigator penile plaque modeling on Day 3. Subjects returned to the study unit on Day 4, Day 8, and Day 29 for follow-up PK and safety assessments. Eligible subjects who completed this study could have received up to three additional treatment cycles (for a total of four treatment cycles) in the Phase 3 open-label study, AUX-CC-802 (ie, AUX-CC-805/ AUX-CC-802 rollover subjects). The data collected for subjects during the AUX-CC-805 screening  visit  were  used  as  the  screening  data  for  any  additional  treatment  cycles  these  subjects received in Study AUX-CC-802. · Number of subjects (planned and analyzed) 20 subjects were planned; 20 subjects were included in the intent-to-treat (ITT) population, and 19 were included in the PK population. · Test product, dose and mode of administration, batch number AA4500 0.58 mg injected directly into the penile plaque, after reconstitution with sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride). The volume of injection was 0.25 mL. Lot numbers were C0370 for AA4500 and C0358 for diluent. · Duration of treatment Subjects received one treatment cycle (two injections of study drug with 24 hours between injections). Medicinal product no longer authorised

## · Criteria for evaluation

Clostridial type I collagenase (AUX-I) and clostridial type II collagenase (AUX-II) enzyme concentrations, maximum concentration from 0 hour to 24 hour evaluation following each injection (Cmax), elapsed hours  to  reach  Cmax  within  24  hours  following  each  injection  (Tmax),  time  of  last  quantifiable concentration from 0 hour to 24 hour evaluation following each injection (tlast), area under the curve of concentration from 0 to the last time point with a quantifiable concentration within 24 hours following each injection (AUC0-tlast), and area under the curve of concentration from 0 to the last time point with a quantifiable concentration and extrapolated to infinity for each injection (AUC0-infinity).

Safety was evaluated through the monitoring of adverse events (AEs), clinical laboratory evaluation, vital signs, and immunogenicity data.

## · Statistical Methods

<div style=\"page-break-after: always\"></div>

The ITT population was defined as all enrolled subjects who had at least one injection of AA4500. All safety, immunogenicity, and subject baseline characteristics were summarized based on this population. The PK population was defined as all ITT subjects who had 0 to 24-hour blood concentration results for AUX-I  and/or  AUX-II  post  an  injection  of  AA4500.  The  PK  parameters  were  summarized  using  this population. Subjects unable to receive the second injection at the 24-hour time point were not included in the PK analyses for the second injection.

## · Pharmacokinetics

Pharmacokinetic parameters (Cmax and AUC0-tlast) were determined by non-compartmental analyses using validated software (SAS, version 9.1.3, Cary, NC). AUC0-infinity values were not evaluated, as only three of 20 subjects' profiles had an acceptable extrapolation that was ≤20% of the total area. AUC0-tlast was based on the linear/log-linear trapezoidal rule. Estimation of PK parameter estimates were derived from the following standardized analysis conventions:

1. The concentration at t=0 time point was set to zero if the measured value was &lt;limit of quantification (LOQ)

2. All post treatment values &lt;LOQ were set to 'missing data' 3. If concentrations from a subject were all &lt;LOQ then AUC0-tlast and Cmax were imputed to be 0.000 while Tmax was set to 'missing data.' Drug accumulation was assessed by ratios of the geometric means and 95% confidence intervals (CIs) for ratios of means of Cmax and AUC0-tlast on Day 2:Day 1 for the 10 subjects with quantifiable profiles after both the first and second injections. · Safety All treatment-emergent AEs (TEAEs) were summarized by frequency and relationship to study drug. For each  of  these  parameters,  TEAEs  were  presented  overall,  by  preferred  term,  and  severity.  Clinical laboratory data (chemistry and hematology) were summarized with descriptive statistics for actual value and change from baseline to Day 29. The count and percentage of subjects with Sponsor-defined clinically significant laboratory values at anytime during the study were also presented. Vital signs were summarized with descriptive statistics for actual value and change from baseline. Vital signs taken on the injection day were summarized across the different time points 15 minutes after, 30 minutes after, 45 minutes after, and 60 minutes after). The baseline value was the vital sign measure immediately predose for that injection. The summary was done by for each injection and time point. Vital signs were also summarized on Day 3, Day 4, Day 8, and Day 29. The count and percentage of subjects with  Sponsor-defined  clinically  significant  vital  sign  values  at  any  time  during  the  study  were  also presented. Medicinal product no longer authorised

Titer values for antibody response to AUX-I and AUX-II were summarized with descriptive statistics after log-transformation at baseline (screening) and Day 29. Missing values were not imputed.

Neutralizing  antibody  responses  (negative/positive)  to  AUX-I  and  AUX-II  were  summarized  with descriptive statistics at baseline (screening) and Day 29.

## · Analytical methods

The assay methods are summarized in Table 1.

Table 1: Pharmacokinetic Assay Format for AUX-I and AUX-II in Human Plasma

|                         | AUX-I                                          | AUX-II                                          |
|-------------------------|------------------------------------------------|-------------------------------------------------|
| Assay format            | ELISA                                          | ELISA                                           |
| Capture antibody        | Rabbit affinity-purified anti-AUX-I polyclonal | Rabbit affinity-purified anti-AUX-II polyclonal |
| Detection antibody      | Biotinylated version of capture antibody       | Biotinylated version of capture antibody        |
| Test matrix             | Human plasma (lithium-heparin)                 | Human plasma (lithium-heparin)                  |
| Dilution of test matrix | 1 in 50                                        | 1 in 50                                         |

<div style=\"page-break-after: always\"></div>

| Quantitation range                          | 0.1 - 0.8 ng/ml   | 0.5 - 10 ng/ml   |
|---------------------------------------------|-------------------|------------------|
| LOQ in undiluted matrix                     | 5 ng/ml           | 25 ng/ml         |
| Validation study number                     | AA41767CH-EB-03   | AA41768CH-EB-01  |
| Validation study number long-term stability | AA41767CH-EB-04   | AA41768CH-EB-02  |

## · Results

Pharmacokinetics:  Subjects  were  to  have  plasma  samples  analyzed  for  AUX-I  and  AUX-II  at predetermined time points before and after Injection 1 and Injection 2; thus, for each subject, two separate concentration-time profiles, one for each analyte (ie, AUX-I and AUX-II), were obtained. Of the 20 subjects enrolled in this study, one subject was excluded from all concentration-time profiles and PK analyses due to insufficient quantities of plasma for bioanalysis. The 19 remaining subjects had plasma samples analyzed at all planned time points after Injection 1 and Injection 2.

Of the 38 AUX-I profiles, 18% (7/38) had no quantifiable plasma concentrations at any time point through 24  hours  post  injection.  Of  the  38  AUX-II  profiles,  60%  (23/38)  had  no  quantifiable  plasma concentrations at any time point through 24 hours post injection.

Two subjects had pre-dose and post-dose plasma values for AUX-I at ≥LOQ at the majority of the collection times through Day 29, which was consistent with possible interference in the AUX-I ELISA. Therefore, the AUX-I concentration-time profiles for these two subjects were considered 'not evaluable' and were not included in the AUX-I PK analyses.

Mean AUX-I and AUX-II PK parameter estimates on Day 1 and Day 2 are shown in Table 2.

Table 2: Mean AUX-I and AUX-II Pharmacokinetic Parameters After Injection 1 and 2

| product   | no   |
|-----------|------|

interference).

Medicinal product no longer authorised

For PK evaluable subjects with quantifiable plasma levels of AUX-I and AUX-II, concentrations were low and transient (ie, detected only through the 0.5-hour post-injection time point) on both Day 1 and Day 2. The maximum individual subject concentrations were 28.2 ng/mL for AUX-I and 70.8 ng/mL for AUX-II. In addition, no subject had quantifiable plasma levels 15 minutes after modeling of the plaque on Day 3, which suggests that manual modeling of the penis performed 24 hours after the Day 2 injection does not result in release of AA4500 from the injection site.

The 95% CIs for the ratios of the geometric means for Cmax and AUC0-tlast on Day2:Day 1 each contained 1.00, indicating that the Cmax and AUC0-tlast on Day 2 were not significantly different from that observed on Day 1. These findings confirm that there is no evidence of accumulation of AA4500 in plasma following two sequential injections of AA4500 administered 24 hours apart.

Safety: The most common (≥20.0% of subjects) TEAEs were penile haemorrhage (penile ecchymosis) (95.0%),  injection  site  pain  (75.0%),  procedural  pain  (45.0%),  penile  swelling  (30.0%),  painful erection (20.0%), and penile pain (20.0%). The majority of subjects had TEAEs or treatment-related

<div style=\"page-break-after: always\"></div>

TEAEs that were at most mild or moderate in severity, as assessed by the investigator. All subjects had at least one TEAE that was related to study drug, as assessed by the investigator.

No subject died, experienced a serious AE, prematurely discontinued due to an AE, experienced a spontaneous  penile  event,  corporal  rupture,  erectile  dysfunction,  genital  disorder  male,  or  sexual dysfunction during the study.

No clinically concerning trends were observed with regard to hematology and chemistry laboratory parameter results or vital sign results.

The  immunogenicity  profile  was  as  expected,  with  50%  and  30%  of  the  subjects  having  positive antibodies to AUX-I and/or AUX-II, respectively, at Day 29. Antibodies titer levels did not appear to be predictive of neutralizing antibody status. No systemic immunologic events were reported. There was no evidence of systemic hypersensitivity or anaphylaxis in any subject immediately after dosing or at any time during the study.

## Distribution

No tissue distribution studies have been performed with AA4500, as the absence of significant systemic exposure either in animal studies or human subjects following local administration of AA4500 indicates that AA4500 primarily remains confined to the tissues near the injection site and/or is rapidly inactivated either before or upon reaching the systemic circulation.

## Elimination

## · Excretion

Excretion  has  not  been  formally  examined  after  treatment  with  AA4500,  and  because  there  is  only minimal and transient exposure after local administration directly into Peyronie's plaques and the class nature of AA4500 (a protein), no such studies have been performed with AA4500.

## · Metabolism

AA4500 is not a substrate for cytochrome P450 or other drug metabolizing enzyme pathways, and thus no  active  metabolites  are  expected.    Therefore,  no  metabolism  studies  have  been  performed  with AA4500.

## · Pharmacokinetics of metabolites

AA4500 is a protein that is active in its native form, and does not require proteolytic cleavage for activity. Active metabolites are not anticipated for AA4500 by its suggested elimination pathway. Therefore, no work has been done on identification of active metabolites.

Medicinal product no longer authorised

## Dose proportionality and time dependencies

Because pharmacodynamic activity cannot be evaluated directly or by surrogate biomarkers in subjects and is not a function of systemic exposure, dose and time dependencies have only been evaluated in in vitro model systems.

## Special populations

The Phase 3 clinical studies in Peyronie's disease conducted by the MAH have evaluated the safety and efficacy of AA4500 in a subject population that is representative (ie, in age, gender, and race) of the population targeted for commercialization. As systemic exposure to AA4500 was minimal and transient after local administration directly into Peyronie's plaques, no studies are deemed necessary to evaluate

<div style=\"page-break-after: always\"></div>

the effects of AA4500 in subjects with impaired hepatic or renal function. In addition, review of the clinical safety database did not show clinically meaningful changes in hepatic or renal function parameters.

## Pharmacokinetic interaction studies

Pharmacokinetic drug interactions have not been evaluated.  AA4500 is not a substrate for cytochrome P450 or other drug metabolizing enzyme pathways; therefore P450 related metabolic drug interaction is not expected.

## Exposure relevant for safety evaluation

Safety pharmacology studies have not been conducted with AA4500. This is in accordance with ICH guidance S7A Safety Pharmacology Studies for Human Pharmaceuticals, 2000) indicating that that the conduct of safety pharmacology studies are not required for components with low or absent systemic exposure or where distribution to other organs or tissues is limited.

2.3.3. Pharmacodynamics Collagenases are proteinases that hydrolyze collagen under physiological conditions. Xiapex is comprised of a mixture of Class I (AUX-I) and Class II (AUX-II) clostridial collagenases in a defined mass ratio. The two classes of collagenases have similar but complementary substrate specificity. Both collagenases effectively cleave interstitial collagen but at different sites on the molecule; additionally, they prefer different conformations (triple helical versus denatured or cleaved). These differences account for the ability of the two classes of enzymes to digest collagen in a complementary manner. Class I collagenases (α, β, γ, and η) are the products of the colG gene, they initiate collagen hydrolysis near the amino and carboxy termini of triple helical domains, and generate large proteolytic fragments. In contrast, the Class II collagenases (δ, ε, and ζ,) are products of colH gene, their initial cleavage sites are located within the interior of the collagen molecule, and generate smaller collagen fragments. Both classes of collagenases readily hydrolyze gelatin (denatured collagen) and small collagen peptides, whereas Class II has higher affinity for small collagen fragments. Class I cleaves insoluble triple helical collagen with higher affinity than Class II collagenase. Together, these collagenases work to provide broad hydrolytic activity towards collagen. Injection of Xiapex into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced. Medicinal product no longer authorised

## Primary and secondary pharmacology

The pharmacologic activity of AA4500 involves selective lysis of collagen at the site of injection (ie, the Peyronie's plaque).  Because its therapeutic activity is localized and does not require or result in quantifiable systemic exposure, the primary pharmacodynamic activity of AA4500 cannot be evaluated in subjects and, therefore, such studies have not been undertaken.  Instead, evidence for primary pharmacodynamic activity of clinical relevance has been obtained from in vitro studies using excised Dupuytren's cords and Peyronie's plaques and in vivo studies of subcutaneous administration in minipigs. No systemic secondary pharmacodynamic effects have been evaluated or noted in clinical or animal studies.  AA4500 is intended for local use, and no quantifiable systemic circulation has been shown

<div style=\"page-break-after: always\"></div>

following local administration via the intended route of administration. Therefore, plasma concentration-effect relationships cannot be established.

In vitro inactivation of clostridial collagenase by some antibiotics has been described in the literature. Tetracycline derivatives have been shown to inhibit matrix metalloproteinase-mediated collagen degradation at pharmacologically relevant concentrations  and because of a potential confounding influence on efficacy evaluation, subjects who had received doxycycline or another tetracycline derivative during the 14 days before the first dose of study drug were excluded from participation in the clinical studies. Appropriate statement is included in the SmPC.

## 2.3.4. PK/PD modelling

N/A

2.3.5. Discussion on clinical pharmacology A pharmacokinetic study has been conducted in the target population. Data from study AUX-CC-805 indicate that there is only low systemic exposure following two injections of AA4500 0.58 mg (separated by 24 hours) into the primary penile plaque of men with Peyronie's disease.  Of the 38 AUX-I profiles, 81.6% (31/38) had quantifiable plasma concentrations, of the 38 AUX-II profiles, 39.5% (15/38) had quantifiable plasma concentrations. The maximum individual subject concentrations were 28.2 ng/mL for AUX-I and 70.8 ng/mL for AUX-II. After 30minutes all plasma levels were below the limits of quantification. There was no evidence of accumulation. Further, no patients had quantifiable plasma levels 15 minutes after modelling of the penis performed 24 hours after the Day 2 injection suggesting that manual modeling does not result in release of AA4500 from the injection site. Because AA4500 is not intended for systemic use and systemic exposure was either non-quantifiable or limited only at the first few hours following the initial dose via clinically relevant routes of administration, there are no systemic primary or secondary pharmacodynamic actions of relevance and no safety pharmacology concerns. Tetracycline derivatives have been shown to inhibit matrix metalloproteinase-mediated collagen degradation at pharmacologically relevant concentrations. Whilst there is no clinical evidence of an interaction use of Xiapex in patients who have received tetracycline antibiotics (e.g., doxycycline) within 14 days prior to receiving an injection of Xiapex is not recommended. This is appropriately reflected in 4.5 of the SmPC. Medicinal product no longer authorised

## 2.3.6. Conclusions on clinical pharmacology

Due  to  the  route  of  administration  (local  injection)  and  non-quantifiable  systemic  bioavailability significant interactions are unlikely. The application is considered approvable from a clinical pharmacology perspective.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

## Early Clinical Phase 1 and Phase 2 Studies

Two hundred ninety-nine subjects with Peyronie's disease participated in the early clinical studies of AA4500,  which  were  conducted  by  BTC  (open-label  pilot,  double-blind  pilot,  PEY-1001,  PEY-1025, PEY-1030 and PEY-1035). Of these, 66 subjects received at least one intralesional injection of AA4500 10,000 U (equivalent to 0.58 mg) into the plaque of the penis. Each of these studies was led by individual clinical investigators seeking to build on the work previously conducted, and each had a different study end point, different methods of evaluation, and different study procedures. The total dose of AA4500 administered in these early studies ranged from 1410 U to 90,000 U.

Efficacy findings from these early studies suggested that the treatment regime utilized in the Phase 2 study  PEY-1035  may  be  effective  in  the  treatment  of  Peyronie's  disease.  This  treatment  regimen consisted of:

- Single injections of AA4500 10,000 U administered into the penile plaque every 2nd or 3rd day of the treatment cycle (for a total of 3 injections) and followed by penile plaque modeling to facilitate disruption of the plaque. This regimen had the option for re-treatment every 6 weeks and 12 weeks, for a total of up to three treatment cycles (total dose: up to 90,000 U).

In  study  AUX-CC-801  a  similar  treatment  regimen  (ie,  2  injections/week  for  a  maximum  of  three treatment cycles [total dose: up to 3.48 mg or equivalent to 60,000 U]) was tested along with the effect of penile plaque modeling versus no penile plaque modeling on the efficacy and safety of Xiapex in treatment of Peyronie's disease.

## AUX-CC-801

## A  Phase  2b,  Double-Blind,  Randomized,  Placebo-Controlled  Study  of  the  Safety  and Effectiveness of AA4500 Administered Two Times a Week for Up to Three Treatment Cycles (2 x 3) in Subjects With Peyronie's Disease

Investigators: Multicenter / 12 sites in the United States

Studied period (years): 36 weeks

Date first subject enrolled: 19 August 2008

Data last subject completed: 16 October 2009

Objectives:

The objectives of this study were to:

- assess  the  treatment  sensitivity  of  the  Peyronie's  Patient  Reported  Outcome  (PRO) Questionnaire (hereafter referred to as the Peyronie's Disease Questionnaire [PDQ])

Medicinal product no longer authorised

- assess the effectiveness of AA4500 in improving penile curvature in men with Peyronie's disease
- Assess the safety of AA4500 in men with Peyronie's disease.

One hundred forty-seven (n=147) eligible men (111 AA4500 and 36 placebo) were enrolled in the study. Before dosing, subjects were stratified by degree of penile curvature (ie, 30º to 60º or &gt;60º) and then randomized into four treatment groups to receive in a 3:1 ratio either AA4500 0.58 mg or placebo, and in a 1:1 ratio to receive either penile plaque modeling or no penile plaque modeling, as shown in the Table below.

<div style=\"page-break-after: always\"></div>

Table 33: Study Drug Assignment in AUX-CC-801

| Study Drug                | InjectionVolume           | Treatment Cycle                                                                                                                                                                        |
|---------------------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PenilePlaque Modeling     | PenilePlaque Modeling     | PenilePlaque Modeling                                                                                                                                                                  |
| AA45000.58mgorplacebo     | 0.25mLinjectionvolume     | 2 injections separated by 24 to 72 hours, followed by penile plaque modeling 24 to 72 hours after the final injection of each cycle. Up to3 treatment cycles eachseparated by 6 weeks. |
| No Penile Plaque Modeling | No Penile Plaque Modeling | No Penile Plaque Modeling                                                                                                                                                              |
| AA45000.58mgorplacebo     | 0.25mLinjectionvolume     | 2 injections separated by 24 to 72 hours. Up to 3 treatment cycles each separated by 6 weeks.                                                                                          |

Penile plaque modelling For subjects randomized to penile plaque modeling, the investigator or qualified designee modeled the plaque at least 24 hours, but not more than 72 hours, after the final injection of the treatment cycle, and after penile anesthesia had been administered. Each injection of AA4500 into the plaque is intended to enzymatically weaken/soften the collagen, which is present in the plaque. After injection of AA4500 in tissue culture explants from Peyronie's plaque, the majority of the biochemically detectable collagen digestion occurred within the first 24 hours in culture. This  time  point  also  correlated  with  significant  structural  disruption  of  the  collagen  fibers  observed histologically  (Gelbard  et  al,  1982;  RU-001).  Therefore,  in  Study  AUX-CC-801,  gentle  to  moderate modeling  (stretching  or  elongating)  of  the  plaque  24  to  72  hours  after  the  second  injection  of  the treatment cycle was included to potentially allow for additional mechanical disruption of the plaque at a time at which the collagen fibers were expected to be weakest. If the subject's penile curvature had been reduced to &lt;15° after the first or second cycle of injections or if further treatment was not clinically indicated, subsequent treatment cycles were not administered. Following the maximum three treatment cycles, each subject was followed for additional safety and efficacy assessments at Weeks 18, 24, and 36. Subjects who were randomized to placebo in this study had the opportunity to receive AA4500 in a subsequent protocol. Diagnosis and main criteria for inclusion Medicinal product no longer authorised

Healthy heterosexual male subjects ≥18 years of age with a diagnosis of Peyronie's disease for at least six months before the first dose of study drug and a penile curvature of at least 30° in the dorsal, lateral, or dorsal/lateral plane were eligible.

## Test product, method of administration

AA4500 0.58 mg or placebo injected directly into the penile plaque, after reconstitution with sterile diluent (0.9% NaCl containing 2 mM CaCl2). The volume of injection was 0.25 mL.

## Duration of treatment

Subjects received up to three treatment cycles; each cycle was separated by a period of six weeks. During each treatment cycle, subjects received two injections of study drug, with at least 24 hours, but not more than 72 hours, between injections.

## Criteria for evaluation

<div style=\"page-break-after: always\"></div>

## Efficacy

The following parameters were measured in order to establish clinical effectiveness of AA4500 0.58 mg:

- change/percentage change from baseline in penile curvature
- change from baseline total score for each PDQ parameter (Intercourse Discomfort, Intercourse Constraint, Penile Pain, and Peyronie's disease Symptom Bother)
- Change  from  baseline  total  score  of  the  International  Index  of Erectile  Function  IIEF Questionnaire  for  each  of  five  domains  (erectile  function,  orgasmic  function,  sexual  desire, intercourse satisfaction, and overall satisfaction)
- change from baseline in penile length, plaque length, plaque width, and plaque area; Peyronie's symptomatology; Peyronie's disease Global Assessment; and the relationship between penile curvature measurements and PDQ response.

## Safety

Safety was evaluated through the monitoring of adverse events (AEs), clinical laboratory evaluation, vital signs, immunogenicity, and duplex Doppler ultrasound data.

Efficacy  analyses  (except  for  total  score  of  PDQ  responses  by  scale,  which  were  based  on  the  PDQ population) were based on the modified intent-to-treat (mITT) population, defined as all intent-to-treat (ITT) subjects who had at least one penile curvature measurement post-first injection of the study drug.

The ITT population was defined as all randomized subjects who had at least one injection of study drug.

## Statistical Methods

Penile  curvature,  change  from  baseline,  and  percent  change  from  baseline  in  penile  curvature  were summarized with descriptive statistics at each visit window. Comparison between treatment groups was based on an analysis of variance (ANOVA) with factors for drug (placebo or AA4500 0.58 mg) and modeling (yes/no) and drug-by-modeling interaction. The primary analysis was at Week 36.

Total scores and change from baseline total scores for each of the four scales of the PDQ were analyzed separately with descriptive statistics at each visit window. The comparison between treatment groups was based on the change from baseline using an ANOVA with factors for drug (placebo or AA4500 0.58 mg) and modeling (yes/no) and drug-by-modeling interaction. The primary analysis was at Week 36.

## Peyronie's Disease Questionnaire (PDQ)

The PDQ is a disease-specific 15-item, self-administered, paper-and-pencil instrument designed and validated by Auxilium to measure the psychosexual consequences of PD. The PDQ assesses the impact of PD in the following three domains:

- Peyronie's Psychological and Physical Symptoms (6 items)

Medicinal product no longer authorised

- Penile Pain (3 items)
- Peyronie's Symptom Bother (6 items).

Subjects completed the items assessing the Peyronie's Psychological and Physical Symptoms based on the last time they had vaginal intercourse (within the last 3 months). A 5-point Likert-type response scale measured  the  severity  of  each  symptom  (none,  mild,  moderate,  severe,  very  severe).  Subjects completed the items assessing Penile Pain based on the last 24 hours or their most recent experience (erection or vaginal intercourse). An 11-point numeric rating scale was used to assess the extent of subjects' pain. Subjects completed the items assessing Peyronie's Symptom Bother based on their most recent/current experience. A 5-point Likert-type response scale (not at all bothered, a little bit bothered, moderately bothered, very bothered, extremely bothered) measured the amount of bother with each item.

## Results

## Disposition of Subjects

<div style=\"page-break-after: always\"></div>

A total of 147 subjects were randomized in the study; 74 subjects were randomized to the modeling group (54 AA4500, 20 placebo) and 73 subjects were randomized to the group without modeling (57 AA4500, 16  placebo).  Overall,  the  most  common  reason  for  premature  discontinuation  from  the  study  was withdrawal of consent (6 subjects).

## Demographic and Other Baseline Characteristics

No statistically significant differences were observed among treatment groups (AA4500 with and without modeling,  placebo  with  and  without  modeling)  for  any  demographic  or  baseline  characteristic.  The majority (95.2%) of subjects were white and between 45 and 64 years of age (80.3%). The median age of subjects overall was 58.0 years.

The majority of subjects had not had trauma to the erect penis (77.6%) or penile pain (54.4%). Erectile dysfunction was reported by 44.2% of all subjects. Median duration of Peyronie's disease was shortest in the placebo/without modeling group (1.200 years) and longest in the AA4500/modeling (2.250 years) and placebo/modeling (2.000) groups.

At screening, the majority of subjects had mild or moderate plaque palpability and no pain resp. pain on erection.

No statistically  significant  differences  among  treatment  groups  (AA4500  with  and  without  modeling, placebo with and without modeling) were observed for penile measurements (curvature, penile length, and flaccid measurements of plaque length, width, and area) at screening. Baseline severity of penile curvature was low (i.e. ≤60°) for the majority (70.1%) of subjects.

Table 19:

|           | no   |
|-----------|------|
| product   |      |
| Medicinal |      |

Medicinal product no longer authorised

Data source:Table14.1.3

<div style=\"page-break-after: always\"></div>

## Overall results

## Penile curvature

Subjects  who  received  AA4500  demonstrated  a  mean  reduction  (improvement)  of  29.7%  in  penile curvature  from  baseline  to  Week  36  (LOCF)  (54.4°  to  38.2°)  compared  with  an  11.0%  mean improvement in curvature seen in placebo subjects (50.6° to 45.1°) (p=0.001) (Table below).

Table 21: MeanChangeandMeanPercentChangeFromBaselineinPenileCurvature atWeek36 (LOCF)(mITT Population)

| authorised   |
|--------------|

The reduction in penile curvature in AA4500-treated subjects was statistically significantly greater than in placebo subjects at Weeks 18, 24, and 36 (no statistical testing was performed at earlier timepoints) (Figure below). Reduction in AA4500-treated subjects was observed after the first treatment cycle (Week 6), with continued reduction observed through Week 36.

Figure 4:

<!-- image -->

Medicinal product no longer authorised

Datasource:Table14.2.2.1.1

*Statistically significant difference vs.placebo for mean change(p=0.007)and mean percent change (p0.016)(Table 14.2.2.1).

## Results With/Without Modeling

Among  subjects  who  received  modeling,  AA4500-treated  subjects  demonstrated  a  mean  reduction (improvement) of 32.4% in penile curvature from baseline to Week 36 (LOCF) (54.7° to 37.2°) compared with a 2.5% mean worsening in curvature for placebo subjects (51.9° to 52.5°) (p&lt;0.001).

<!-- image -->

<div style=\"page-break-after: always\"></div>

Among subjects who did not receive modeling, AA4500-treated subjects experienced a 27.1% mean improvement in penile curvature from baseline to Week 36 (LOCF) (54.1° to 39.1°), which was not statistically  significantly  different  from  the  27.9%  mean  improvement  observed  in  placebo  subjects (48.9° to 35.9°); (p=0.913) (Table below).

Table 22: MeanChangeand MeanPercentChangeFromBaselineinPenileCurvature atWeek36(LOCF)WithandWithoutModeling(mITTPopulation)

<!-- image -->

## MDL=modeling

The drug-by-modeling interaction was statistically significant for mean change and mean percent change from baseline to Week 36 (LOCF) in penile curvature (p≤0.004). These significant interactions indicate a statistically significant difference between the treatment effect (AA4500 versus placebo) observed in the modeling group versus the treatment effect observed in the group without modeling.

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Figure 7: Mean Penile Curvature Over Time, With/Without Modeling (mITT Population)

<!-- image -->

The improvement in the placebo subjects is likely due to the fact that five subjects in the placebo/without modeling  had  an  improvement  (reduction)  in  penile  curvature  of  more  than  40%.  The  duration  of Peyronie's disease for all five of these subjects was ≤1.3 years at screening.

Table 23:

| Medicinal   |
|-------------|

Medicinal product no longer authorised

Data source: Appendix 16.2, Listings 16.2.4 and 16.2.6.1

Among the 16 subjects in the placebo no-modeling group, 63% had Peyronie's disease for ≤ 1.5 years compared with only 45% of the 55 subjects in the AA4500 no-modeling group.

The spontaneous remissions in the five placebo subjects support the variable nature of the acute phase of Peyronie's disease, which has been described as typically lasting from 6 to 12 months. Most surgeons will avoid surgical correction of penile curvature during the acute phase due to the variable nature of the disease (Hellstrom and Bivalacqua, 2000) and the possibility of spontaneous remission. This variability likely explains the placebo response demonstrated in this small number of subjects. In addition, due to the  small  sample  sizes  in  the  placebo  groups  (ie,  20  with  modeling;  16  no-modeling)  and  the  3:1 randomization, this impact was greater than expected.

Mean penile curvature at baseline and Week 36 (LOCF) is shown graphically in the Figure below.

<div style=\"page-break-after: always\"></div>

## MeanPenileCurvatureatBaselineandWeek36(LOCF),With/Without Modeling (mITT Population)

<!-- image -->

## Peyronie's disease Questionnaire (PDQ) results

Mean improvement (reduction) from baseline to Week 36 (LOCF) in the Peyronie's disease Symptom Bother domain of the PDQ was statistically significantly greater in the AA4500 group than in the placebo group (p=0.046) (Table below). No statistically significant differences between AA4500 and placebo were observed for the scales of Intercourse Discomfort, Intercourse Constraint, or Penile Pain.

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## Mean ChangeFromBaselinein PDQ Total Score for Each Scale at Week 36 (LOCF) -PDQ Population Overall in AUX-CC-801 (PDQ Version 3)

| authorised   |
|--------------|
| longer       |

a

b

c

d score=40

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

MeanChangeFroimBaselineinPDQTotalScoreforEachScaleatWeek36(LOCF)PDQ PopulationWith Modeling in AUX-CC-801 (PDQ Version 3)

| authorised   |
|--------------|
| longer       |

- b
- P score=40

As already shown for penile curvature reduction, there was no statistically significant difference between AA4500  and  placebo  in  the  change  from  baseline  in  the  Peyronie's  disease  bother  domain  in  the no-modeling group.

Table35: MeanChangeFromBaselineinPDQPeyronie'sDiseaseBotheratWeek36 (LOCF)-PDQPopulation,No-ModelingGroupin AUX-CC-801

Medicinal product no longer authorised

|                                                           | AA4500 (N=50)   | Placebo (N=16)   |
|-----------------------------------------------------------|-----------------|------------------|
| Peyronie'sDiseaseSy'mptomBothera Screening(baseline)value |                 |                  |
| Mean(SD)                                                  | 7.5 (3.86)      | 8.7 (3.77)       |
| Week36value(L0CF)                                         |                 |                  |
| Mean (SD)                                                 | 6.1 (4.05)      | 7.2 (5.49)       |
| Mean(SD)changefrombaseline                                | -1.5 (3.97)     | -1.5 (4.65)      |
| p-valueb                                                  | 0.991           |                  |

Datasource:AUX-CC-801CSRTable14.2.3.4

LOCF=lastobservation camiedforward;SD=standarddeviation

- Questions14,15,16,18,20;Scale0（notatallbothered)to4（extremelybothered);Maximumscore=20

AA4500versusplacebo

<div style=\"page-break-after: always\"></div>

## Rationales for Dosing and Penile Plaque Modelling in the Phase 3 Program

## Dosing Cycles

The dosing regimen for the Phase 3 program consisted of two injections of AA4500 0.58 mg with an interval of approximately 24 hours but not more than 72 hours between injections. This regimen was shown to be safe in the Phase 2b study (AUX-CC-801). Treatment cycles in the AUX-CC-801 were six weeks (~42 days) apart for a total of three treatment cycles. Based on the safety results from this study, which showed that most adverse effects of AA4500 were local and resolved before the next injection cycle (see safety section below), the proposed interval between treatment cycles in the Phase 3 program remained at 42 days (± 5 days) and a fourth treatment cycle was added to further support and improve the efficacy results AUX-CC-801 study.

The addition of the fourth treatment cycle is supported by the efficacy and safety findings from the early Phase 2 study, PEY-1035, in which men with Peyronie's disease received up to 9 injections of AA4500 (3 injections/week for up to 3 treatment cycles; total dose up to 90,000 U).

## Penile Plaque Modeling

Each injection of AA4500 into the plaque is intended to enzymatically weaken/soften the collagen, which is present in the plaque. After injection of AA4500 in tissue culture explants from Peyronie's plaque, the majority of the biochemically detectable collagen digestion occurred within the first 24 hours in culture. This  time  point  also  correlated  with  significant  structural  disruption  of  the  collagen  fibers  observed histologically (Gelbard et al, 1982). Therefore, in the Study AUX-CC-801, gentle to moderate modeling (stretching or elongating) of the plaque 24 to 72 hours after the second injection of the treatment cycle was included to potentially allow for additional mechanical disruption of the plaque at a time at which the collagen fibers were expected to be weakest. In analyses of the treatment effect specifically examining the effect of AA4500 with or without penile plaque modeling, a statistically significant effect of AA4500 was observed only among subjects who received  modeling.  Men  who  received  AA4500  and  modeling  had  significant  improvement  in  penile curvature (32.4% improvement versus a 2.5% worsening; p&lt;0.001) and a significant improvement in the  Peyronie's  disease  bother  domain  score  (-3.6  versus  -0.1;  p=0.004)  of  the  PDQ.  There  was  no statistically  significant  difference  between  AA4500  and  placebo  in  the  group  with  no-modeling. Importantly,  there  were  no  clinically  meaningful  differences  in  the  safety  profile  of  subjects  in  the modeling versus the no-modeling groups. Based on the findings from early Phase 2 studies and the AUX-CC-801 study investigators in the Phase 3 program had the option of administering two intralesional injections of AA4500 0.58 mg with an interval of at least 24 hours but no more 72 hours between injections and followed by penile plaque modeling 24 to 72 hours after the final injection of the cycle. Subjects could receive up to four treatment cycles (up to 8 injections; total dose: up to a total dose of 4.64 mg equivalent to 80,000 U). Medicinal product no longer authorised

## 2.4.2. Main studies

Studies AUX-CC-803 and AUX-CC-804 are identical double-blind, placebo-controlled studies of the efficacy and safety of AA4500 0.58 mg in the treatment of subjects with Peyronie's disease. These studies provide the pivotal efficacy data in support of the use of AA4500 for the treatment of Peyronie's disease. Studies AUX-CC-803 and AUX-CC-804 were conducted in the United States and Australia with AA4500 produced by Auxilium's commercial manufacturing process.

## Methods

To demonstrate the efficacy of AA4500 0.58 mg in the treatment of Peyronie's disease, the data from two identical, large, well-controlled, multicenter 12-month Phase 3 studies (AUX-CC-803 and AUX-CC-804) were analyzed. To be eligible for these Phase 3 studies, men had to be at least 18 years of age; be in a stable relationship with a female partner/spouse for at least 3 months before screening and be willing to have vaginal intercourse with that partner/spouse; have symptom(s) of Peyronie's disease for at least 12 months before the first dose of study drug and have evidence of stable disease, as determined by the investigator;  have  penile  curvature  of  at  least  30°  in  the  dorsal,  lateral,  or  dorsal/lateral  plane  at screening; and be judged to be in good health, based upon the results of a medical history, physical

<div style=\"page-break-after: always\"></div>

examination, and laboratory profile. Before treatment in each study, subjects were stratified by degree of penile curvature (ie, 30º to 60º or 61° to 90º) and then randomized in a 2:1 ratio into two treatment groups to receive either AA4500 or placebo.

## Study participants

To be eligible for these studies, men had to:

- Be at least 18 years of age
- Be in a stable relationship with a female partner/spouse for at least 3 months before screening and be willing to have vaginal intercourse with that partner/spouse
- Have symptom(s) of Peyronie's disease for at least 12 months before the first dose of study drug and have evidence of stable disease as determined by the investigator
- Have penile curvature of at least 30° in the dorsal, lateral, or dorsal/lateral plane at screening

· Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile. Before treatment in each study, subjects were stratified by degree of penile curvature (ie, 30º to 60º or 61° to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo. Treatments Treatment Cycles Qualified subjects could have received up to four treatment cycles; each cycle was separated by a period of 42 days (±5 days). During each treatment cycle, subjects received two injections of study drug with approximately  24  hours  to  72  hours  between  injections.  Twenty-four  to  72  hours  after  the  second injection of each treatment cycle, the investigator or qualified designee modeled the plaque in an attempt to stretch or elongate the plaque. If the subject's curvature deformity was reduced to &lt;15° after the first, second, or third treatment cycle or if the investigator determined that further treatment was not clinically indicated  (eg,  adverse  events  [AEs];  allergic  reaction),  subsequent  treatment  cycles  were  not administered. Following the maximum of four treatment cycles, each subject was followed for additional safety and efficacy assessments on Days 169 (±7 days), 232 (±7 days), 295 (±7 days), and 365 (±7 days) (nominal weeks 24, 33, 42, and 52). Eligible subjects randomized to placebo in Studies AUX-CC-803 or AUX-C-804 could  receive  open-label AA4500 treatment at the completion of their double-blind study as part of open-label study AUX-CC-806. Medicinal product no longer authorised

Prostaglandin E1 (PGE1) or trimix (ie, papaverine, phentolamine, and PGE1) was injected into the corpora cavernosa of the penis to induce an erection, which in the opinion of the investigator was sufficient for determining penile curvature during the screening visit; before the 1st injection of the 2nd, 3rd, and 4th treatment cycles; and at the Week 24, Week 42, and Week 52 follow-up visits. As described in the statistical analysis plan, changes from baseline at Week 24, Week 42, and Week 52 were analyzed. At each time point, the angle of curvature deformity was measured with a goniometer protractor device using a standardized method.

Before each injection of AA4500 or placebo and before penile plaque modeling, the investigator could have administered a dorsal and/or a circumferential penile block according to the practice of his/her institution and the subject's willingness to receive penile anesthesia. If preferred, topical anesthesia (eg, EMLA cream) could have been applied before injection and modeling. Anesthesia was supplied by the investigator and administered in accordance with the pharmacy practices at the institution.

After local anaesthesia had been provided (if desired) subjects received either AA4500 or placebo (10 mM tris, 60 mM sucrose; ie, lyophilized formulation buffer) according to the randomization schedule. Study drug was injected directly into the primary penile plaque (at point of maximal concavity) of the flaccid penis using a 1 mL (cc) syringe with a permanently attached 26 or 27 gauge ½ inch (13 mm) needle.

<div style=\"page-break-after: always\"></div>

During each treatment cycle, subjects received 2 injections of study drug. Approximately 24 hours to 72 hours  after  the  second  injection  of  each  treatment  cycle  and  after  penile  anaesthesia  had  been administered (if desired) the investigator modelled the plaque.

## Investigator Penile Plaque Modeling

Approximately 24 hours to 72 hours after the final injection of the treatment cycle and after penile anesthesia had been administered (if needed) the investigator or qualified designee modelled the plaque three times according to the instructions of the protocol. If investigator penile plaque modelling was not performed at a protocol-specified time point, the reason for not performing the modelling was to be documented in the eCRF.

Before discharge from the study unit, the investigator or qualified designee instructed subjects in the modeling procedure to be performed at home.

## Objectives

The objectives of these studies were to assess the effectiveness of AA4500 as determined by the following analyses at Day 365 (nominal week 52):

· Primary objective: The effectiveness of AA4500 in the treatment of Peyronie's disease based on the co-primary endpoints of change from baseline in the Peyronie's disease bother domain of the PDQ and percent improvement from baseline in penile curvature

- Secondary objectives:
- Reduction in the severity of Peyronie's disease physical and psychological symptoms
- Change in the penile pain domain of the PDQ in subjects with pain at baseline
- A responder analysis based on subject global assessment
- Change in the overall satisfaction domain of the International Index of Erectile Function (IIEF)
- Change in penile plaque consistency
- Change in penile length

Study objective was also to determine the safety of AA4500 in men with Peyronie's disease.

## Outcomes/endpoints

The following efficacy endpoints include the co-primary endpoints and the secondary endpoints (ie, first family and second family), which were analyzed in Studies AUX-CC-803 and AUX-CC-804.

Medicinal product no longer authorised

A meta-analysis of the pooled data from Studies AUX-CC-803 and AUX-CC-804 is also presented and includes analysis of the same co-primary and secondary endpoints.

## Co-Primary Endpoints

The  co-primary  endpoints  were  the  percent  reduction  from  baseline  in  curvature  deformity  and  the change from baseline in the patient-reported Peyronie's disease bother domain score at Week 52 (LOCF).

## Secondary Efficacy Endpoints

The first family of secondary endpoints (SE#1) included:

- Responder analysis based on the global assessment of the symptoms and effects of PD
- Change from baseline in severity of PD symptoms of the PDQ
- Change in overall satisfaction domain of the International Index of Erectile Function (IIEF)

<div style=\"page-break-after: always\"></div>

The second family of secondary endpoints (SE#2) consisted of:

- Penile plaque consistency
- Change in penile length
- Composite responder #1 (ITT population). Composite responder #1 was defined a-priori as a percent reduction from baseline in penile curvature of ≥20% and mean reduction from baseline in patient-reported  PD  bother  score  of  ≥1  or  a  change  from  having  no  vaginal  intercourse  at screening  to  having  vaginal  intercourse  during  the  study.  The  threshold  values  for  percent reduction in curvature deformity and mean change in patient-reported bother in this analysis were based on data from the Phase 2b study (AUX-CC-801).

The composite responder #1 analysis represents a sensitivity analysis because it incorporates two groups of subjects who were not counted in the mITT population as follows:

- ITT subjects  who  were  not  having  vaginal  intercourse  at  baseline  but  who  began  having  vaginal intercourse during the study were considered 'responders'.

- ITT subjects who were having vaginal intercourse at baseline but had no vaginal intercourse during the study were considered 'non-responders'.

- Change from baseline in penile pain of the PDQ in a subset of subjects with a baseline pain score of at least 4

## Tertiary Endpoint

A tertiary endpoint was planned a-priori where the threshold values for percent reduction from baseline in curvature deformity and mean reduction from baseline in patient-reported PD bother score were to be determined  post-hoc  from  the  data  collected  in  Phase  3  Studies  AUX-CC-803  and  AUX-CC-804  (ie, composite  responder  #  2).  The  PD  bother  threshold  value  of  2  was  based  on  the  treatment responsiveness analysis as described in Appendix J.2 of the PRO Dossier.

- Composite responder #2 (ITT population): Composite responder #2 was defined as a percent reduction from baseline in patient-reported PD bother score of ≥2 or a change from having no vaginal intercourse at screening to having vaginal intercourse during the study

Post- hoc analyses based on the mITT population and on the percent reduction in curvature deformity and the change in bother were defined for the Summary of Clinical Efficacy.

- Composite responder #3 (mITT population): Composite responder #3 was defined as a percent reduction from baseline in penile curvature of ≥20% and reduction from baseline in PD bother score of ≥1.
- Composite responder #4 (mITT population): Composite responder #4 was defined as a percent reduction from baseline in penile curvature of ≥20% and reduction from baseline in PD bother score of ≥2.

Medicinal product no longer authorised

## Side-by-Side Efficacy Analyses

Efficacy  results  for  the  co-primary  and  the  seven  secondary  efficacy  parameters  are  presented side-by-side  for  each  of  the  double-blind,  placebo-controlled  clinical  studies  (AUX-CC-803  and AUX-CC-804) to allow direct comparison of the results from each study.

A multiple comparison algorithm was utilized for the co-primary and the secondary endpoints in each of these studies. Inferential statistics were used to determine significant treatment effects on the efficacy parameters. The analysis of variance (ANOVA) model used the factors of treatment and severity of baseline curvature deformity.

## Sample size

An analysis was performed in the AUX-CC-801 study to determine how to define a clinically meaningful change in the bother domain of the PDQ as it relates to improvement in penile curvature.

<div style=\"page-break-after: always\"></div>

This analysis was based on the global assessment question (GAQ5) \"Since you began your treatment has there been an overall change in the symptoms and effects of Peyronie's disease in your life?\". It was determined  that  a  2.2  point  change  in  the  bother  domain  of  the  PDQ  corresponded  to  clinical improvement and on the basis of this information, a delta of 2.2 for improvement in the Bother domain was selected for the Phase 3 protocol sample size calculations.

For both pivotal trials: The sample size of 252 subjects with an allocation (2:1) of 168 to active and 84 to placebo would have a power of at least 95% to detect a change in curvature deformity (delta=19%, SD=30%) and bother (delta=2.2, SD=4.5). To have a sufficient safety database, to account for a 15% dropout  rate,  and  to  account  for  subjects  who  may  not  have  qualified  for  the  mITT  population, approximately 400 subjects were planned, with 267 randomized to active and 133 to placebo.

## Randomisation

Before dosing, subjects were stratified by degree of penile curvature (ie, 30º to 60º or &gt;60º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo.

## Blinding (masking)

- Investigator, study subject, and other study personnel were blinded to study drug treatment. Unblinding was not be permitted unless it was deemed necessary for appropriate treatment of a medical emergency. The  study  site  had  the  ability  to  immediately  determine  treatment  identification  in  the  event  of  an emergency by swiping the label portion of the drug kit with an alcohol pad. Statistical methods Efficacy Analysis Populations The predefined efficacy analysis populations are as follows: · Intent-to-Treat (ITT) Population: A total of 832 subjects (AA4500, N=551; placebo, N=281) who received at least one dose of study drug in one of the double-blind studies (AUX-CC-803 or AUX-CC-804). Subjects were included regardless of their eligibility to complete the PDQ or the existence of curvature deformity measurements. · Modified Intent-to-Treat (mITT) Population: The mITT population is the pre-specified efficacy population. A total of 612 intent-to-treat subjects (AA4500, N=401; placebo, N=211) who had both  a  curvature  deformity  measurement  and  a  PDQ  response  at  baseline  and  at  least  one subsequent time point in their respective double-blind studies were included in the mITT. The mITT population appropriately did not include 220 subjects for the reasons shown in the Table below. Most (n=154) of these subjects were ineligible to complete the PDQ because they reported no  vaginal  intercourse  within  3  months  before  the  screening  visit,  and  consequently  were ineligible for the mITT population. All 220 of these subjects were allowed to enroll in the study and were included in the ITT population and followed for safety. Medicinal product no longer authorised

## Table 3: mITT Population

| NumberofITTsubjectsineligibleforthemITTpopulationas prescribed bytheprotocol:                                                | 220   |
|------------------------------------------------------------------------------------------------------------------------------|-------|
| Reasons:                                                                                                                     |       |
| Novaginalintercoursewithin3monthsbeforescreening.                                                                            | 154   |
| Hadvaginalintercoursewithin3monthsbeforescreeningbutdidnot completethePDQevaluation atanyof thepost-screeningvisits.         | 38    |
| Hadvaginalintercoursewithin3monthsofscreeningbutreportedno vaginalintercoursewithin3monthsofanypost-screeningPDQ evaluation. | 25    |
| Protocolviolations: Nopost-screening curvature deformitymeasurements(n=2) Receivedverapamil(n=1)                             | 3     |

<div style=\"page-break-after: always\"></div>

## Efficacy Analyses

## Multiple Comparison Algorithm Summary: Studies AUX-CC-803, AUX-CC-804, and the Meta-Analysis

For  both  the  individual  studies  and  the  meta-analysis,  individual  p-values  (i.e.,  observed  p-values) formed a basis for multiple comparisons with type 1 error controlled for the a-priori efficacy endpoints. The overall type 1 error rate was 0.05. Gatekeeping procedures were used to control the family-wise error rate between families of efficacy endpoints (primary and secondary endpoints). The tests of the two co-primary endpoints were the gatekeepers (serial gatekeeping procedure) for the secondary efficacy endpoints (SE). The global test for the family SE#1 of secondary endpoints was the gatekeeper (parallel gatekeeping  procedure)  for  the  family  SE#2  of  secondary  endpoints.  Within  each  family  of  efficacy endpoints, multiple tests to control family-wise error were as shown in the Table below.

## Table 4: MultipleComparisonsforEfficacyEndpointsinStudiesAUX-CC-803and AUX-CC-804and theMeta-Analysis

|                   | no longer authorised   |
|-------------------|------------------------|
| Medicinal product |                        |

<div style=\"page-break-after: always\"></div>

| Type of Endpoints          | EfficacyEndpoint                                                                                                                                                                                                                                                              | Evaluate Timepointa   | StatisticalInference                                                                                                                                                                                                                                                                                                                                                                                      |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Secondary Family #2 (SE#2) | Changefrombaselinein penile plaque consistency score Changefrombaselinein penile length Compositeresponderbased onchangeinpenilecurvature andchangeinPDbother (ITTpopulation[composite responder #1]) Changefrombaselinein the penilepain scoreofthePDQ imsubjectswithpain at | Week 52 (LOCF)        | Oneormoresecondaryendpoints inthefamily#1（SE#1)and adjustedoverallforsecondary endpointsinthefamily #2（SE#2) must besignificantin order to furthertestsecondaryendpointsm thefamily #2（SE#2) Two-sided, overall level of significance = 0.05/(4-s1) where s isnumberofstatisticallysignificant testsforsecondaryendpointsintlhe family#1(SE#1) Hochberg (1988)procedure is used formultiplecomparisonsfor |

## Results

## Participant flow

A total of 832 subjects (AA4500 551 and placebo 281) were enrolled and received up to four treatment cycles (total of up to 8 injections) of AA4500 or placebo to treat the primary penile plaque causing the curvature deformity. The majority (~90%) of subjects in each treatment group completed the study (Table below).

Table 6:

<!-- image -->

Medicinal product no longer authorised

| Medicinal   |
|-------------|

Data source:ISS Table 14.1.1

## Recruitment

Study AUX-CC-804:

First Subject Enrolled 04 October 2010

<div style=\"page-break-after: always\"></div>

Last Subject Completed 30 March 2012

Study AUX-CC-804:

First Subject Enrolled 30 September 2010

Last Subject Completed 11 April 2012

## Conduct of the study

Three amendments to the original protocols were carried out which are not considered to influence on the conduct of the study.

## Baseline data

Demographics

Demographics (Table below) were similar between the AA4500 and placebo groups at baseline. The vast majority (&gt;95%) of subjects were white. Most subjects were between the ages of 45 to 64 years. The distribution of degree of curvature deformity at baseline was also similar between treatment groups.

Table 7:

|                   | no longer   |
|-------------------|-------------|
| Medicinal product |             |

Medicinal product no longer authorised

Data source:ISS Table 14.1.2

<div style=\"page-break-after: always\"></div>

## Peyronie's Disease Risk Factors and History

Risk factors for Peyronie's disease were similar between the AA4500 and placebo groups at baseline (Table below). On average, subjects had a history of Peyronie's disease for 4 years. Approximately 50% of subjects in each group reported a history of erectile dysfunction and approximately 25% experienced trauma to the penis. The most commonly used medical treatment for Peyronie's disease was Vitamin E.

Table8: SubjectHistoryandRiskFactorsAssociatedWithPeyronie'sDisease, Intent-to-TreatSubjectsStudies-AUX-CC-803and AUX-CC-804

|         | authorised   |
|---------|--------------|
|         | no longer    |
| product |              |

## Numbers analysed

In these pivotal studies, a total of 832 subjects with Peyronie's disease were enrolled in the United States and Australia. For details on the predefined efficacy analysis populations see above chapter 'Statistical methods'.

## Outcomes and estimation

## Co-primary endpoint results

The co-primary endpoints were achieved in each of the double-blind, placebo-controlled studies; i.e., AA4500 was statistically significantly superior to placebo with respect to the percent improvement from baseline  in  curvature  deformity  and  the  improvement  from  baseline  in  patient-reported  Peyronie's disease bother based on the multiple comparison algorithm.

## Percent Change in Curvature Deformity

Mean  curvature  deformity  at  baseline  was  similar  between  treatment  groups  in  both  studies  and consistent  across  both  studies.  As  shown  in  the  Table  below,  AA4500  was  consistently  superior

<div style=\"page-break-after: always\"></div>

(p≤0.0059) to placebo with respect to the percent improvement from baseline in curvature deformity in both studies.

Table10: MeanPercentChangeinCurvatureDeformityFromBaselinetoWeek52 StudiesAUX-CC-803andAUX-CC-804,ModifiedIntent-to-Treat

|                                   | AUX-CC-803    | AUX-CC-803    | AUX-CC-804    | AUX-CC-804    |
|-----------------------------------|---------------|---------------|---------------|---------------|
|                                   | AA4500 N=199  | Placebo N=104 | AA4500 N=202  | Placebo N=107 |
| Curvaturedeformity(degrees):      |               |               |               |               |
| Baseline                          |               |               |               |               |
| Mean (SD)                         | 48.8°(13.90)  | 49.0°(13.89)  | 51.3° (14.77) | 49.6° (14.06) |
| Week 52                           |               |               |               |               |
| Mean (SD)                         | 31.0° (18.05) | 39.0° (17.72) | 35.1°(15.13)  | 41.1° (14.0)  |
| %changefrombaseline               | -37.6%        | -21.3%        | -30.5%        | -15.2%        |
| Observed p-valueb                 | 0.0005        |               | 0.0059        |               |
| p-valuebasedonmultiplecomparision |               |               |               |               |

Datas0urce:AUX-CC-803CSRTable14.2.3.1;AUX-CC-804CSRTable14.2.3.1

The mean reduction from baseline in curvature deformity over time (Figure below) and the mean percent improvement from baseline in curvature deformity over time (not shown here in detail, please refer to study report) were statistically significantly greater in the AA4500 group compared with the placebo group in both studies starting at Week 24 (approximately 6 weeks after the fourth treatment cycle) and continued through Week 52.

<!-- image -->

Medicinal product no longer authorised

AUX-CC-803CSRTable14.2.3.1

Week52:Lastobservationcariedforward(LoCF)

p-valuesarebasedonanANOVAwithfactorsfordrugstratumofbaselinecurvaturedeformityandtheirinteraction.P-value forthecomparisonofreductionfrombaselinetoWeek52(LOCF)ofAA4500versusplacebo.

<div style=\"page-break-after: always\"></div>

Figure 4: MeanDegreeofCurvatureDeformityOvertheTreatmentandFollow-up Periods-StudyAUX-CC-804

<!-- image -->

## PDQ Patient-Reported Peyronie's Disease Bother

The  PDQ  is  a  disease-specific  15-item,  self-administered,  paper-and-pencil  instrument  designed  to measure the psychosexual consequences of PD. The PDQ assesses the impact of PD in the following three domains:  Peyronie's  Psychological  and  Physical  Symptoms  (6  items),  Penile  Pain  (3  items),  and Peyronie's Symptom Bother (6 items).

Peyronie's disease bother as measured by the PDQ included: bother associated with painful erections; bother associated with appearance of erect penis; bother associated with the impact of Peyronie's disease during intercourse and impact of Peyronie's disease on intercourse frequency. Subjects were asked to rate their bother on a 5-point scale (0 [not bothered at all] to 4 [extremely bothered]) at screening, Week 24, and Week 52.

Medicinal product no longer authorised

The mean patient-reported PD bother score at baseline was similar between treatment groups in both studies  and  was  consistent  across  studies.  As  shown  in  the  Table  and  Figures  below,  AA4500  was consistently superior (p≤0.0496 to placebo in both studies with respect to the mean reduction from baseline in patient-reported PD bother.

<div style=\"page-break-after: always\"></div>

Table 11: MeanChangeinPatient-Reported Peyronie'sDiseaseBotherFromBaseline toWeek52-StudiesAUX-CC-803andAUX-CC-804,MIodifiedIntent-toTreat

|                                   | AUX-CC-803   | AUX-CC-803    | AUX-CC-804   | AUX-CC-804    |
|-----------------------------------|--------------|---------------|--------------|---------------|
|                                   | AA4500 N=199 | Placebo N=104 | AA4500 N=202 | Placebo N=107 |
| Patient-reportedPDbother:         |              |               |              |               |
| Baseline Mean (SD)                | 7.5 (3.51)   | 7.4 (3.57)    | 7.4 (3.56)   | 8.2 (3.72)    |
| Week 52a                          |              |               |              |               |
| Mean (SD)                         | 4.2 (3.71)   | 5.4 (3.78)    | 5.0 (3.93)   | 6.5 (4.20)    |
| Changefrombaseline                | -3.3         | -2.0          | -2.4         | -1.6          |
| Observedp-valueb                  | 0.0451       |               | 0.0496       |               |
| p-valuebasedonmultiplecomparisond |              |               |              |               |

Mean patient-reported Peyronie's disease bother over time is depicted for AUX-CC-803 and AUX-CC-804 in the Figures below.

<!-- image -->

Medicinal product no longer authorised

Data source:AUX-CC-803CSRTable14.2.4.3.1

Week52=Lastobservationcaiedforward(LOCF)

P-valuebasedonanANOVAwithfactorsfordrugstratumofbaselinecurvaturedefomity，andtheirinteraction.

P-valuesbasedonthechangefrombaseline toWeek52(LoCF)ofAA4500versusplacebo.

PDBotherScore:0-16.Highernumbersrepresentgreaterbother.

<div style=\"page-break-after: always\"></div>

Figure 8: MeanPatient-ReportedPeyronie'sDiseaseBotherOverTime atBaseline, Week24andWeek52-ModifiedIntent-to-TreatinStudyAUX-CC-804

<!-- image -->

Co-Primary Endpoints by Curvature Deformity Stratum

## Curvature deformity reduction

A clinically meaningful response to treatment with AA4500 at Week 52 (LOCF) was observed regardless of baseline curvature deformity stratum (Table below, study AUX-CC-803). It should be noted that the number of subjects with a curvature deformity of 61º to 90º at baseline (36 AA4500 subjects and 17 placebo subjects) was lower than that of subjects with a curvature deformity 30º to 60º at baseline (163 AA4500 subjects and 87 placebo subjects).

Table 24:

|                       | 30°to60° N=250)   | 30°to60° N=250)   | 06019 (N=53)   | 06019 (N=53)   |
|-----------------------|-------------------|-------------------|----------------|----------------|
|                       | AA4500 (N=163)    | Placebo (N=87)    | AA4500 (N=30)  | Placebo (N=17) |
| Baseline value        |                   |                   |                |                |
| Mean (SD)             | 43.7 (9.03)       | 44.6 (9.74)       | 72.0 (6.37)    | 71.9 (8.10)    |
| Min, Max              | 30,60             | 30,60             | 62,85          | 61,89          |
| Weelk 52 value (L0CF) |                   |                   |                |                |
| Mean (SD)             | 26.8 (14.84)      | 34.4 (14.56)      | 50.2 (19.03)   | 62.4 (13.66)   |
| Min, Max              | 0,79              | 0.65              | 0,90           | 32,79          |
| %change frombaseline  |                   |                   |                |                |
| Mean (SD)             | -39.1 (31.46)     | -22.9 (31.21)     | -30.9 (23.51)  | -12.8 (20.60)  |
| Min, Max              | -100,66           | -100,94           | -100,6         | -51,30         |

Medicinal product no longer authorised

Data source:Table14.2.3.2

## PDQ Bother scale

<div style=\"page-break-after: always\"></div>

In general at baseline, subjects with a curvature deformity 30° to 60º at baseline had as much bother as those  with  curvature  deformity  61º  to  90°  at  baseline  (Table  below,  study  AUX-CC-803).  A  mean decrease in Peyronie's disease bother score was observed regardless of baseline curvature deformity stratum, with the treatment difference favouring AA4500 over placebo.

Table 25: MeanChangeFromBaselineinPeyronie'sDiseaseBotlherScoreat Week52(LOCF)byBaselineCurvatureDeformityStratum (mITT Population)

|                    | BaselineCurvatureDefornityStratun   | BaselineCurvatureDefornityStratun   | BaselineCurvatureDefornityStratun   | BaselineCurvatureDefornityStratun   |
|--------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                    | 30°to60° N=250)                     | 30°to60° N=250)                     | 06019 (N=53)                        | 06019 (N=53)                        |
|                    | AA4500 (N=163)                      | Placebo (=87)                       | AA4500 N=30                         | Placebo (N=17)                      |
| Baseline value     |                                     |                                     |                                     |                                     |
| Mean (SD)          | 7.6 (3.41)                          | 7.0 (3.61)                          | 7.0 (3.97)                          | 9.2 (2.83)                          |
| Min,Max            | 0,15                                | 1,15                                | 0,15                                | 5.14                                |
| Weel52value (L0CF) |                                     |                                     |                                     |                                     |
| Mean (SD)          | 4.0 (3.44)                          | 4.9 (3.59)                          | 5.1 (4.70)                          | 8.2 (3.63)                          |
| Min, Max           |                                     |                                     |                                     | 2.13                                |
| Mean (SD)          |                                     |                                     |                                     | -1.0 (3.37)                         |
| Min, Max           |                                     |                                     |                                     | -8.4                                |

## Secondary endpoints

Evaluation  of  the  secondary  endpoints  (SE)  was  robust,  with  a  hierarchical  testing  procedure prospectively defined in both studies. The hypotheses of secondary endpoints in the family SE#1 were tested  only  when  both  co-primary  endpoints  were  statistically  significant  (p-value  ≤  0.05),  while secondary endpoints in the family SE#2 were tested only when at least one of the secondary endpoints in the family #1 was statistically significant.

## First Family of Secondary Endpoints (SE#1)

The  first  family  of  secondary  endpoints  includes  incidence  of  responders  based  on  overall  global assessment of the symptoms and effects of PD; change from baseline in PDQ PD symptom score; and change from baseline in IIEF

## Responders Based on Overall Global Assessment of the Symptoms and Effects of Peyronie's Disease

At Week 24 and Week 52, subjects were asked to assess and record the overall change (much improved to much worse) in the symptoms and effects of Peyronie's disease in their lives. A responder was defined as a subject who recorded that his Peyronie's disease was improved in a small but important way; was moderately improved; or was much improved following treatment.

Medicinal product no longer authorised

As shown in the Table below, AA4500 was consistently superior (based on the multiple comparison algorithm) to placebo in both studies with respect to the percentage of responders (ie, improvement in the symptoms and effects of Peyronie's disease).

<div style=\"page-break-after: always\"></div>

Table 12: PercentRespondersatWeek52BasedonOverallGlobalAssessmentofthe SymptomsandEffectsofPeyronie'sDisease-StudiesAUX-CC-803and AUX-CC-804,ModifiedIntent-to-Treat

|                                        | AUX-CC-803   | AUX-CC-803    | AUX-CC-804   | AUX-CC-804    |
|----------------------------------------|--------------|---------------|--------------|---------------|
| Week52a                                | AA4500 N=199 | Placebo N=104 | AA4500 N=202 | Placebo N=107 |
| Much worse (-3)                        | 4 (2.0)      | 1 (1.0)       | 3 (1.5)      | 5 (4.7)       |
| Moderatelyworse(-2)                    | 5 (2.5)      | 4 (3.9)       | 9 (4.5)      | 2 (1.9)       |
| A littleworse(-1)                      | 8 (4.0)      | 8 (7.8)       | 15 (7.4)     | 12 (11.2)     |
| Stayedaboutthesame(O)                  | 50 (25.3)    | 60 (58.3)     | 63 (31.2)    | 56 (52.3)     |
| Improved ina small butimportantway(+1) | 35 (17.7)    | 9 (8.7)       | 25 (12.4)    | 14 (13.1)     |
| Moderately improved (+2)               | 39 (19.7)    | 11 (10.7)     | 49 (24.3)    | 8(7.5)        |
| Much improved (+3)                     | 57 (28.8)    | 10 (9.7)      | 38 (18.8)    | 10 (9.3)      |
| Missing                                |              | 1             | 0            |               |
| Responder, N (%):                      |              |               |              |               |
| No                                     | 67 (33.8)    | 73 (70.9)     | 90 (44.6)    | 75 (70.1)     |
| Yes                                    | 131 (66.2)   | 30 (29.1)     | 112 (55.4)   | 32 (29.9)     |
| Missing                                | 1            | 1             | 0            | 0             |
| Observed p-valueb                      |              |               |              |               |

a

In  both  studies,  there  were  strong  correlations  between  improvement  in  each  of  the  co-primary endpoints, and improvement based on the overall global assessment of the symptoms and effects of Peyronie's disease.

- Subjects who reported 'improved' symptoms and effects of Peyronie's disease in their lives had a mean reduction of at least a 20% from baseline in curvature deformity compared with those subjects who reported 'stable or worsening' symptoms and effects of Peyronie's disease (Figures below).

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 9: MeanPercentImprovementinCurvatureDeformitybySubjectGlobal AssessmentofPeyronie'sDisease-ModifiedIntent-to-TreatSubjectsWho ReceivedAA4500inStudyAUX-CC-803

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

Data source:data onfile

Week52:Lastobservationcamiedforward(LoCF)

Thedottedlinerepresentstheseparationbetweenrespondersandnonresponders.

<div style=\"page-break-after: always\"></div>

- Subjects who reported 'improved' symptoms and effects of Peyronie's disease in their lives had a mean reduction of at least one point from baseline in their Peyronie's disease bother symptom score compared with those subjects who reported 'stable or worsening' symptoms and effects of Peyronie's disease (Figures below).

Figure 10: MeanreductioninPatient-ReportedPDBother bySubject Global AssessmentofPeyronie'sDisease-ModifiedIntent-to-TreatSubjectsWho Received AA4500 inStudy AUX-CC-803

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 12: MeanReductioninPatient-ReportedPDBotherbySubjectGlobal Assessment-ModifiedIntent-to-TreatSubjectsWhoReceivedAA4500in Study AUX-CC-804

<!-- image -->

## PDQ Patient-Reported Peyronie's Disease Physical and Psychological Symptoms

Peyronie's disease physical and psychological problems as measured by the PDQ included: concern about damaging penis; bending or collapsing of penis; trouble inserting erect penis; and difficulty, awkwardness or discomfort with some sexual positions. Subjects were asked to rate the severity of each question on a 5-point scale (0 [none] to 4 [very severe]) at screening, Week 24, and Week 52.

The mean patient-reported PD symptom score at baseline was similar between treatment groups in both studies and consistent across studies. Although there was greater improvement (decrease) from baseline in  the  severity of  PD physical and psychological symptoms in the AA4500 group compared with the placebo group in both studies, the difference between the groups was not statistically significant based on the multiple comparison algorithm (Table below).

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 13: MeanChangeinPatient-ReportedPeyronie'sDiseasePhysicaland PsychologicalSymptomsFromBaselinetoWeek52-StudiesAUX-CC-803 andAUX-CC-804,ModifiedIntent-to-Treat

|                                      | AUX-CC-803   | AUX-CC-803    | AUX-CC-804   | AUX-CC-804    |
|--------------------------------------|--------------|---------------|--------------|---------------|
| Week 52a                             | AA4500 N=199 | Placebo N=104 | AA4500 N=202 | Placebo N=107 |
| Patient-reportedPDsymptoms: Baseline |              |               |              |               |
| Mean (SD)                            | 10.9 (5.14)  | 9.9 (4.97)    | 10.6 (4.82)  | 11.2 (5.14)   |
| Week52                               |              |               |              |               |
| Mean (SD)                            | 7.7 (5.37)   | 8.4 (5.10)    | 8.0 (5.29)   | 10.2 (5.87)   |
| Changefrombaseline                   | -3.2         | -1.6          | -2.6         | -1.0          |
| Observed p-valueb                    | 0.0268       |               | 0.0340       |               |
| p-alue based on multiple comparison° | NS           |               | NS           |               |

Data source:AUX-CC-803CSRTable14.2.4.1.1;AUX-CC-804CSRTable14.2.4.1.1

a Lastobservationcarriedforward(LoCF)

- b CalculatedusinganANOVAwithfactorsfordrugbaselinecurvaturedeformitystratumandtheirinteraction

C NSrepresentsnotstatisticallysignificantbased onthemultiplecomparison algorithm

## International Index of Erectile Function (IIEF) Overall Satisfaction

Subjects completed the IIEF questionnaire during screening, Week 24, and Week 52 to determine their response  to  each  domain  of  the  IIEF.  The  overall  satisfaction  domain  of  the  IIEF  consisted  of  two questions: 'How satisfied are you with your overall sex life?' and 'How satisfied have you been with your sexual relationship with your partner?'

The mean IIEF overall satisfaction scores at baseline were similar between the treatment groups in both studies and consistent across studies. Although there was greater improvement (increase) in IIEF overall satisfaction domain score in the AA4500 group compared with the placebo group in both studies, the difference  between  the  groups  was  not  statistically  significant  based  on  the  multiple  comparison algorithm (Table below).

Table14:

| Medicinal   |
|-------------|

Medicinal product no longer authorised

AUX-CC-803CSRTab1e14.2.5.5.1;AUX-CC-804CSRTab1e14.2.5.5.1

Lastobservationcamiedforward(LoCF).

- CalculatedusinganANOVAwithfactorsfordrug.baselinecurvaturedeformitystratumandtheirinteraction

NSrepresentsnotstatisticallysignificantbasedonthemultiplecomparisonalgorithm

IEFoverallsatisfactionscore:O-10.Higherscoresindicateimprovedsatisfaction.

## Second Family of Secondary Endpoints (SE#2)

The second family of secondary endpoints includes composite responders based on change in curvature deformity and patient-reported PD bother; change from baseline in penile plaque consistency; change from baseline in penile length; and change from baseline in the PD penile pain score.

## Composite Responder #1

A composite responder #1 was defined as a subject in the ITT population who satisfied the following two criteria:

<div style=\"page-break-after: always\"></div>

- ≥20% reduction from baseline in curvature deformity
- Reduction from baseline in patient-reported PD bother of ≥1 OR a change from having no sexual activity at screening to having sexual activity at the assessment visit

AA4500 was statistically significantly superior to placebo, based on the multiple comparison algorithm, in Study AUX-CC-803 with respect to the percentage of subjects who were composite responders. Although there were more composite responders in the AA4500 group compared with the placebo group in Study AUX-CC-804, the difference between the groups was not statistically significant based on the multiple comparison algorithm (Table below).

Table 15: Composite Responder #1? at Week 52 -Studies AUX-CC-803 and AUX-CC804,Intent-to-Treat

|                           | AUX-CC-803   | AUX-CC-803    | AUX-CC-804   | AUX-CC-804    |
|---------------------------|--------------|---------------|--------------|---------------|
| Week 52b                  | AA4500 N=277 | Placebo N=140 | AA4500 N=274 | Placebo N=141 |
| Compositeresponder,N (%): |              |               |              |               |
| Yes                       |              |               |              | 41 (30.6)     |
| No                        |              |               |              | 93 (69.4)     |
| Missing                   |              |               |              | 7             |
| Observed p-valuec         |              |               |              |               |

b

C

d

## Penile Plaque Consistency

The  consistency  of  the  primary  plaque  in  the  flaccid  penis  was  classified  as  hard  [solid]  =5;  firm throughout  =4;  moderate  firmness=3;  soft=2;  non-palpable=1.  Primary  plaque  consistency  was assessed at baseline, before each treatment cycle, and at Weeks 24, 33, 42, and 52.

More penile plaques classified as 'hard or solid' or 'firm throughout' at baseline became softer after treatment with AA4500; approximately 10% of palpable plaques at baseline became non-palpable after treatment with AA4500 in both studies; however, the difference between the groups was not statistically significant in Studies AUX-CC-803 and AUX-CC-804 based on the multiple comparison algorithm.

## PDQ Patient-Reported Peyronie's Disease Penile Pain

Peyronie's disease pain as measured by the PDQ included: pain/discomfort associated with the penis in the flaccid state; pain/discomfort associated with the penis in the erect state; and pain/discomfort in the penis during vaginal intercourse. Subjects were asked to rate the severity of each question on an 11-point scale (0 [no pain/discomfort] to 10 [extreme pain/discomfort]) at screening, Week 24, and Week 52. Pain is a symptom of Peyronie's disease usually present in the early unstable phase of the disease.

Medicinal product no longer authorised

Pain typically resolves with stabilization of the plaque over time. In both AUX-CC-803 and AUX-CC-804, subjects were enrolled with at least 12 months of PD (stable disease). Therefore, only subjects in the modified intent-to-treat population who had a penile pain score of ≥4 at screening were eligible for this analysis. Only about one third of subjects in both studies had pain scores of at least 4 at baseline.

In both studies, the difference between the treatment groups in improvement from baseline in penile pain was  not  statistically  significant  in  Studies  AUX-CC-803  and  AUX-CC-804  based  on  the  multiple comparison algorithm, suggesting that pain improved over the 52-week study in all subjects who had pain at baseline. Resolution of penile pain over time in men with Peyronie's disease is characteristic of the disease and may explain these findings.

## Meta-Analysis of Secondary Endpoints

<div style=\"page-break-after: always\"></div>

As Studies AUX-CC-803 and AUX-CC-804 were identical in design, data from these two studies were pooled in a meta-analysis (post-hoc) to increase the precision for estimation and to further understand and characterize the secondary efficacy endpoints of AA4500 in the treatment of Peyronie's disease. The same multiple comparison algorithm was utilized for the a-priori co-primary and the secondary endpoints in the meta-analysis.

Evaluation of the secondary endpoints (SE) in the meta-analysis was robust, with a hierarchical testing procedure that was prospectively defined in each individual study. As was carried out in each individual study, the hypotheses of secondary endpoints in the family SE#1 were tested only when both co-primary endpoints were statistically significant (p-value ≤ 0.05), while secondary endpoints in the family SE#2 were  tested  only  when  at  least  one  of  the  secondary  endpoints  in  the  family  #1  was  statistically significant.

## First Family of Secondary Endpoints (SE#1)

The  first  family  of  secondary  endpoints  includes  incidence  of  responders  based  on  overall  global assessment of the symptoms and effects of PD; change from baseline in PDQ PD symptom score; and change from baseline in IIEF overall satisfaction.

## Responders Based on Overall Global Assessment of the Symptoms and Effects of Peyronie's Disease

At Week 24 and Week 52, subjects were asked to assess and record the overall change (much improved to much worse) in the symptoms and effects of Peyronie's disease in their lives. A responder was defined as a subject who recorded that his Peyronie's disease was improved in a small but important way; was moderately improved; or was much improved following treatment.

As shown in the Table below, AA4500 was statistically significantly superior to placebo (based on the multiple  comparison  algorithm)  with  respect  to  the  percentage  of  responders  at  Week  52  (ie, improvement in the symptoms and effects of PD).

Table22:

| Medicinal   |
|-------------|

Medicinal product no longer authorised

Datasource:ISETables14.1.7.1and14.1.7.2

Lastobservation carriedforward(LoCF)

CalculatedusingtheCMH testcontrollingforstratumofcurvaturedeformity atbaselineandstudy.

*Representsstatistical significancebasedonthemultiplecomparisonalgorithm.

## PDQ Patient-Reported Peyronie's Disease Physical and Psychological Symptoms

The mean patient-reported PD symptom score was similar between the AA4500 and placebo groups at baseline. As shown in the Table below, AA4500 was statistically significantly superior to placebo (based on the multiple comparison algorithm) with respect to the improvement (ie, decrease in score) from baseline in patient-reported PD physical and psychological symptoms of Peyronie's disease.

<div style=\"page-break-after: always\"></div>

Table23: Meta-Analysis:MeanChangeinPatient-ReportedPeyronie'sDisease PhysicalandPsychologicalSymptomsFromBaselinetoWeek52,Modified Intent-to-Treat-StudiesAUX-CC-803andAUX-CC-804Pooled

| Week52*                               | AA4500 N=401   | Placebo N=211   |
|---------------------------------------|----------------|-----------------|
| Patient-reported PDsymptoms: Baseline |                |                 |
| Mean(SD)                              | 10.8 (4.98)    | 10.6 (5.09)     |
| Week52a                               |                |                 |
| Mean (SD)                             | 7.9 (5.33)     | 9.3 (5.56)      |
| Changefrombaseline                    | -2.9           | -1.3            |
| Observed p-valueb                     | 0.0021         |                 |
| p-valne based on multiple comparison  |                |                 |

Datasource:ISE Table14.1.3

a Lastobservationcarriedforward(LoCF)

b CalculatedusinganANOVAwithfactorsfordrug,baselinecurvaturedeformitystratumstudy,andtheirinteraction.

*representsstatisticalsignificantbasedonthemultiplecomparison algorithm

PDSymptomScore:0-24.Highernumbersrepresentgreatersymptoms.

## International Index of Erectile Function (IIEF) Overall Satisfaction

<!-- image -->

The  mean  IIEF  overall  satisfaction  scores  were  similar  between  the  AA4500  and  placebo  groups  at baseline. AA4500 was statistically significantly superior to placebo (based on the multiple comparison algorithm) in the mean improvement (increase in score) from baseline in the IIEF overall satisfaction domain (Table below).

Table 24:

| no      |
|---------|
| product |

Medicinal product no longer authorised

## Second Family of Secondary Endpoints (SE#2)

## Composite Responder #1

A composite responder #1 was defined as a subject who satisfied the following two criteria:

- ≥20% reduction from baseline in curvature deformity
- Reduction from baseline in patient-reported PD bother of ≥1 OR a change from having no sexual activity at screening to having sexual activity at the assessment visit

The composite responder #1 analysis represents a sensitivity analysis because it incorporates two groups of subjects who were not counted in the mITT population as follows:

- ITT subjects  who  were  not  having  vaginal  intercourse  at  baseline  but  who  began  having  vaginal intercourse during the study were considered 'responders'.

<div style=\"page-break-after: always\"></div>

- ITT subjects who were having vaginal intercourse at baseline but had no vaginal intercourse during the study were considered 'non-responders'.

As shown in the Table below, AA4500 was statistically significantly superior to placebo (based on the multiple  comparison  algorithm)  with  respect  to  the  percentage  of  subjects  who  were  composite responders #1 at the end of the study.

Table 25: Meta-Analysis:CompositeResponder#1atWeek52,Intent-to-TreatStudiesAUX-CC-803andAUX-CC-804Pooled

| Week 52b                                                                                                                            | AA4500 N=551                                                                                                                        | Placebo N=281                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Compositeresponder:20%Improvement inCurvatureDeformity andReductionof≥linPDBotherScoreorChange FromNoSexualActivitytoSexualActivity | Compositeresponder:20%Improvement inCurvatureDeformity andReductionof≥linPDBotherScoreorChange FromNoSexualActivitytoSexualActivity | Compositeresponder:20%Improvement inCurvatureDeformity andReductionof≥linPDBotherScoreorChange FromNoSexualActivitytoSexualActivity |
| Composite responder,N(%):                                                                                                           |                                                                                                                                     |                                                                                                                                     |
| Yes                                                                                                                                 | 237 (46.6)                                                                                                                          | 74 (28.0)                                                                                                                           |
| No                                                                                                                                  | 272 (53.4)                                                                                                                          | 190 (72.0)                                                                                                                          |
| Missing                                                                                                                             | 42                                                                                                                                  | 17                                                                                                                                  |
| Observedp-valuec                                                                                                                    |                                                                                                                                     |                                                                                                                                     |

sexualactivity.

9

d

## Comparison of Results in Subpopulations in Studies AUX-CC-803 and AUX-CC-804

## Co-Primary Endpoints Subset by Degree of Baseline Curvature Deformity

The  mean  percent  improvement  in  curvature  deformity  was  similar  among  subjects  with  baseline curvature  deformity  between  30  and  45  degrees  (n=194,  34.1%);  those  with  curvature  deformity between 46 and 60 degrees (n=124, 33.3%), and those with curvature deformity between 61 and 90 degrees (n=83, 35.1%). These findings are consistent with the mean percent improvement in curvature deformity that was observed in the AA4500 group overall (n=401, 34.0%).

The  mean  reduction  in  patient-reported  Peyronie's  disease  bother  was  similar  among  subjects  with baseline curvature deformity between 30 and 45 degrees (n=194, 3.1); those with curvature deformity between 46 and 60 degrees (n=124, 2.7); and those with curvature deformity between 61 and 90 degrees  (n=83,  2.5).  These  findings  are  consistent  with  the  mean  reduction  in  patient-reported Peyronie's disease bother that was observed in the AA4500 group overall (n=401, 2.8).

## Co-Primary Endpoints Subset by Selected Intrinsic and Extrinsic Factors

Medicinal product no longer authorised

The  co-primary  endpoints,  percent  change  from  baseline  in  curvature  deformity  and  change  from baseline  in  patient-reported  Peyronie's  disease  bother,  were  analyzed  by  selected  intrinsic  factors (duration of disease, age category, race, history of diabetes [yes or no], history of penile trauma [yes or no], history of prior treatment for Peyronie's disease [yes or no])), IIEF Erectile Function at baseline (≤5 [no sexual activity]; 6 to 16 [moderate/severe, severe erectile dysfunction]; 17-30 [mild/moderate, mild, no erectile dysfunction]), and concomitant PDE5 inhibitor usage (yes, no) and by the extrinsic factor of country location for subjects in the mITT population who received AA4500 in Studies AUX-CC-803 and AUX-CC-804.

## Duration of Disease

When the percent reduction in curvature deformity was analyzed at Week 52 by duration of Peyronie's disease, there appeared to be a trend toward greater improvement in curvature deformity as the duration of PD increased from ≤2 years (n=134, -28.9%), &gt;2 to &lt; 4 years (n=136, -33.8%) to &gt;4 years (n=131, 39.6%). The reduction of penile curvature in the overall population (n=401) was -34.0%.

<div style=\"page-break-after: always\"></div>

Subjects with a duration of disease &gt;4 years also had a greater mean reduction in patient-reported PD bother (-3 vs -2.8 in the overall population).

## Age Category

When mean percent improvement in curvature deformity and mean reduction in patient-reported PD bother  were  analyzed  at  Week  52  by  age  categories,  younger  men  (&lt;45  years,  n=29,  -37.8%  in curvature, -4.7 in Bother domain) tended to have a greater mean percent improvement in curvature deformity and a greater improvement in patient-reported PD bother compared with older men (between 45 and 74 years of age, n=370, -31.3% to -36.0% in curvature, -2.6 to -2.8 in Bother domain).

Patients &gt; 75 years had the lowest deformity reduction (-14.5%) on the one hand, but the highest Bother domain reduction (-5.5) of all age groups on the other hand. Since there were so few (N=2) men who were ≥75 years, no definitive conclusions could be drawn about the efficacy of AA4500 in this age category.

<!-- image -->

| Week52b                                                                                                                             | N=551                                                                                                                               | N=281                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Compositeresponder:20%ImprorementinCurvatureDeformityandImprovementof≥2inPDBotherScoreor ChangeFromNoSexualActivitytoSexualActivity | Compositeresponder:20%ImprorementinCurvatureDeformityandImprovementof≥2inPDBotherScoreor ChangeFromNoSexualActivitytoSexualActivity | Compositeresponder:20%ImprorementinCurvatureDeformityandImprovementof≥2inPDBotherScoreor ChangeFromNoSexualActivitytoSexualActivity |
| Compositeresponder,N(%):                                                                                                            |                                                                                                                                     |                                                                                                                                     |
| Yes                                                                                                                                 | 213 (41.8)                                                                                                                          | 64 (24.2)                                                                                                                           |
| No                                                                                                                                  | 296 (58.2)                                                                                                                          | 200 (75.8)                                                                                                                          |
| Missing                                                                                                                             | 42                                                                                                                                  | 17                                                                                                                                  |
| Observed p-value                                                                                                                    | <0.0001                                                                                                                             |                                                                                                                                     |

Ancillary analyses Composite Responder #2 The composite responder #2 was planned a-priori where the threshold values for percent reduction from baseline in curvature deformity and mean reduction from baseline in patient-reported PD bother score were to be determined post-hoc from the data collected in Phase 3 Studies AUX-CC-803 and AUX-CC-804 (ie, composite responder # 2). The PD bother threshold value of 2 in the composite responder #2 analysis was based on the treatment responsiveness analysis as described in Appendix J.2 of the PRO Dossier (Module 5.3.5.3 [Peyronie's disease]). A composite responder #2 was defined as a subject who satisfied the following two criteria: · ≥20% reduction from baseline in curvature deformity · Reduction from baseline in patient-reported PD bother of ≥2 OR a change from having no sexual activity at screening to having sexual activity at the assessment visit As shown in the Table below, AA4500 was statistically significantly (p&lt;0.0001) superior to placebo for the percentage of subjects who were composite responders #2. Medicinal product no longer authorised Table29:

Datasource:ISETable14.2.1

&gt;20%improvementincurvaturedeformityandimprovementof≥2inPDbotherscoreorchangefromnosexualactivityto sexual activity.

Lastobservationcamiedforward(LoCF).

Basedoncompositeresponder(yes/no)usingCMHtestcontrollingforbaselinecurvaturedeformitystratumandstudy.

Co-Primary Endpoints by Investigative Site in Studies AUX-CC-803 and AUX-CC-804

The distribution of treatment effect for each co-primary endpoint across individual investigator sites support the overall treatment effect observed in each study (ie, AA4500 is statistically superior to placebo

<div style=\"page-break-after: always\"></div>

based on the multiple comparison algorithm). The treatment response was greater in the AA4500 group compared with the placebo group in the majority of the investigative sites in both studies.

<!-- image -->

Neutralizing Antibodies (Nab) Neutralizing Antibodies and Possible Effects on the Efficacy of AA4500 If  neutralizing antibodies were to affect the efficacy of AA4500 (ie, curvature deformity) it would be expected that once a subject develops neutralizing antibodies to AUX-I and/or AUX-II there would be little or no further improvement in curvature deformity with subsequent injections and treatment cycles. To determine  the  potential  clinical  effect  of  neutralizing  antibodies  on  the  efficacy  (ie,  improvement  in curvature deformity) man curvature deformity was assessed in subjects who developed neutralizing antibodies  at  different  time  points  up  to  week  52  and  compared  to  subjects  who  were  neutralizing antibody negative. Medicinal product no longer authorised D -20

There was no clinically meaningful difference between subjects who were neutralizing antibody positive and those who were neutralizing antibody negative in the degree of curvature deformity. Subjects had similar improvements in curvature deformity regardless of their neutralizing antibody status.

<div style=\"page-break-after: always\"></div>

Figure 50: MeanDegreeofImprovementinCurvatureDeformityOverTimeSubsetby SubjectNeutralizingAntibodyStatusatWeek24-StudiesAUX-CC-803and AUX-CC-804Pooled

<!-- image -->

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 1 .  Summary of Efficacy for trial AUX-CC-803

| Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE'S DISEASE   | Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE'S DISEASE   | Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE'S DISEASE   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                               | AUX-CC-803                                                                                                                                                                                                                     | AUX-CC-803                                                                                                                                                                                                                     |
| Design                                                                                                                                                                                                                         | Phase 3, double-blind, placebo controlled study                                                                                                                                                                                | Phase 3, double-blind, placebo controlled study                                                                                                                                                                                |
|                                                                                                                                                                                                                                | Duration of main phase: Duration of run-in phase: Duration of extension phase:                                                                                                                                                 | 12 months not applicable not applicable                                                                                                                                                                                        |
| Hypothesis                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                    |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Treatment groups          | Active                                          | AA4500 0.58 mg Two injections separated by approximately 24 to 72 hours, repeated after 42 days (±5 days) for up to four treatment cycles N=278                                                                                                                                                                                           |
|---------------------------|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment groups          | Placebo                                         | Placebo Two injections separated by approximately 24 to 72 hours, repeated after 42 days (±5 days) for up to four treatment cycles N=140                                                                                                                                                                                                  |
| Endpoints and definitions | Co-primary endpoints                            | Percent change from baseline in curvature deformity Change from baseline total score in Peyronie's disease bother domain of the PDQ                                                                                                                                                                                                       |
| Endpoints and definitions | The first family of secondary endpoints (SE#1)  | included: • responder analysis based on the global assessment of Peyronie's disease • change from baseline in severity of Peyronie's disease symptoms of the PDQ • change in overall satisfaction domain of the IIEF authorised                                                                                                           |
| Endpoints and definitions | The second family of secondary endpoints (SE#2) | • composite responder based on change from baseline in curvature deformity and either Peyronie's disease bother score or the reporting of sexual activity • penile plaque consistency • change in penile length • change from baseline in penile pain of the PDQ in subset of subjects with a baseline pain score of at least 4 no longer |
| Database lock             | 08 May 2012 product                             | 08 May 2012 product                                                                                                                                                                                                                                                                                                                       |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Analysis description                            | analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                             | analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                             | analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Primary analysis The modified intent-to-treat (mITT) population: defined as all ITT subjects who were both in the Peyronie's disease questionnaire (PDQ) and penile measurement (PM) populations. Subjects must have had vaginal intercourse within 3 months of any PDQ assessment. If subjects were not sexually active within 3 months of baseline they could not be included in the primary analysis for efficacy since they were ineligible to complete the PDQ. | Primary analysis The modified intent-to-treat (mITT) population: defined as all ITT subjects who were both in the Peyronie's disease questionnaire (PDQ) and penile measurement (PM) populations. Subjects must have had vaginal intercourse within 3 months of any PDQ assessment. If subjects were not sexually active within 3 months of baseline they could not be included in the primary analysis for efficacy since they were ineligible to complete the PDQ. | Primary analysis The modified intent-to-treat (mITT) population: defined as all ITT subjects who were both in the Peyronie's disease questionnaire (PDQ) and penile measurement (PM) populations. Subjects must have had vaginal intercourse within 3 months of any PDQ assessment. If subjects were not sexually active within 3 months of baseline they could not be included in the primary analysis for efficacy since they were ineligible to complete the PDQ. |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                      | AA4500                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 199                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 104                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Mean %change from baseline in curvature deformity                                                                                                                                                                                                                                                                                                                                                                                                                    | -37.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -21.3 authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | Standard deviation                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30.29                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29.89                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability | Mean change from baseline in PD bother                                                                                                                                                                                                                                                                                                                                                                                                                               | -3.3 longer                                                                                                                                                                                                                                                                                                                                                                                                                                                          | -2.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | Standard deviation                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 3.83 no                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 3.53                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Effect estimate per comparison                  | Mean %change from baseline in curvature deformity product                                                                                                                                                                                                                                                                                                                                                                                                            | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                    | AA4500 versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                  | Mean %change from baseline in curvature deformity product                                                                                                                                                                                                                                                                                                                                                                                                            | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.0005 Significant based on multiple comparison algorithm                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | Mean change from baseline in PD bother Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                    | AA4500 versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimate per comparison                  | Mean change from baseline in PD bother Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0.0451 Significant based on multiple comparison algorithm                                                                                                                                                                                                                                                                                                                                                                                                            |
| Notes                                           | P-values are calculated using ANOVA with factors for drug (TRT), stratum of                                                                                                                                                                                                                                                                                                                                                                                          | P-values are calculated using ANOVA with factors for drug (TRT), stratum of                                                                                                                                                                                                                                                                                                                                                                                          | P-values are calculated using ANOVA with factors for drug (TRT), stratum of                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Secondary endpoint analyses                                                                                                                                                                                                                                                                                  | Secondary endpoint analyses                                                                                                                                                                                                                                                                                  | Secondary endpoint analyses                                                                                                                                                                                                                                                                                  |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                              | AA4500                                                                                                                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                           | 199                                                                                                                                                                                                                                                                                                          | 104                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Incidence of responders based on overall global assessment of PD                                                                                                                                                                                                                                             | 66.2%                                                                                                                                                                                                                                                                                                        | 29.1%                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | Incidence of responders based on overall global assessment of PD                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                            | AA4500 versus placebo                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | Incidence of responders based on overall global assessment of PD                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                                      | <0.0001 Significant based on multiple comparison algorithm                                                                                                                                                                                                                                                   |
| Notes                                           | A Responder is defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question. P-value is calculated using CMH test controlling for stratum of baseline penile curvature. authorised | A Responder is defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question. P-value is calculated using CMH test controlling for stratum of baseline penile curvature. authorised | A Responder is defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question. P-value is calculated using CMH test controlling for stratum of baseline penile curvature. authorised |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                              | AA4500                                                                                                                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                                                                                           | 199                                                                                                                                                                                                                                                                                                          | 104                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Mean change from baseline in PD physical and psychological symptoms                                                                                                                                                                                                                                          | -3.2 longer                                                                                                                                                                                                                                                                                                  | -1.6                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Standard deviation                                                                                                                                                                                                                                                                                           | 5.23 no                                                                                                                                                                                                                                                                                                      | 4.50                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                  | Mean change from baseline in PD physical and psychological symptoms Medicinal product                                                                                                                                                                                                                        | Comparison groups                                                                                                                                                                                                                                                                                            | AA4500 versus placebo                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | Mean change from baseline in PD physical and psychological symptoms Medicinal product                                                                                                                                                                                                                        | P-value                                                                                                                                                                                                                                                                                                      | 0.0268 Not significant based on multiple comparison algorithm                                                                                                                                                                                                                                                |
| Notes                                           | P-values are calculated using ANOVA with factors for drug (TRT), stratum of                                                                                                                                                                                                                                  | P-values are calculated using ANOVA with factors for drug (TRT), stratum of                                                                                                                                                                                                                                  | P-values are calculated using ANOVA with factors for drug (TRT), stratum of                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Treatment group                                                                                                                               | AA4500                                                                                                                                        | Placebo                                                                                                                                       |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                            | 199                                                                                                                                           | 104                                                                                                                                           |
| Descriptive statistics and estimate variability   | Mean change from baseline in IIEF overall satisfaction                                                                                        | 1.0                                                                                                                                           | 0.5                                                                                                                                           |
| Descriptive statistics and estimate variability   | Standard deviation                                                                                                                            | 2.55                                                                                                                                          | 2.42                                                                                                                                          |
| Effect estimate per comparison                    | Mean change from baseline in IIEF overall satisfaction                                                                                        | Comparison groups                                                                                                                             | AA4500 versus placebo                                                                                                                         |
| Effect estimate per comparison                    | Mean change from baseline in IIEF overall satisfaction                                                                                        | P-value                                                                                                                                       | 0.0800 Not significant based on multiple comparison algorithm                                                                                 |
| Notes                                             | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | AA4500                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 277                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 140                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability   | Incidence of composite responder based on change from baseline in curvature deformity and either PD bother or the reporting of sexual activity                                                                                                                                                                                                                                                                                                                                                                             | 50.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                    | Incidence of composite responder based on change from baseline in curvature deformity and either PD bother or the reporting of                                                                                                                                                                                                                                                                                                                                                                                             | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | AA4500 versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                    | Incidence of composite responder based on change from baseline in curvature deformity and either PD bother or the reporting of                                                                                                                                                                                                                                                                                                                                                                                             | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | <0.0001 Significant based on multiple comparison algorithm authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Notes                                             | sexual activity A Responder is defined as a subject who satisfied the following two criteria at that visit: percent reduction from baseline in penile curvature is 20% or more and reduction from baseline in PDQ PD bother score is 1 or more, or change from reporting no sexual activity at Screening to reporting sexual activity. P-value is calculated based on composite responder (Yes or No) using CMH test controlling for stratum of baseline penile curvature. NOTE: the analysis population product no longer | sexual activity A Responder is defined as a subject who satisfied the following two criteria at that visit: percent reduction from baseline in penile curvature is 20% or more and reduction from baseline in PDQ PD bother score is 1 or more, or change from reporting no sexual activity at Screening to reporting sexual activity. P-value is calculated based on composite responder (Yes or No) using CMH test controlling for stratum of baseline penile curvature. NOTE: the analysis population product no longer | sexual activity A Responder is defined as a subject who satisfied the following two criteria at that visit: percent reduction from baseline in penile curvature is 20% or more and reduction from baseline in PDQ PD bother score is 1 or more, or change from reporting no sexual activity at Screening to reporting sexual activity. P-value is calculated based on composite responder (Yes or No) using CMH test controlling for stratum of baseline penile curvature. NOTE: the analysis population product no longer |
| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | AA4500                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 199                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 104                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability   | is ITT. Mean change from baseline in penile plaque consistency Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                   | -0.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | -0.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability   | Standard deviation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.97                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.84                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                    | Mean change from baseline in penile plaque consistency                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | AA4500 versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimate per comparison                    | Mean change from baseline in penile plaque consistency                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.3085 Not significant based on multiple comparison algorithm                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Notes                                             | P-values are calculated based on the difference in penile plaque consistency score from baseline (score @visit - score @baseline) using ANOVA with factors for drug                                                                                                                                                                                                                                                                                                                                                        | P-values are calculated based on the difference in penile plaque consistency score from baseline (score @visit - score @baseline) using ANOVA with factors for drug                                                                                                                                                                                                                                                                                                                                                        | P-values are calculated based on the difference in penile plaque consistency score from baseline (score @visit - score @baseline) using ANOVA with factors for drug                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                  | AA4500                                                                                                                                                           | Placebo                                                                                                                                                          |
|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                               | 199                                                                                                                                                              | 104                                                                                                                                                              |
| Descriptive statistics and estimate variability   | Mean change from baseline in penile length                                                                                                                       | 0.4                                                                                                                                                              | 0.1                                                                                                                                                              |
| Descriptive statistics and estimate variability   | Standard deviation                                                                                                                                               | 1.29                                                                                                                                                             | 1.11                                                                                                                                                             |
| Effect estimate per comparison                    | Mean change from baseline in penile length                                                                                                                       | Comparison groups                                                                                                                                                | AA4500 versus placebo                                                                                                                                            |
| Effect estimate per comparison                    | Mean change from baseline in penile length                                                                                                                       | P-value                                                                                                                                                          | 0.6321 Not significant based on multiple comparison algorithm                                                                                                    |
| Notes                                             | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). authorised         | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). authorised         | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). authorised         |
| Descriptive statistics and estimate variability   | Treatment group                                                                                                                                                  | AA4500                                                                                                                                                           | Placebo                                                                                                                                                          |
| Descriptive statistics and estimate variability   | Number of subjects                                                                                                                                               | 77                                                                                                                                                               | 40                                                                                                                                                               |
| Descriptive statistics and estimate variability   | Mean change from baseline in PD penile pain                                                                                                                      | -5.1                                                                                                                                                             | -4.0                                                                                                                                                             |
| Descriptive statistics and estimate variability   | Standard deviation                                                                                                                                               | 5.16                                                                                                                                                             | 4.09                                                                                                                                                             |
| Effect estimate per comparison                    | Mean change from baseline in PD penile pain                                                                                                                      | Comparison groups no longer                                                                                                                                      | AA4500 versus placebo                                                                                                                                            |
| Effect estimate per comparison                    | Mean change from baseline in PD penile pain                                                                                                                      | P-value                                                                                                                                                          | 0.7965 Not significant based on multiple comparison algorithm                                                                                                    |
| Notes                                             | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). NOTE: mITT product | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). NOTE: mITT product | P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). NOTE: mITT product |

•

- Table 2 .  Summary of Efficacy for trial AUX-CC-804

| • Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE'S DISEASE   | • Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE'S DISEASE   | • Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE'S DISEASE   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Study identifier                                                                                                                                                                                                               | • AUX-CC-804 •                                                                                                                                                                                                                   | • AUX-CC-804 •                                                                                                                                                                                                                   |
| • Design                                                                                                                                                                                                                         | • Phase 3, double-blind, placebo controlled study                                                                                                                                                                                | • Phase 3, double-blind, placebo controlled study                                                                                                                                                                                |
|                                                                                                                                                                                                                                  | • Duration of main phase: • Duration of run-in phase:                                                                                                                                                                            | • 12 months • not applicable                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                             | • Duration of extension phase:                                          | • not applicable                                                                                                                                                                                                                                                                                                                |
|-----------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Hypothesis                | • Superiority                                                           | • Superiority                                                                                                                                                                                                                                                                                                                   |
| • Treatment groups          | • Active                                                                | • AA4500 0.58 mg • Two injections separated by approximately 24 to 72 hours, repeated after 42 days (±5 days) for up to four treatment cycles • N=274                                                                                                                                                                           |
| • Treatment groups          | • Placebo                                                               | • Placebo • Two injections separated by approximately 24 to 72 hours, repeated after 42 days (±5 days) for up to four treatment cycles • N=141                                                                                                                                                                                  |
| • Endpoints and definitions | • Co-pri mary endpo ints • •                                            | • Percent change from baseline in curvature deformity • Change from baseline total score in Peyronie's disease bother domain of the PDQ longer authorised                                                                                                                                                                       |
| • Endpoints and definitions | • The first family of secon dary endpo ints (SE#1 ) • Medicinal product | • included: • responder analysis based on the global assessment of Peyronie's disease • change from baseline in severity of Peyronie's disease symptoms of the PDQ • change in overall satisfaction domain of the IIEF no                                                                                                       |
| • Endpoints and definitions | • The secon d family of secon dary endpo ints (SE#2 )                   | • composite responder based on change from baseline in curvature deformity and either Peyronie's disease bother score or the reporting of sexual activity • penile plaque consistency • change in penile length • change from baseline in penile pain of the PDQ in subset of subjects with a baseline pain score of at least 4 |
| • Database lock             | • 21 May 2012                                                           | • 21 May 2012                                                                                                                                                                                                                                                                                                                   |
| • Results and analysis      | • Results and analysis                                                  | • Results and analysis                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| • Analysis description                            | • Primary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                      | • Primary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                      | • Primary analysis                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Analysis population and time point description  | • The modified intent-to-treat (mITT) population: defined as all ITT subjects who were both in the Peyronie's disease questionnaire (PDQ) and penile measurement (PM) populations. Subjects must have had vaginal intercourse within 3 months of any PDQ assessment. If subjects were not sexually active within 3 months of baseline they could not be included in the primary analysis for efficacy since they were ineligible to complete the PDQ. • | • The modified intent-to-treat (mITT) population: defined as all ITT subjects who were both in the Peyronie's disease questionnaire (PDQ) and penile measurement (PM) populations. Subjects must have had vaginal intercourse within 3 months of any PDQ assessment. If subjects were not sexually active within 3 months of baseline they could not be included in the primary analysis for efficacy since they were ineligible to complete the PDQ. • | • The modified intent-to-treat (mITT) population: defined as all ITT subjects who were both in the Peyronie's disease questionnaire (PDQ) and penile measurement (PM) populations. Subjects must have had vaginal intercourse within 3 months of any PDQ assessment. If subjects were not sexually active within 3 months of baseline they could not be included in the primary analysis for efficacy since they were ineligible to complete the PDQ. • |
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                       | • AA4500                                                                                                                                                                                                                                                                                                                                                                                                                                                | • Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| • Descriptive statistics and estimate variability | • Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                    | • 202                                                                                                                                                                                                                                                                                                                                                                                                                                                   | • 107 authorised                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| • Descriptive statistics and estimate variability | • Mean% change from baseline in curvature deformity                                                                                                                                                                                                                                                                                                                                                                                                     | • -30.5                                                                                                                                                                                                                                                                                                                                                                                                                                                 | • -15.2                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| • Descriptive statistics and estimate variability | • Standard deviation                                                                                                                                                                                                                                                                                                                                                                                                                                    | • 27.70 no longer                                                                                                                                                                                                                                                                                                                                                                                                                                       | • 28.66                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| • Descriptive statistics and estimate variability | • Mean change from baseline in PD bother Medicinal product                                                                                                                                                                                                                                                                                                                                                                                              | • -2.4                                                                                                                                                                                                                                                                                                                                                                                                                                                  | • -1.6                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| • Descriptive statistics and estimate variability | • Standard deviation                                                                                                                                                                                                                                                                                                                                                                                                                                    | • 3.62                                                                                                                                                                                                                                                                                                                                                                                                                                                  | • 3.52                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| • Effect estimate per comparison                  | • Mean% change from baseline in curvature deformity                                                                                                                                                                                                                                                                                                                                                                                                     | • Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                     | • AA4500 versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| • Effect estimate per comparison                  | • Mean% change from baseline in curvature deformity                                                                                                                                                                                                                                                                                                                                                                                                     | • P-value                                                                                                                                                                                                                                                                                                                                                                                                                                               | • 0.0059 • Significant based on multiple comparison algorithm                                                                                                                                                                                                                                                                                                                                                                                           |
| • Effect estimate per comparison                  | • Mean change from baseline in PD bother                                                                                                                                                                                                                                                                                                                                                                                                                | • Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                     | • AA4500 versus placebo                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| • Effect estimate per comparison                  | • Mean change from baseline in PD bother                                                                                                                                                                                                                                                                                                                                                                                                                | • P-value                                                                                                                                                                                                                                                                                                                                                                                                                                               | • 0.0496 • Significant based on multiple comparison algorithm                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| • Notes                                           | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).                                                                                                                                                                         | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).                                                                                                                                                                         | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).                                                                                                                                                                         |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Analysis description                            | • Secondary endpoint analyses                                                                                                                                                                                                                                                                                           | • Secondary endpoint analyses                                                                                                                                                                                                                                                                                           | • Secondary endpoint analyses                                                                                                                                                                                                                                                                                           |
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                                                                                                                                                                                       | • AA4500                                                                                                                                                                                                                                                                                                                | • Placebo                                                                                                                                                                                                                                                                                                               |
| • Descriptive statistics and estimate variability | • Number of subjects                                                                                                                                                                                                                                                                                                    | • 202                                                                                                                                                                                                                                                                                                                   | • 107                                                                                                                                                                                                                                                                                                                   |
| • Descriptive statistics and estimate variability | • Incidence of responder s based on overall global assessme nt of PD                                                                                                                                                                                                                                                    | • 55.4%                                                                                                                                                                                                                                                                                                                 | • 29.9%                                                                                                                                                                                                                                                                                                                 |
| • Effect estimate per comparison                  | • Incidence of responder s based on overall global assessme nt of PD                                                                                                                                                                                                                                                    | • Comparison groups • P-value no longer authorised                                                                                                                                                                                                                                                                      | • AA4500 versus placebo • <0.0001 • Significant based on multiple comparison algorithm                                                                                                                                                                                                                                  |
| • Notes                                           | • A Responder is defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question. • P-value is calculated using CMH test controlling for stratum of baseline penile curvature. Medicinal product | • A Responder is defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question. • P-value is calculated using CMH test controlling for stratum of baseline penile curvature. Medicinal product | • A Responder is defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question. • P-value is calculated using CMH test controlling for stratum of baseline penile curvature. Medicinal product |
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                                                                                                                                                                                       | • AA4500                                                                                                                                                                                                                                                                                                                | • Placebo                                                                                                                                                                                                                                                                                                               |
| • Descriptive statistics and estimate variability | • Number of subjects                                                                                                                                                                                                                                                                                                    | • 202                                                                                                                                                                                                                                                                                                                   | • 107                                                                                                                                                                                                                                                                                                                   |
| • Descriptive statistics and estimate variability | • Mean change from baseline in PD physical and psychologi cal symptoms                                                                                                                                                                                                                                                  | • -2.6                                                                                                                                                                                                                                                                                                                  | • -1.0                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                   | • Standard deviation                                                                                                                                       | • 4.83                                                                                                                                                     | • 4.78                                                                                                                                                     |
|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Effect estimate per comparison                  | • Mean change from baseline in PD physical and psychologi cal                                                                                              | • Comparison groups                                                                                                                                        | • AA4500 versus placebo                                                                                                                                    |
| • Effect estimate per comparison                  | symptoms                                                                                                                                                   | • P-value                                                                                                                                                  | • 0.0340 • Not significant based on multiple comparison algorithm                                                                                          |
| • Notes                                           | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). authorised | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). authorised | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). authorised |
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                          | • AA4500                                                                                                                                                   | • Placebo                                                                                                                                                  |
| • Descriptive statistics and estimate variability | • Number of subjects                                                                                                                                       | • 202                                                                                                                                                      | • 107                                                                                                                                                      |
| • Descriptive statistics and estimate variability | • Mean change from baseline in IIEF overall satisfactio n product                                                                                          | • 1.0 no longer                                                                                                                                            | • 0.3                                                                                                                                                      |
| • Descriptive statistics and estimate variability | • Standard deviation                                                                                                                                       | • 2.33                                                                                                                                                     | • 2.35                                                                                                                                                     |
| • Effect estimate per comparison                  | • Mean change from baseline in IIEF overall satisfactio Medicinal                                                                                          | • Comparison groups                                                                                                                                        | • AA4500 versus placebo                                                                                                                                    |
| • Effect estimate per comparison                  | n                                                                                                                                                          | • P-value                                                                                                                                                  | • 0.1169 • Not significant based on multiple comparison algorithm                                                                                          |
| • Notes                                           | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).            | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).            | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).            |
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                          | • AA4500                                                                                                                                                   | • Placebo                                                                                                                                                  |
| • Descriptive statistics and estimate variability | • Number of subjects                                                                                                                                       | • 274                                                                                                                                                      | • 141                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                   | • Incidence of composite responder based on change from baseline in curvature deformity and either PD bother or the reporting of sexual activity                                                                                                                                                                                                                                                                                                                                                               | • 42.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | • 30.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Effect estimate per comparison                  | • Incidence of composite responder based on change from baseline in curvature deformity and either PD bother or the reporting of sexual • product no                                                                                                                                                                                                                                                                                                                                                           | • Comparison groups P-value longer authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | • AA4500 versus placebo • 0.0249 • Not significant on multiple comparison algorithm                                                                                                                                                                                                                                                                                                                                                                                                                            |
| • Notes                                           | • A Responder is defined as a subject who satisfied the following two criteria at that visit: percent reduction from baseline in penile curvature is 20% or more and reduction from baseline in PDQ PD bother score is 1 or more, or change from reporting no sexual activity at Screening to reporting sexual activity. • P-value is calculated based on composite responder (Yes or No) using CMH test controlling for stratum of baseline penile curvature. NOTE: the analysis population is ITT. Medicinal | • A Responder is defined as a subject who satisfied the following two criteria at that visit: percent reduction from baseline in penile curvature is 20% or more and reduction from baseline in PDQ PD bother score is 1 or more, or change from reporting no sexual activity at Screening to reporting sexual activity. • P-value is calculated based on composite responder (Yes or No) using CMH test controlling for stratum of baseline penile curvature. NOTE: the analysis population is ITT. Medicinal | • A Responder is defined as a subject who satisfied the following two criteria at that visit: percent reduction from baseline in penile curvature is 20% or more and reduction from baseline in PDQ PD bother score is 1 or more, or change from reporting no sexual activity at Screening to reporting sexual activity. • P-value is calculated based on composite responder (Yes or No) using CMH test controlling for stratum of baseline penile curvature. NOTE: the analysis population is ITT. Medicinal |
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | • AA4500                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | • Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| • Descriptive statistics and estimate variability | • Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | • 202                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | • 107                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                   | • Mean change from baseline in penile plaque consistenc y                                                                                                                                                                                                                     | • -0.8                                                                                                                                                                                                                                                                        | • -0.4                                                                                                                                                                                                                                                                        |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                   | • Standard deviation                                                                                                                                                                                                                                                          | • 0.97                                                                                                                                                                                                                                                                        | • 0.86                                                                                                                                                                                                                                                                        |
| • Effect estimate per comparison                  | • Mean change from baseline in penile plaque consistenc y                                                                                                                                                                                                                     | • Comparison groups                                                                                                                                                                                                                                                           | • AA4500 versus placebo                                                                                                                                                                                                                                                       |
| • Effect estimate per comparison                  | • Mean change from baseline in penile plaque consistenc y                                                                                                                                                                                                                     | • P-value                                                                                                                                                                                                                                                                     | • 0.0144 • Not significant based on multiple comparison algorithm                                                                                                                                                                                                             |
| • Notes                                           | • P-values are calculated based on the difference in penile plaque consistency score from baseline (score @ visit - score @ baseline) using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). longer authorised | • P-values are calculated based on the difference in penile plaque consistency score from baseline (score @ visit - score @ baseline) using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). longer authorised | • P-values are calculated based on the difference in penile plaque consistency score from baseline (score @ visit - score @ baseline) using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). longer authorised |
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                                                                                                                                             | • AA4500 no                                                                                                                                                                                                                                                                   | • Placebo                                                                                                                                                                                                                                                                     |
| • Descriptive statistics and estimate variability | • Number of subjects product                                                                                                                                                                                                                                                  | • 202                                                                                                                                                                                                                                                                         | • 107                                                                                                                                                                                                                                                                         |
| • Descriptive statistics and estimate variability | • Mean change from baseline in penile length Medicinal                                                                                                                                                                                                                        | • 0.5                                                                                                                                                                                                                                                                         | • 0.2                                                                                                                                                                                                                                                                         |
| • Descriptive statistics and estimate variability | • Standard deviation                                                                                                                                                                                                                                                          | • 1.34                                                                                                                                                                                                                                                                        | • 1.49                                                                                                                                                                                                                                                                        |
| • Effect estimate per comparison                  | • Mean change from baseline in penile length                                                                                                                                                                                                                                  | • Comparison groups                                                                                                                                                                                                                                                           | • AA4500 versus placebo                                                                                                                                                                                                                                                       |
| • Effect estimate per comparison                  | • Mean change from baseline in penile length                                                                                                                                                                                                                                  | • P-value                                                                                                                                                                                                                                                                     | • 0.0248 • Not significant based on multiple comparison algorithm                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| • Notes                                           | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).          | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).          | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV).          |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Descriptive statistics and estimate variability | • Treatment group                                                                                                                                        | • AA4500                                                                                                                                                 | • Placebo                                                                                                                                                |
| • Descriptive statistics and estimate variability | • Number of subjects                                                                                                                                     | • 87                                                                                                                                                     | • 51                                                                                                                                                     |
| • Descriptive statistics and estimate variability | • Mean change from baseline in PD penile pain                                                                                                            | • -3.8                                                                                                                                                   | • -4.5                                                                                                                                                   |
| • Descriptive statistics and estimate variability | • Standard deviation                                                                                                                                     | • 5.93                                                                                                                                                   | • 5.39                                                                                                                                                   |
| • Effect estimate per comparison                  | • Mean change from baseline in PD penile pain                                                                                                            | • Comparison groups authorised                                                                                                                           | • AA4500 versus placebo                                                                                                                                  |
| • Effect estimate per comparison                  | • Mean change from baseline in PD penile pain                                                                                                            | • P-value longer                                                                                                                                         | • 0.6949 • Not significant based on multiple comparison algorithm                                                                                        |
| • Notes                                           | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). NOTE: no | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). NOTE: no | • P-values are calculated using ANOVA with factors for drug (TRT), stratum of baseline penile curvature (SEV), and their interaction (TRT*SEV). NOTE: no |

## Analysis performed across trials (pooled analyses and meta-analysis)

Because Studies AUX-CC-803 and AUX-CC-804 were identical in design and powered to evaluate the co-primary efficacy endpoints, data from these two studies were pooled in a post-hoc meta-analysis to increase the precision for estimation and to further understand and characterize the secondary efficacy endpoints of AA4500 in the treatment of Peyronie's disease. The same multiple comparison algorithm that was  utilized  for  the  a-priori  co-primary  and  the  secondary  endpoints  in  the  individual  studies  was repeated for the meta analysis. Data is shown in paragraphs above.

Medicinal product no longer authorised

## Clinical studies in special populations

Dedicated studies in special populations were not performed.

## Supportive study

Results from the supportive phase III study AUX-CC-802

The inclusion/exclusion criteria, the efficacy and safety endpoints, and the dosing regimen in this study were identical to the Phase 3 double-blind, placebo-controlled studies (AUX-CC-803 and AUX-CC-804).

The primary purpose of this open-label study was to treat approximately 300 additional subjects, so that when added to the AA4500-treated subjects in the Phase 3 double-blind, placebo-controlled studies, sufficient numbers of AA4500-treated subjects are available to provide an adequate evaluation of safety for the proposed indication.

<div style=\"page-break-after: always\"></div>

One further purpose was to include EU subjects to demonstrate transferability of the overall clinical data package to a EU treatment setting. Demographics, baseline medical condition and PD history between all subjects (incl. US, New Zealand, EU) and EU subjects were largely similar.

## AUX-CC-802 Study Design

Study AUX-CC-802 was a Phase 3 open-label study in which subjects received up to four treatment cycles of AA4500 0.58 mg in the treatment of Peyronie's disease. Subjects were screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle. Enrolment included all subjects who met the eligibility criteria and who received placebo in a previous Auxilium-sponsored study (including the Phase 2b study AUX-CC-801), subjects who received one treatment cycle of AA4500 in the pharmacokinetic study (AUX-CC-805), and naïve subjects in the United States, New Zealand, and Europe. AA4500 was administered and dosed in the same way as in previous phase III trials.

Table37: StudyDrugAssignment

| authorised   |
|--------------|

Most subjects (88.2% all enrolled subjects, 91.1% EU subjects) completed the study. The most common reason for premature discontinuation from the study was withdrawal of consent among all subjects (5.2%) and lost to follow-up in EU subjects (3.1%).

After the final injection (24 to 72 hours) of each treatment cycle, the investigator or qualified designee (ie, qualified by license, education, and training to perform the study procedure according to local, state, and country  requirements)  modeled  the  plaque  in  an  attempt  to  stretch  or  elongate  the  plaque.  If  the subject's penile curvature was reduced to &lt;15° after the first, second, or third cycle of injections or if the investigator determined further treatment was not clinically indicated (eg, adverse events [AEs], allergic reaction), subsequent treatment cycles were not administered. Following the maximum of four treatment cycles, each subject was followed for additional safety and efficacy assessments on Days 168 (±7 days) and 252 (±7 days) (nominal weeks 24 and 36). Enrolment A total of 348 subjects, including 192 EU subjects, were enrolled in the study. 328 subjects were enrolled directly into this study and 20 subjects were rolled over from AUX-CC-805 (pharmacokinetic study). Medicinal product no longer authorised StudyDrug AA45000.58mg

## AUX-CC-802: Demographics

Demographic and baseline characteristics were similar in all subjects and EU subjects. The majority of subjects were white (96.0% all subjects, 97.9% EU subjects) and between 45 and 64 years of age (73.2% all subjects, 77.0% EU subjects). The median age of subjects overall was 57.0 years in all subjects and 55.0 years in EU subjects.

<div style=\"page-break-after: always\"></div>

Table 15: Peyronie'sDiseaseHistory(ITTPopulation)

|                                            | AA4500             | AA4500            |
|--------------------------------------------|--------------------|-------------------|
| Paraneter                                  | All Subjects N=347 | EU Subjects N=191 |
| Duration (years) of Peyronie's disease     |                    |                   |
| Mean (SD)                                  | 2.97 (2.815)       | 2.38 (1.876)      |
| Median                                     | 2.00               | 1.70              |
| Min, Max                                   | 0.6,29.4           | 0.6,15.4          |
| Erectile dysfunction, n (%)                |                    |                   |
| No                                         | 227 (65.4)         | 147 (77.0)        |
| Yes                                        | 120 (34.6)         | 44 (23.0)         |
| Trauma to the penis, n (%)                 |                    |                   |
| No                                         | 290 (83.6)         | 168 (88.0)        |
| Yes                                        | 57 (16.4)          | 23 (12.0)         |
| Family history of Peyronie’s disease,n (%) |                    |                   |
| No                                         | 276 (97.2)         | 156 (96.9)        |
| s                                          | 8 (2.8)            | 5 (3.1)           |
| Unknown                                    |                    |                   |
| No                                         |                    |                   |
| s                                          |                    | 0                 |

Data source:

At screening, most subjects who received at least one dose of AA4500 had no calcification of the penis (62.2% all subjects, 63.4% EU subjects). The majority of subjects who received at least one dose of AA4500 had:

- Curvature deformity between 30º and 60º (69.5% all subjects, 62.8% EU subjects)
- One penile plaque (84.1% all subjects, 80.1% EU subjects)
- Moderate  firmness  or  firm  throughout  plaque  consistency  (77.2%  all  subjects,  75.9%  EU subjects)
- No pain on palpation (84.7% all subjects, 79.1% EU subjects)

The most common (≥10.0% in either population) medical conditions among subjects who received at least one dose of AA4500  included hypertension (29.1%  all subjects, 28.3%  EU  subjects), hypercholesterolaemia (14.7% all subjects, 13.6% EU subjects), and Dupuytren's contracture (10.4% all subjects, 8.4% EU subjects).

The co-primary endpoints were:

Medicinal product no longer authorised

- change/percent change from baseline curvature deformity from baseline to Week 36
- change from baseline total score in PD bother of the PDQ from baseline to Week 36

## Analysis of Efficacy

The visit distribution of Week 36 (LOCF) by primary endpoint in the final analysis is provided for all subjects and EU subjects, respectively.

## Change from baseline in curvature deformity at week 36

Improvement in curvature deformity was similar in all subjects and EU subjects. A statistically significant mean percent improvement of 34.4% and 34.7% in curvature deformity from baseline to Week 36 (LOCF) was observed among all subjects and EU subjects, respectively (Table below).

<div style=\"page-break-after: always\"></div>

Table19: MeanPercentImprovementFromBaselineinCurvatureDeformityat Week36(LOCF) (mITTPopulation)

|                         | AA4500             | AA4500            |
|-------------------------|--------------------|-------------------|
|                         | All Subjects N=238 | EU Subjects N=138 |
| Baselinevalue           |                    |                   |
| Mean (SD)               | 53.0 (14.82)       | 55.7 (15.37)      |
| Min, Max                | 30,90              | 30,90             |
| Week36value(LOCF)       |                    |                   |
| Mean (SD)               | 34.7 (15.26)       | 36.2 (14.81)      |
| Min, Max                | 0,75               | 0,70              |
| Mean%changefrombaseline | -34.4              | -34.7             |
| 95%CIofmean             | -37.6,-31.2*       | -38.6,-30.8*      |

Datasource:Table14.2.2.1andEUTable14.2.2.1

Based on the95%CIofthemeannotincludingzero,thepercentchangefrombaseline wasconsidered statisticallvsignificant

The  mean  degree  of  curvature  deformity  and  mean  percent  change  in  curvature  deformity  were statistically significant at Weeks 24 and 36 (LOCF) for all subjects and EU subjects in the mITT population. The  improvement in  curvature  deformity  began  after  the  first  treatment  cycle  (Week  6);  continued improvement was seen following each dosing cycle (at least 18 weeks after the first injection), and improvement was maintained through Week 36 (LOCF).

<!-- image -->

Medicinal product no longer authorised

Data source:Table 14.2.2.1 andEUTable 14.2.2.1

Note:Week36value isLOCF.

Change from baseline in subject-reported Peyronie's Disease Bother Score

Improvement in subject-reported Peyronie's disease bother score was similar in all subjects and EU subjects. A statistically significant mean reduction of 3.3 and 2.8 in subject-reported Peyronie's disease bother from baseline to Week 36 (LOCF) was observed among all subjects and EU subjects, respectively (Table below).

<div style=\"page-break-after: always\"></div>

Table20: MeanChangeFromBaselineinPeyronie'sDiseaseBotherScoreat Week36(LOCF) (mITTPopulation)

|                    | AA4500             | AA4500            |
|--------------------|--------------------|-------------------|
|                    | All Subjects N=238 | EU Subjects N=138 |
| Baselinevaluie     |                    |                   |
| Mean (SD)          | 7.3 (3.52)         | 6.9 (3.59)        |
| Min, Max           | 0,16               | 0,14              |
| Week36value(L0CF)  |                    |                   |
| Mean (SD)          | 4.1 (3.50)         | 4.1 (3.46)        |
| Min, Max           | 0,15               | 0,15              |
| Changefrombaseline |                    |                   |
| Mean               | -3.3               | -2.8              |
| 95%CIofmean        | -3.7,-2.8*         | -3.4,-2.3*        |

Data source:Table 14.2.3.3.1and EUTable 14.2.3.3.1

Based on the95%CIofthemeannotincludingzero,thechangefrombaselinewasconsideredstatistically significant.

## Secondary Endpoints

Secondary endpoint efficacy results were similar in all subjects and EU subjects.

<!-- image -->

Incidence of Responders Based on Overall Global Assessment of Peyronie's Disease

The incidence of responders based on the overall global assessment of Peyronie's disease at Week 36 (LOCF) was statistically significant in both populations (72.3% all subjects, 71.7% EU subjects).

Table 23:

| product no   |
|--------------|

Medicinal product no longer authorised

Based on the 95% CI of the responder rate not including zero, the responder rate at Week 36 (LOCF) was consideredstatisticallysignificant.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

With study AUX-CC-801 it could be shown that in those patients receiving Xiapex plus modelling the largest treatment effect in terms of %-penile curvature reduction (-32.4%) was achieved as compared to the reduction in the overall Xiapex group with or without modelling (-29.7%) and those patients receiving Xiapex but no modelling (-27.1%). Hence, modelling 24 to 72 hours after the second injection of one treatment cycle was taken forward into subsequent phase III studies AUX-CC-803 and AUX-CC-804.

According  to  the  leading  expert  consensus  paper  (Ralph  et  al.  2010)  correction  of  the  erect  penile deformity (i.e. curve, narrowing, shortening) is the most critical outcome measure. Peyronie's disease has a significant psychological impact on the patient suffering from the disease. In order to introduce a

<div style=\"page-break-after: always\"></div>

subjective  patient-reported  outcome  measure,  the  applicant  had  designed  and  developed  the  first validated  instrument  to  assess  the  psychosexual  consequences  of  PD.  The  PDQ  is  considered  a meaningful  and  acceptable  efficacy  patient  reported  outcome  measure  in  PD  trials.  The  choice  of co-primary endpoints for the pivotal trials was undertaken on the basis of results received from phase IIb study AUX-CC-801

The efficacy of Xiapex was evaluated in two randomized, double-blind, placebo-controlled, multi-centred trials in 832 (ITT) adult males with Peyronie's disease (Studies 803 and 804). At study entry, patients must have had penile curvature deformity of at least 30 degrees in the stable phase of Peyronie's disease. Patients were excluded if they had a ventral curvature deformity, an isolated hourglass deformity or a calcified plaque that could have interfered with the injection technique. At baseline, the mean duration of PD history of included men (mean age 57-58 years) was 3-5 years. Typically for this stable stage of the disease, pain was not an issue for the vast majority of patients, however, mean penile curvature was pronounced at baseline (48-52° degrees). The curvature deformity often leads to significant bother, distress, and sexual dysfunction among PD patients. Patient Bother was quantified by means of the Peyronie's Disease Bother scale (0-16) and was recorded as 7.4-8.2 across treatment groups at baseline (corresponding to the 'moderately bothered' category). The Bother domain score is a composite of the following patient-reported items: concern about erection pain, erection appearance, and the impact of Peyronie's disease on intercourse and on frequency of intercourse. About every second included subject (46.2-53.9% across treatment groups) had a history of erectile dysfunction.

The studies appear to be well designed and adequate to demonstrate efficacy in Peyronie's disease. The chosen  co-primary  endpoints  and  the  definition  of  the  study  population  are  acceptable.  The  set  of secondary and other endpoints is considered appropriate. Furthermore the strategy used to control the type I error for multiplicity of comparisons is appropriate. The conduct of the studies is considered to be according to expectations.

In these trials, patients were given up to 4 treatment cycles of Xiapex or placebo (weeks 0, 6, 12, 18), and were  followed  in  a  non-treatment  follow-up  period  (weeks  24  -52).  In  each  treatment  cycle,  two injections of XIAPEX or two injections of placebo were administered 1 to 3 days apart. A penile modelling procedure was performed on patients at the study site 1 to 3 days after the second injection of the cycle. The treatment cycle was repeated at approximately six-week intervals for up to three additional times, for a maximum of 8 total injection procedures and 4 total modelling procedures. In addition, patients were instructed to perform penile modelling at home for six weeks after each treatment cycle. Before the first dose of study drug was administered, eligible subjects were stratified by the degree of curvature deformity (30 to 60 degrees, and 61 to 90 degrees) and then randomized into two treatment groups to receive either Xiapex or placebo in a 2:1 ratio. The efficacy population (modified intent-to-treat (mITT) population) comprised a total of 612 intent-to-treat subjects who had both a curvature deformity measurement and a PDQ assessment at baseline, and at one or more subsequent time points in Studies 803 and 804, and had engaged in vaginal intercourse within 3 months prior to each PDQ assessment. The pivotal studies 803 and 804 were conducted in Australia and the US. A further open-label study AUX-CC-802 (including 192/348 EU subjects) was conducted to increase the safety database and to obtain  efficacy  and  safety  results  in  European  subjects.  Study  802  did  not  point  to  any  relevant differences between the US/Australian patient population and Europeans in terms of baseline disease conditions and treatment outcome of AA4500. Medicinal product no longer authorised

## Efficacy data and additional analyses

## Co-Primary endpoints

As confirmed by prior CHMP Scientific Advice, the co-primary endpoints were defined as:

- the percent change from baseline to Week 52 in penile curvature deformity and;
- the change from baseline to Week 52 in the Bother domain score of the PDQ

AA4500 0.58 mg was statistically superior to placebo with respect to the co-primary endpoints (ie, curvature deformity and patient-reported Peyronie's disease bother) in both clinical studies:

In  each  study,  men  treated  with  AA4500  had  a  statistically  significant  (p≤0.0059)  greater  percent reduction in curvature deformity compared with men treated with placebo. A relative reduction of penile

<div style=\"page-break-after: always\"></div>

curvature deformity (48.8°-51.3° at baseline) of -37.6% (placebo -21.3%, study 803), resp. -30.5% (placebo -15.2%, study 804) was achieved. Hence, at the end of the 1-year observation period a residual curvature of 31.0°-35.1° remained.

Improvement in curvature deformity was apparent after the first treatment cycle (Week 6) with continued improvement noted after each of the three subsequent treatment cycles. The improvement in curvature deformity  was  maintained  through  the  end  of  each  study  (Week  52).  No  data  are  available  for administration of more than four treatment cycles. Likewise, no data are available on recurrence of penile curvature after more than one year after the first AA4500 injection. The lack of data for more than one course is outlined in the product information and a long term study AUX-CC-810 will be performed to follow  up  on  recurrence  rate,  immunogenicity  (kinetics  of  titre  levels  of  potentially  neutralising collagenase antibodies, long-term effects of MMP cross-allergy), and the potential risks of retreating patients (in relation to immunogenicity) as outlined in the RMP.

Reduction in penile curvature translated in a reduction of patients' bother about PD.

The baseline bother score was 7.4 to 8.2 across treatment arms and studies. Translating the score into bother categories, patients were about moderately bothered at baseline. The PDQ Bother score was assessed at three time points (screening, week 24 and week 52). Hence, increasing reduction of the bother score with increasing number of treatment cycles could not be assessed.

Like already observed for the curvature reduction endpoint, the active and the placebo curves display a similar course with no recurrence of bother between week 24 (assessment of the final injection) and week 52 (end of double-blind treatment period).

At the pre-defined time point at the end of the observation period (week 52), AA4500 was borderline statistically  superior  to  placebo  in  terms  of  PDQ  Bother  score  reduction  (AUX-CC-803:  p=0.0451; AUX-CC-804: p=0.0496).

## Secondary endpoints

When being asked the global assessment / overall change in symptoms at week 52, overall 66% (study AUX-CC-803) resp. 55% (AUX-CC-804) rated themselves as having improved in a small but important way, having moderately improved or even having much improved and were thus defined as responders. These responders had a mean reduction in curvature of at least 20% and a reduction of the PDQ Bother score of at least one point as compared to baseline.

The  observed  reductions  in  curvature  and  PDQ  Bother  score  of  those  rating  themselves  as  having improved (at least in a small but important way) points to the clinical relevance of the therapeutic effect achieved with AA4500 after the four treatment cycles.

Other secondary endpoints (e.g. PDQ Physical and Psychological Symptom Score or International Index of  Erectile  Dysfunction  Overall  Satisfaction  (IIED)  did  not  demonstrate  significant  superiority  over placebo. when both pivotal studies were separately assessed, however, delivered statistical significance in the pooled analysis of study 803 and 804.

Medicinal product no longer authorised

The detection of neutralizing antibodies to either AUX-I or AUX-II did not negatively affect the efficacy of Xiapex in the treatment of PD over the 4-cycle one-year observation period.

## 2.4.4. Conclusions on the clinical efficacy

Overall, it is concluded that the efficacy of AA4500 in adult men in a stable stage of Peyronie's disease was adequately demonstrated for a course of up to four treatment cycles (corresponding to 8 injections) and an observation period of up to one year.

Limitation of the long term data are outlined in the Product information and additional data on recurrence rate, immunogenicity, and the potential risks of retreating patients will be provided post authorisation from study AUX-CC-810 as outlined in the RMP.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

The safety of AA4500 was assessed in 7 clinical studies conducted in subjects with Peyronie's disease (Table 3).

Table 3: Studies Included in the Formal Integrated Safety Database

| Phase 2 Program         | Phase 2 Program                          | Phase 2 Program                           | Phase 2 Program                                | Phase 2 Program                        | Phase 3 Program                                 | Phase 3 Program                        |
|-------------------------|------------------------------------------|-------------------------------------------|------------------------------------------------|----------------------------------------|-------------------------------------------------|----------------------------------------|
| Study Type              | Dose/Regimen Evaluation                  | Dose/Regimen Evaluation                   | Dose/Regimen Evaluation                        | Pharmaco- kinetic                      | Phase 3 Open-Label Program                      | Phase 3 Doubl Program (Ide Studies)    |
| Study Designation       | AUX-CC-1030-PEY                          | AUX-CC-1035-PEY                           | AUX-CC- 801                                    | AUX-CC-805                             | AUX-CC-802                                      | AUX-CC-803                             |
| Number of Subjects      | N=25 AA4500=25                           | N=10 AA4500=10                            | N=147 AA4500=111 Placebo=36 a                  | N=20 AA4500=20 b                       | N=347 (1 c ) AA4500=347 (23 a +20 b +304)       | N=417 (1 c ) AA4500=277 Placebo=140    |
| Injection Regimen       | Six injections 0.58 mg (10,000 U) -M d   | Nine injections 0.58 mg (10,000 U) +M d   | Six injections 0.58 mg +/-M d                  | Two injections 0.58 mg +M d authorised | Eight injections 0.58 mg +M d                   | Eight injections 0.58 mg +M d          |
| Treatment Cycle Regimen | Three injections for two cycles 3 months | Three injections for three cycles 6 weeks | Two injections for three cycles 6 weeks longer | Two injections for one cycle           | Two injections for four cycles 6 weeks          | Two injections for four cycles 6 weeks |
| Start Date              | Nov 1998                                 | Jan 2004                                  | Aug 2008                                       | Sep 2011                               | Nov 2010                                        | Oct 2010                               |
| Location                | United States (One site)                 | United States (One site) no               | United States (multi-site)                     | United States (One site)               | United States, New Zealand, Europe (multi-site) | United States, Australia (multi-site)  |

The integrated electronic safety database includes 1044 subjects who received at least one dose of AA4500 0.58 mg. All subgroup analyses were performed on the Phase 3 Studies analysis population, which includes 898 subjects.

Medicinal product no longer authorised

Four studies (two Phase 1 studies [Gelbard et al., 1985 and Gelbard et al., 1993] and two Phase 2 studies [AUX-CC-1001-PEY  and  AUX-CC-1025-PEY])  were  not  included  in  the  integrated  electronic  safety database (N=245 who received at least one dose of AA4500), since the Phase 1 studies were pilot studies and AUX-CC-1001-PEY and AUX-CC-1025-PEY were terminated during the early stage of development due to lack of efficacy. Results from these studies are presented separately.

Three main integrated analysis populations were analyzed in order to demonstrate the safety of AA4500 in the treatment of Peyronie's disease:

- The Phase 3 Double-Blind, Placebo-Controlled Studies analysis population comprised 551 AA4500 (0.58 mg) subjects and 281 placebo subjects who received at least one injection of double-blind study drug in AUX-CC-803 or AUX-CC-804.
- The Phase  3  Studies  analysis  population comprised  898  subjects  who  received  at  least  one injection of AA4500 (0.58 mg) in AUX-CC-802, AUX-CC-803, or AUX-CC-804. These three studies

<div style=\"page-break-after: always\"></div>

had the same treatment plan, which consisted of four treatment cycles, eight injections per subject, and penile modeling.

- The All Subjects Who Received At Least 1 Dose of AA4500 0.58 mg analysis population (hereafter referred to as the Global Safety analysis population ) comprised 1044 subjects who received at least one injection of AA4500 (0.58 mg) in any of the seven studies included in the integrated electronic safety database. These studies included a mixture of treatment plans.

Additionally,  a  safety  sub-analysis  was  performed  on  those  subjects  from  investigator  sites  in  EU countries that participated in Study AUX-CC-802.

## Patient exposure

The extent of exposure for the Phase 3 Double-Blind, Placebo-Controlled Studies analysis population is summarized in Table 4. Eight hundred thirty-two (832) subjects (551 AA4500 and 281 placebo) received 6215 (4069 AA4500 and 2146 placebo) injections of study drug. The majority of AA4500 (78.8%) and placebo (87.9%) subjects received all eight injections (ie, four treatment cycles) of study drug.

Table 4: Extent of Exposure - Phase 3 Double-Blind, Placebo-Controlled Studies

|         | authorised   |
|---------|--------------|
| longer  |              |
| no      |              |
| product |              |

Data source: ISS Table 14.1.3

The extent of exposure for the Phase 3 Studies analysis population is summarized in Table 5. Eight hundred ninety-eight (898) AA4500 subjects received 6614 injections of study drug. The majority of AA4500 subjects (78.4%) received all eight injections (ie, four treatment cycles) of study drug.

<div style=\"page-break-after: always\"></div>

Table 5: Extent of Exposure - Phase 3 Studies

| authorised   |
|--------------|

The extent of exposure for the Global Safety analysis population is summarized in Table 6. One thousand forty-four (1044) AA4500 subjects received 7466 injections of study drug (mean of 7.0 injections per subject). The majority of AA4500 subjects (67.4%) received eight injections (ie, four treatment cycles) of study drug.

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 6: Extent of Exposure - Global Safety

| longer authorised   |
|---------------------|

## Adverse events

Common Adverse Events: Phase 3 Double-Blind, Placebo-Controlled Studies

Medicinal product no longer authorised

Treatment-emergent AEs occurring in ≥2.0% of subjects in the Phase 3 Double-Blind, Placebo-Controlled Studies analysis population are presented in Table 7.

<div style=\"page-break-after: always\"></div>

Table  7:  Percentage  of  Subjects  With  Treatment-Emergent  (≥2.0%  of  Subjects  in  Either Treatment Group) and Treatment-Related Adverse Events -Phase 3 Double-Blind, Placebo-Controlled Studies

|         | authorised   |
|---------|--------------|
| longer  |              |
| no      |              |
| product |              |

a

b haematomahadtheverbatim\"penilebruising.\"

100% of TEAEs and treatment-related AEs of penile haemorrhage had the verbatim \"penile ecchymosis.\" C

The majority of subjects  with  these  TEAEs  had  events  that  were  considered  treatment-related.  The majority of subjects with events of upper respiratory tract infection, headache, back pain, musculoskeletal pain, and hypertension had events considered by the investigator to be not related to treatment.  None  of  the  events  of  nasopharyngitis,  sinusitis,  or  arthralgia  were  considered  by  the investigator to be related to treatment.

The majority of subjects treated with AA4500 had higher rates of TEAEs and treatment-related AEs compared with subjects treated with placebo. The most frequently reported (≥25.0% of subjects) TEAEs and treatment-related AEs in the AA4500 group were penile haematoma, penile pain, and penile swelling.

## Adverse Events in Support of the Product Label

Due to investigator differences in the use of verbatim terms and the subsequent coding of these terms, some preferred terms were grouped to mitigate this disparity in coding. Specifically, penile ecchymosis

<div style=\"page-break-after: always\"></div>

included events of injection site haematoma (87% of these events had the verbatim 'bruising'), penile haematoma (92.1% of these events had the verbatim 'penile bruising'), contusion, ecchymosis, penile haemorrhage  (100%  of  these  events  had  the  verbatim  'penile  ecchymosis'),  and  injection  site haemorrhage (all events except for one had the verbatim 'ecchymosis'); penile pain included injection site pain, penile pain, and injection site discomfort; and penile swelling included injection site swelling, penile oedema, penile swelling, local swelling, scrotal swelling, and injection site oedema.

Table 8 displays treatment-related AEs (occurring in ≥1.0% of AA4500-treated subjects and at a greater incidence than placebo) for subjects in the Phase 3 Double-Blind, Placebo-Controlled Studies analysis population in  support of  the  product  label,  using  the  grouped  AE  conventions  described  above.  The majority of these treatment-related AEs were confined to the site of injection. The percentage of subjects with  treatment-related  AEs  confined  to  the  site  of  injection  was  higher  in  AA4500-treated  subjects compared to placebo-treated subjects for all treatment-related AEs.

## Table 8: Treatment-Related Adverse Events Occurring in ≥1.0% of AA4500 Subjects and at a Greater Incidence Than Placebo After Up to Four Treatment Cycles - Phase 3 Double-Blind, Placebo-Controlled Studies

|         | authorised   |
|---------|--------------|
| longer  |              |
| no      |              |
| product |              |

a

b

Medicinal product no longer authorised

## Adverse Event Summaries by Population Subgroup

## Baseline IIEF Erectile Function domain score

No clinically meaningful differences in the incidences and severity of TEAEs by baseline IIEF erectile function  domain  score  ( ≤ 5  [no  sexual  activity/no  sexual  intercourse];  6  to  16  [moderate/severe, severe]; 17-30 [mild/moderate, mild, none]) were observed.

## Concomitant PDE5 usage

No clinically meaningful differences in the incidences of TEAEs by concomitant PDE5 usage (yes/no) were observed.

<div style=\"page-break-after: always\"></div>

## Age

Although the incidence of contusion, ecchymosis, local swelling, and injection site discomfort appeared to increase with age, no clinically meaningful comparisons of the incidence of these TEAEs by age group (&lt;45, 45-54, 55-64, 65-74, ≥75 years) could be made due to the variability in the sample size for each age group.

## Race

Due to the small sample size of non-white subjects (N=37) compared to white subjects (N=861), no clinically meaningful comparisons of the incidence of TEAEs between white and non-white subjects could be made.

## Duration of Peyronie's Disease

No clinically meaningful differences in the incidences of TEAEs by duration of Peyronie's disease (≤2 years, &gt;2 to ≤ 4 years, &gt; 4 years) were observed.

## Baseline Penile Curvature Deformity Severity

No clinically meaningful differences in the incidences of TEAEs by baseline penile curvature deformity severity (30-45°, 46-60°, 61-90°) were observed.

## Penile Trauma History

No clinically meaningful differences in the incidences of TEAEs by penile trauma history (yes/no) were observed.

## Diabetes History

No  clinically  meaningful  differences  in  the  incidences  of  TEAEs  by  diabetes  history  (yes/no)  were observed.

## Prior Peyronie's Disease Treatment

No clinically meaningful differences in the incidences of TEAEs by prior Peyronie's disease treatment (yes/no).

## Geographic Location

Some differences in the incidence of specific events (eg, penile haematoma, penile haemorrhage, penile oedema, contusion, ecchymosis) were observed among geographic locations (United States, Australia, Europe); however, these are most likely due to differences in local diagnostic classification of TEAEs.

Medicinal product no longer authorised

## Serious adverse event/deaths/other significant events

## Death

Three of the 1044 AA4500 subjects (two in AUX-CC-803 and one in AUX-CC-804) in the Global Safety analysis population died due to events of:

- Road traffic accident, motorcycle accident (1232-2255).
- Pulmonary embolism (6013-4019): The subject had a history of bronchogenic carcinoma with partial right pneumonectomy and bronchogenic carcinoma metastatic to bone.
- Hypertrophic cardiomyopathy (1209-4963): The subject had a history of atrial fibrillation; atrial flutter;  coronary  artery  disease;  ventricular  tachycardia;  hyperlipidemia;  cerebral  vascular accident; pulmonary hypertension; hypertension; cardiac ablation (x3); and cardiac conversion.

All deaths were considered unrelated to study drug by the investigators. Narratives for all subject deaths have been provided and allow excluding a relation to treatment.

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events

A total of 60 (5.7%) AA4500 subjects in the Global Safety analysis population experienced at least one treatment-emergent SAE. Of these, nine subjects experienced SAEs that were considered by the investigator to be related to study drug (Table 9).

## Table 9: Subjects With Non-Fatal Serious Adverse Events Considered by the Investigator to be Related to Study Drug - Global Safety

<!-- image -->

| Subje ct Numb er   | Ag e           | Preferre d Term/ Verbatim Term                        | Onset Day/ Stop Day Trt Cycle, Inj   | Days to Onset Day Relativ e to Last Injecti   | Severity/ Relations hip   | Action Taken/ SAE Code                                             | Comme nts                                                                                                                                                                                                                        |
|--------------------|----------------|-------------------------------------------------------|--------------------------------------|-----------------------------------------------|---------------------------|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| on AUX-CC-8 02     | on AUX-CC-8 02 | on AUX-CC-8 02                                        | on AUX-CC-8 02                       | on AUX-CC-8 02                                | on AUX-CC-8 02            | on AUX-CC-8 02                                                     | on AUX-CC-8 02                                                                                                                                                                                                                   |
| 1101-7 806         | 6 9            | Penile haemato ma/ Hematom a of penile shaft and base | 24/ 51 1, 2                          | 2 2                                           | Moderat e/ Related        | Drug interrupted/ Inpatient hospitalizati on longer authorised     | Occurred during intercourse with partner in female dominant position. Was hospitalized and underwent ultrasound. Managed conservatively. Subject resumed regularly scheduled injections and completed all four treatment cycles. |
| 1229-8 027         | 4 2            | Fracture of penis/ Corporal rupture                   | 34/ 34 1, 2                          | 3 1 product                                   | Sever e/ Relat ed no      | Drug withdrawn/ Inpatient hospitalizati on                         | Occurred during vigorous sexual intercourse. Surgical repair.                                                                                                                                                                    |
| 5028-7 173         | 3 2            | Penile haemato ma/ Penile bruising Medicinal          | 3/ 4 1, 2                            | 1                                             | Mild/ Probab ly           | Dose not changed/ Inpatient hospitalizati on                       | Mild bruising at the site of injection was noted. Admitted to the hospital overnight and ultrasound revealed no convincing evidence of a tunical or corporal disruption. Resolved spontaneously.                                 |
| AUX-CC-8 03        | AUX-CC-8 03    | AUX-CC-8 03                                           | AUX-CC-8 03                          | AUX-CC-8 03                                   | AUX-CC-8 03               | AUX-CC-8 03                                                        | AUX-CC-8 03                                                                                                                                                                                                                      |
| 1096-3 408         | 4 3            | Fracture of penis/ Corporal rupture                   | 96/1 51 3,2                          | 1 2                                           | Sever e/ Relat ed         | Drug Withdrawn/ Other medically important event                    | History of penile trauma. Occurred during intercourse; subject did not wait the requested 2-week hiatus. Surgical repair.                                                                                                        |
| 1096-3 418         | 5 0            | Penile haemato ma/ Penile hematom a                   | 109/1 92 3,2                         | 1 3                                           | Sever e/ Relat ed         | Drug interrupted/ Persistent or significant disability/ incapacity | Healed spontaneously; subject did not wait the requested 2-week hiatus.                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| 6013-4 028                                                                                                                                                                                                                                                   | 6 7                                                                                                                                                                                                                                                          | Penile haemato ma/ Penile hematom a                                                                                                                                                                                                                          | 40/ 66 2,2                                                                                                                                                                                                                                                   | 2                                                                                                                                                                                                                                                            | Sever e/ Relat ed                                                                                                                                                                                                                                            | Drug withdrawn/ Inpatient hospitalizati on & other medically important event                                                                                                                                                                                 | Ultrasound on Day 61 suggested a possible corporal rupture; as a result, subject underwent , surgical exploration on Day 66 that was notable for cystic hematoma and the absence of any tunical defect.. Nesbit plication performed to correct Peyronie's disease concurrent to hematoma evacuation.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AUX-CC-8 04                                                                                                                                                                                                                                                  | AUX-CC-8 04                                                                                                                                                                                                                                                  | AUX-CC-8 04                                                                                                                                                                                                                                                  | AUX-CC-8 04                                                                                                                                                                                                                                                  | AUX-CC-8 04                                                                                                                                                                                                                                                  | AUX-CC-8 04                                                                                                                                                                                                                                                  | AUX-CC-8 04                                                                                                                                                                                                                                                  | AUX-CC-8 04                                                                                                                                                                                                                                                                                            |
| 1221-5 007                                                                                                                                                                                                                                                   | 6 1                                                                                                                                                                                                                                                          | Penile haemato ma/ Penile hematom a                                                                                                                                                                                                                          | 119/1 83 4,1                                                                                                                                                                                                                                                 | 0                                                                                                                                                                                                                                                            | Sever e/ Relat ed                                                                                                                                                                                                                                            | Drug withdrawn/ Other medically important event authorised                                                                                                                                                                                                   | Occurred the same day as injection. Superficial hematoma with no evidence of tunical or corporal disruption. In-office aspiration yielded 0.5 cc of blood.                                                                                                                                             |
| 1224-5 053                                                                                                                                                                                                                                                   | 2 7                                                                                                                                                                                                                                                          | Fracture of penis/ Corporal rupture                                                                                                                                                                                                                          | 159/1 60 4,2                                                                                                                                                                                                                                                 | 2 9                                                                                                                                                                                                                                                          | Moderat e/ Related no longer                                                                                                                                                                                                                                 | Dose not changed/ Inpatient hospitalizati on                                                                                                                                                                                                                 | History of penile trauma. Intercourse with misthrust and subsequent corporal rupture. Surgical repair.                                                                                                                                                                                                 |
| 6021-6 663                                                                                                                                                                                                                                                   | 6 4                                                                                                                                                                                                                                                          | Fracture of penis/ Corporal rupture                                                                                                                                                                                                                          | 102/1 92 3,2                                                                                                                                                                                                                                                 | 1 5 product                                                                                                                                                                                                                                                  | Mild/ Relat ed                                                                                                                                                                                                                                               | Dose not changed/ Other medically important event                                                                                                                                                                                                            | History of penile trauma. Vigorous sexual intercourse 14 days after Treatment Cycle 3. History of possible prior rupture. Managed conservatively.                                                                                                                                                      |
| Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal | Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal | Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal | Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal | Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal | Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal | Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal | Data source: ISS Table 14.2.12.2; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-803, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection. Medicinal                                           |

One additional subject (5805-7432) experienced a corporal rupture that was not a serious AE according to the investigator.

## Other significant events

## Other Penile Events

Nine  (0.9%)  AA4500  subjects  in  the  Global  Safety  analysis  population  had  a  combination  of  penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile 'popping' sound or sensation and in these cases, a diagnosis of corporal rupture cannot be excluded (Table 10).

## Table 10: Other Penile Events

| Study AUX-CC-802   | Subject 1100-8710   | Popping sensation during spontaneous erection and penile   |
|--------------------|---------------------|------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                  |                   | ecchymosis                                                                                                               |
|------------------|-------------------|--------------------------------------------------------------------------------------------------------------------------|
| Study AUX-CC-802 | Subject 1101-7806 | Detumescence and ecchymosis with negative penile examinations and negative Duplex unltrasound findings                   |
| Study AUX-CC-803 | Subject 1096-3418 | Detumescence and bruising in absence of popping                                                                          |
| Study AUX-CC-803 | Subject 1233-3261 | Mild eggplant bruising and detumescence in absence of a popping sound after attemping intercourse 2 days after injection |
| Study AUX-CC-804 | Subject 1104-5106 | Popping sound followed by immediate penile bruising                                                                      |
| Study AUX-CC-804 | Subject 1104-5116 | Popping and penile ecchymosis that lasted 1 day                                                                          |
| Study AUX-CC-804 | Subject 1199-4601 | Popping and penile bruising while modeling with an erect penis authorised                                                |
| Study AUX-CC-804 | Subject 1202-5151 | Penile bruising and popping                                                                                              |
| Study AUX-CC-804 | Subject 1217-5601 | Hematoma and popping                                                                                                     |

## Adverse Events Leading to Study Discontinuation

Nine (0.9%) AA4500 subjects (four in AUX-CC-802 and five in AUX-CC-804) experienced at least one non-serious TEAE that led to study discontinuation in the Global Safety analysis population. All but two events were considered by the investigator to be related to study drug (Table 11).

Table 11: Subjects With Non-Serious Treatment-Emergent Adverse Events Leading to Study Discontinuation - Global Safety

<!-- image -->

| Subject Number   | Age       | Preferred Term/ Verbatim Term                                         | Onset Day/ Stop Day Trt Cycle, Inj   | Days to Onset Day Relative to Last Injection   | Severity/ Relationship   |
|------------------|-----------|-----------------------------------------------------------------------|--------------------------------------|------------------------------------------------|--------------------------|
| AUX-CC-802       | Medicinal | Medicinal                                                             | Medicinal                            | Medicinal                                      | Medicinal                |
| 5609-7406        | 72        | Joint dislocation/ Dislocation of left hip                            | 146/not recorded 2, 2                | 102                                            | Moderate/ Not related    |
| 6202-7054        | 54        | Penile haematomaa/ Penile hematoma                                    | 83/87 3, 2                           | 3                                              | Moderate/ Related        |
| 6204-7103        | 57        | Painful erection/ Immediate penile pain on erection with injection of | 44/44 1, 2                           | 42                                             | Moderate/ Not related    |

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             | Caverject                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 9146-7979                                                                                                                                                                                                                                                   | 31                                                                                                                                                                                                                                                          | Blood blister/ Penile blood blisters                                                                                                                                                                                                                        | 1/1 1, 1                                                                                                                                                                                                                                                    | 0                                                                                                                                                                                                                                                           | Mild/ Related                                                                                                                                                                                                                                               |
| AUX-CC-804                                                                                                                                                                                                                                                  | AUX-CC-804                                                                                                                                                                                                                                                  | AUX-CC-804                                                                                                                                                                                                                                                  | AUX-CC-804                                                                                                                                                                                                                                                  | AUX-CC-804                                                                                                                                                                                                                                                  | AUX-CC-804                                                                                                                                                                                                                                                  |
| 1199-4601                                                                                                                                                                                                                                                   | 70                                                                                                                                                                                                                                                          | Penile swelling/ Penile swelling                                                                                                                                                                                                                            | 53/~78 2,2                                                                                                                                                                                                                                                  | 9                                                                                                                                                                                                                                                           | Mild/ Related                                                                                                                                                                                                                                               |
| 1199-4605                                                                                                                                                                                                                                                   | 54                                                                                                                                                                                                                                                          | Erectile dysfunction/ ED                                                                                                                                                                                                                                    | 2/Ongoing 1,2                                                                                                                                                                                                                                               | 0                                                                                                                                                                                                                                                           | Mild/ Related                                                                                                                                                                                                                                               |
| 1222-5918                                                                                                                                                                                                                                                   | 57                                                                                                                                                                                                                                                          | Contusion/ Bruising pelvis                                                                                                                                                                                                                                  | 48/76 2,2                                                                                                                                                                                                                                                   | 3                                                                                                                                                                                                                                                           | Moderate/ Related                                                                                                                                                                                                                                           |
| 6019-6552                                                                                                                                                                                                                                                   | 68                                                                                                                                                                                                                                                          | Penile haematoma/ Penile hematoma                                                                                                                                                                                                                           | 124/302 3,2                                                                                                                                                                                                                                                 | 18 authorised                                                                                                                                                                                                                                               | Moderate/ Related                                                                                                                                                                                                                                           |
| 9146-5260                                                                                                                                                                                                                                                   | 29                                                                                                                                                                                                                                                          | Penis disorder/ Worsening of penile indentation                                                                                                                                                                                                             | 1/82 1,1 no longer                                                                                                                                                                                                                                          | 0                                                                                                                                                                                                                                                           | Moderate/ Related                                                                                                                                                                                                                                           |
| Data source: ISS Table 14.2.12.3; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection a Occurred 2 days after penile modeling in the third treatment cycle. | Data source: ISS Table 14.2.12.3; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection a Occurred 2 days after penile modeling in the third treatment cycle. | Data source: ISS Table 14.2.12.3; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection a Occurred 2 days after penile modeling in the third treatment cycle. | Data source: ISS Table 14.2.12.3; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection a Occurred 2 days after penile modeling in the third treatment cycle. | Data source: ISS Table 14.2.12.3; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection a Occurred 2 days after penile modeling in the third treatment cycle. | Data source: ISS Table 14.2.12.3; AUX-CC-802, Appendix 16.2, Listing 16.2.4 and data on file; AUX-CC-804, Appendix 16.2, Listing 16.2.4 and data on file Trt=Treatment; Inj=Injection a Occurred 2 days after penile modeling in the third treatment cycle. |

## Penile Haematoma

Penile haematoma was the most frequently reported TEAE (50.0% of subjects) and treatment-related AE (50.2% of subjects) in the in the Global Safety analysis population. A total of four events were considered treatment-related SAEs (Table 9). Additionally, a fifth subject (Subject 5028-7173 from AUX-CC-802) experienced a treatment-related SAE of penile haematoma for which the verbatim term was 'penile bruising'.

## Corporal Rupture

Injection of AA4500 into collagen-containing structures such as the corpus cavernosum of the penis may result in damage to those structures and may possibly result in an injury such as corporal rupture (penile fracture). Therefore, investigators were instructed to inject AA4500 only into the Peyronie's plaque and not into the urethra, nerves, blood vessels, corpora cavernosum or other collagen-containing structures of the penis.

Because corporal rupture is a potential risk of intralesional injection of AA4500 into the Peyronie's plaque and because some subjects were reported to have a penile fracture or tunica tear in the early Phase 1 and Phase 2 Peyronie's disease studies, Auxilium devised the following strategy to monitor the potential for corporal rupture in the Peyronie's disease clinical program:

- Corporal rupture was made a targeted adverse event in the Phase 3 clinical studies. As such, a separate eCRF page was created to capture detailed information pertinent to each reported case of corporal rupture among the 898 subjects who received AA44500 in the Phase 3 clinical studies.

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

- To ensure that investigators were aware of the potential risk for corporal rupture, a training video on  the  AA4500  injection  procedure  and  penile  modeling  procedure  was  provided  to  all investigators in Phase 3 studies prior to study initiation. The injection procedure and modeling video was also reviewed during the course of each study.
- Training material on corporal rupture was provided to investigators, and patients were also made aware of the risks in the Patient Information Informed Consent Forms  .  Subjects were also instructed not to resume sexual activity for a minimum of two weeks following injection. A period of two weeks was arbitrarily chosen based on earlier reports of some cases of corporal rupture occurring within that timeframe. This timeframe was also chosen to enable resolution of the majority of local adverse events.
- The injection procedure and modeling procedures were reviewed again with the investigators during the course of the study as was information regarding the potential risk of corporal rupture.
- Reasons for subject withdrawal of consent were also reviewed by the medical monitor for terms possibly associated with corporal rupture/penile fracture.

## Corporal Rupture in the Early Phase 1 and Phase 2 Clinical Studies

Ten of the 280 subjects treated with AA4500 in the early Phase 1 and Phase 2 studies had popping of their penile  plaque  during  a  spontaneous  or  nocturnal  erection  of  the  penis  or  during  penile  stretching exercises.

For  the  remaining  five  subjects,  one  was  treated  with  AA4500  in  the  first  Phase  1  pilot  study  and experienced a corporal rupture when he attempted intercourse 2 weeks after treatment. He experienced pain and a popping sensation at the injection site, which was followed by ecchymosis. The subject was instructed to bandage the penis and avoid erection for 3 weeks. There was no reported intervention and after healing, the subject's penis was straighter compared to before treatment. In the second Phase 1 pilot study, another subject treated with AA4500 experienced the verbatim term of 'small tear of the tunica' 3 weeks after injection, which was felt as a popping sensation during intercourse and was followed by a small ecchymosis, which he noted after intercourse. The event was treated conservatively without any reported intervention and resolved. The final three events (rupture of the tunica) occurred in the open-label extension of the first pilot study. The investigator's patient progress notes for this study were reviewed and no additional information is available for these three men.

Five of these events occurred in Phase 2 Study 1030-PEY. In Study 1030-PEY, subjects were to receive single injections of AA4500 10,000 units in a volume of 0.25mL on 3 separate days within a period of 3 to 10 days. The same treatment was to be repeated 3 months later. During the first treatment series, five subjects had spontaneous popping of their plaques during a spontaneous or nocturnal erection of the penis or during penile stretching exercises. The spontaneous popping of the plaque was classified as a penile fracture in four subjects (Subjects 404, 405, 406, and 421) and as a tear in the tunica albuginea in one subject (Subject 410). All 5 subjects continued in the study and received 2 or 3 additional AA4500 injections during the 2nd treatment series approximately 3 months later. Four of these five events were mild in intensity, and one was  moderate.  No  subject  required  surgical  intervention  and  all  fractures/tear  completely  resolved without  apparent  sequelae.  No  subject  had  difficulty  with  urination  or  gross  hematuria  immediately following the event. All five subjects were either 'much improved' or 'very much improved' in their Peyronie's  disease  after  receiving  AA4500  as  determined  by  the  investigator.  Most  importantly,  the events of penile fracture and tear of the tunica albuginea were not considered serious by the investigator and none met the criteria for a serious adverse event. Medicinal product no longer authorised

## Corporal Ruptures in the  Auxilium-Sponsored Studies (AUX-CC-801, AUX-CC-802, AUX-CC-803, and AUX-CC-804)

Five corporal ruptures/penile fractures were reported in the Auxilium-sponsored Phase 3 clinical studies. Four of these were considered SAEs and are discussed above. One additional subject had a corporal rupture that was not considered a serious adverse event by the investigator.

## Spontaneous Penile Events

The term 'Spontaneous Penile Event' (SPE) was created at the outset of the Phase 2b program following consultation with clinical investigators and review of available early Phase 1 and Phase 2 study safety data. In these early Phase 1 and Phase 2 studies, investigators reported that popping and cracking of the plaque, as well as 'penile fractures' were occurring without evidence of a definitive corporal rupture.

<div style=\"page-break-after: always\"></div>

Many of these events resulting in improved outcomes without interrupting the study drug administration in some cases. In order to qualify these events, the term 'Spontaneous Penile Event' was created. A spontaneous penile event was a penile event experienced by the  subject and considered a positive attribute of study drug treatment by the study subject and/or study investigator.

As shown in Table 12, 199 of the 1009 subjects (19.7%) who received AA4500 in Studies AUX-CC-801, AUX-CC-802, AUX-CC-803, or AUX-CC-804 reported spontaneous penile events.

## Table 12: Spontaneous Events in Subjects Who Received at Least One Injection of AA4500 Intent-to-Treat Population in Studies AUX-CC-801, AUX-CC-802, AUX-CC-803, and AUX-CC-804

| Spontaneous Penile Event   | AUX-CC-801 N=111   | AUX-CC-802 N=347   | AUX-CC-803 N=277   | AUX-CC-804 N=274   | Total N=1009   |
|----------------------------|--------------------|--------------------|--------------------|--------------------|----------------|
| Yes, N (%)                 | 17 (15.3)          | 109 (31.4)         | 36 (12.9)          | 37 (13.54)         | 199 (19.7)     |

Withdrawal by Subject (Informed Consent Withdrawn) A total of 74 subjects (60 AA4500 and 14 placebo) withdrew consent during the Phase 3 studies. The most common reasons for withdrawal of consent were lack of efficacy (20 subjects; 13 AA4500 and seven placebo) and the 'subject no longer wanted to be in the study' (15 subjects; 14 AA4500 and one placebo). Subject 6021-6663 who withdrew consent had a mild corporal rupture that was managed conservatively and considered a serious AE. For all other subjects, there was no reason for withdrawal of consent that was associated with an AE suggestive of corporal rupture or penile fracture. Immunogenicity Based on the nature of the drug product, the potential immunogenicity-related clinical risks for AA4500 were evaluated by examining the antibody-mediated effects on safety. Anti-Drug Antibody Responses For  subjects  who  received  AA4500  in  the  Peyronie's  clinical  studies,  the  development  of  anti-drug antibody titers following each treatment cycle (two injections) was similar to that following successive intermittent single injections in subjects who received AA4500 in the Dupuytren's clinical studies. The majority of subjects developed anti-drug antibodies after a single treatment, and the vast majority ( ≥ 95%) developed anti-drug antibodies after 2 injection cycles (up to 4 injections) in Peyronies disease (Figure 1 and Figure 2). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 1: Anti-AUX-I: Percentage of Peyronie's Subjects With Positive Anti-AUX-I Titers and Log Mean Anti-AUX-I Titer Levels Across Treatment Cycles and Follow-Up - Subjects Who Received At Least 1 Dose of AA4500 0.58 mg and Had an Immunogenicity Evaluation

<!-- image -->

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Figure 2: Anti-AUX-II: Percentage of Peyronie's Subjects With Positive Anti-AUX-II Titers and Log Mean Anti-AUX-II Titer Levels Across Treatment Cycles and Follow-Up - Subjects Who Received At Least 1 Dose of AA4500 0.58 mg and Had an Immunogenicity Evaluation

<!-- image -->

## Neutralizing Antibody Positive Subjects and Anti-Drug Antibody Titers

The percentage of neutralizing antibody positive subjects peaked at Week 24, which corresponds to the time point in  AUX-CC-803 and AUX-CC-804 when anti-drug antibody titers were also at their peak. Among subjects who received up to four treatment cycles of AA4500 for Peyronie's disease, there was no consistent neutralizing antibody profile over the time points tested. In general, subjects tested did not sustain neutralizing antibody positive status over more than one time point.

Medicinal product no longer authorised

## Antibody-Mediated Effects on Clinical Safety

The incidence of the three most frequently reported adverse events (penile hematoma, penile pain, penile swelling) and the four events possibly consistent with an immunologic event (pruritus genital, injection site pruritus, pruritus, lymphadenopathy) were examined in the safety population of 898 subjects in the Phase 3 clinical program who received up to four treatment cycles of AA4500 (up to eight injections of AA4500 0.58 mg). There was no consistent pattern of an increase in the incidence of adverse events with increasing numbers of treatment cycles (up to 8 injections) of AA4500 (and therefore increasing antibody titers). Also, the median duration of adverse events did not increase with increasing numbers of injections of AA4500 (and therefore increasing antibody titers). There was no correlation between the absence or presence  of  an  adverse  event,  or  the  severity  of  that  adverse  event  and  anti-AUX-I  or  anti-AUX-II antibody titers.

## Other Adverse Events Possibly Consistent With Immunologic Events

<div style=\"page-break-after: always\"></div>

Review of the Peyronie's disease global AA4500 safety database (N=954) showed four adverse events coded  as  hypersensitivity  or  drug  hypersensitivity  reactions.  None  of  these  events  were  related  to AA4500  (ie,  allergy  exacerbation,  possible  reaction  to  lidocaine  nerve  block  [2  subjects],  and phenylephrine hypersensitivity). There were no events coded as hypersensitivity that were consistent with a systemic hypersensitivity event.

The global safety database was also reviewed for terms possibly suggestive of/or consistent with localized or systemic hypersensitivity events. There were two reports of urticaria in the AA4500 group.

· One subject in AUX-CC-801 reported hives over his entire body 6 days after the second injection of Treatment Cycle 2. This event was managed with a medrol dose pack and the hives resolved the next day. The subject was retreated with AA4500 approximately six weeks later without premedication and without the re-appearance of hives. This event was considered moderate in intensity and unrelated to study drug.

· One subject in AUX-CC-803 reported urticaria that was local to the extremities; occurred more than 30 days after his final injection; and was considered not related to AA4500.

Three local rashes (local to the injection site, local to an area of the thigh, and local to the penis) were considered related to study drug. Three reports of mild local pruritus were also considered related to study drug.

## Laboratory findings

No clinically meaningful effects on laboratory (haematology and chemistry) parameters were observed for  any  analysis  population.  No  clinically  meaningful  effects  on  vital  sign  parameters  (systolic  blood pressure, diastolic blood pressure, heart rate, respiratory rate, temperature) were observed for any analysis population

## Safety related to drug-drug interactions and other interactions

## Use of Aspirin

No clinically meaningful differences in the incidence of local treatment-related AEs by use of aspirin (low dose [ ≤ 165 mg], no aspirin use]) were observed. The sample size for subjects receiving a high dose (&gt;165 mg) of aspirin (N=27) was too small to make any clinically meaningful comparisons (Table 13).

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

Table 13: Local Treatment-Related Adverse Events by Use of Aspirin - Phase 3 Studies

| authorised   |
|--------------|

Datasource:

## Use of Anti-Coagulant Medication

Due to the small sample size of subjects with anti-coagulant medication use (N=21) compared to subjects with no anti-coagulant medication use (N=885), no clinically meaningful comparisons of the incidence of local treatment-related AEs between subjects with anti-coagulant medication use and subjects with no anti-coagulant medication use could be made.

## Post marketing experience

## Dupuytren's contracture

A search of the Auxilium safety database was performed for all global post-marketing reports received by Auxilium  from  Dupuytren's  contracture  product  launch  until  27  August  2013  (71,388  vials  of XIAFLEX®/XIAPEX® sold). The MAH considers the AE profile demonstrated in post-marketing use to be consistent  with  the  profile  of  the  product  seen  in  the  Dupuytren's  contracture  clinical  trials  and XIAFLEX®/XIAPEX® product insert and medication guide.

Medicinal product no longer authorised

## Peyronie's disease

N/A

## 2.5.1. Discussion on clinical safety

With 1044 subjects who received 7466 injections of AA4500 0.58 mg for the treatment of Peyronie's disease worldwide the safety database contains adequate number of subjects. Most adverse events following  AA4500  injection  were  locally  to  the  penis  or  groin  and  most  commonly  include  penile hematoma, penile pain, penile swelling, injection site pain and injection site hematoma.

<div style=\"page-break-after: always\"></div>

The majority of Peyronie's patients experienced at least one adverse reaction (Global Safety database, 92.5%). Most adverse reactions were locally to the penis or groin and the majority of these events were of mild or moderate severity. Most resolved within 14 days of the injection. The adverse reaction profile was similar after each injection, regardless of the number of injections administered.

The most frequently reported treatment-related AEs in the clinical trials in subjects with Peyronie ' s disease (Global Safety database) were penile hematoma (50.2%), penile pain (33.5%), penile swelling (28.9%) and injection site pain (24.1%).

## Corporal fracture and other serious adverse events related to the penis

Treatment-related SAEs included corporal rupture (fracture of penis) in 4 subjects (0.4%). One additional subject experienced a corporal fracture that was not a serious AE according to the investigator. Nine subjects (0.9%)  reported a combination of penile  ecchymoses  or  hematoma,  sudden  penile detumescence, and/or a penile 'popping' sound or sensation. These subjects were managed without surgical intervention. A diagnosis of corporal rupture cannot be excluded. Treatment-related SAEs also included penile hematoma (n=5). Severe penile hematoma was also reported in 39 patients (3.7%). To these SAEs appropriate warning statements are reflected in the Product Information. Corporal rupture or other serious injuries to the penis are made identified risks in the RMP.

## Use of Anti-Coagulant Medication

Investigator training in the clinical studies included intensive injection technique instructions via manuals and  DVDs,  workshops  and  investigator  meetings.  To  ensure  the  safe  application  of  the  drug  and considering  above  SAEs  the  MAH  will  ensure  that  physicians  are  appropriately  trained  and  provide adequate educational material for the healthcare professionals in the treatment of Peyronie's disease as outlined  in  Annex  II.  The  training  programme  will  be  followed  by  surveys  to  follow  adequate implementation of the training plans as outlined in the RMP. Immunogenicity During clinical studies in Peyronie's disease subjects were tested at multiple time points for antibodies to the protein components of AA4500 (AUX-I and AUX-II). After 6 weeks of cycle 1, 73.7% of patients had antibodies against AUC-I and 53.9% had antibodies against AUX-II. After the 4 th cycle nearly all subjects had antibodies to both AUX-I and AUX-II. Neutralizing antibodies were detected in 43.8% and 31.3%, respectively, of subjects tested. There was no apparent correlation of antibody frequency, antibody titers, or neutralizing status to adverse reactions. There  were  no  observed  cases  of  severe  systemic  hypersensitivity  or  anaphylaxis  in  the  clinical development  programme  for  AA4500  in  Peyronie's  disease.  However,  an  anaphylactic  reaction  was reported in a post-marketing clinical study in a patient who had previous exposure to AA4500 for the treatment of Dupuytren's contracture. Appropriate warnings to this potential risk have been included into the product information and the educational material will cover this aspect. Medicinal product no longer authorised

Except for race and anti-coagulant medication use, which could not be evaluated, no clinically meaningful differences were observed between or among subgroups. No final conclusion can be drawn for subjects receiving a high dose (&gt;165 mg) acetylsalicylic acid since the overall number was too low (27 of 898). The current  PI  contains  the  warning  (Section  4.4)  that  use  of  Xiapex  in  patients  who  have  received anticoagulants (with the exception of up to 150mg acetylsalicylid acid daily) within 7 days prior receiving an injection is not recommended.

## Long-term safety

Follow-up on long term safety is currently ongoing. Study AUC-CC-810 is a long term, non-treatment follow up of patients who received AA450 in the AUX-CC-802, AUX-CC-803 and AUX-CC-804 studies. The final results of study AUC-CC-810 are expected in 4Q 2018. The MAH will submit the long-term results for the use of AA4500 as requested in the RMP.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on clinical safety

The safety results indicate that the majority of adverse reactions were non-serious, mild or moderate in intensity, confined to the treated area, and resolved within a short period without sequelae. Among subjects who received at least one dose of Xiapex most subjects experienced adverse reactions in the treated extremity, with the most frequently reported adverse reactions reported being: penile hematoma, penile pain, penile swelling and injection site pain.

All treatment-related SAEs were related to events of the penis, corporal rupture (fracture of penis) in 4 subjects and penile hematoma in 5 subjects. The influence of investigator training on adverse events related to the penis is considered to be crucial for the safe application of the drug. A physician training plan is part of the risk minimisation plan.

Due to the highly immunogenic potential of Xiapex the majority of subjects developed antibodies to the protein components of Xiapex (AUX-I and AUX-II) after the first injection and all subjects had antibodies after the 4th cycle.  However, no adverse reactions consistent with systemic hypersensitivity or anaphylactic response were observed in the Peyronie's study programme. However, an anaphylactic reaction was reported in a post-marketing clinical study in a patient who had previous exposure to Xiapex for the treatment of Dupuytren's contracture.

The PRAC considered that the risk management plan version 10.0 is acceptable. The PRAC endorsed PRAC Rapporteur assessment report is attached.

No increase in the number of adverse events with subsequent injections were observed. Antibody titres were not predictive of the rate, severity, or duration of any of the adverse events. This suggests that Antibodies to both AUX-I and AUX-II did not affect the safety profile of Xiapex. 2.5.3. PSUR cycle Based on the data submitted, the frequency of PSUR submission should be revised to 6 months. Consequently, the PSUR after the next data lock point, 27 February 2015, should cover the period from 28.02.2015 to 27.08.2015 and be submitted within 70 days of the data lock point. Thereafter PSURs should be submitted in accordance with the updated list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC. 2.6. Risk management plan The CHMP received the following PRAC Advice on the submitted Risk Management Plan: Medicinal product no longer authorised

This advice is based on the following content of the Risk Management Plan:

## Safety concerns

The applicant identified the following safety concerns in the RMP:

Table 14: Summary of the Safety Concerns- Peyronie's disease

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                             |
|------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Corporal rupture or serious injury to the penis                                                                        |
| Important identified risks   | Local reactions                                                                                                        |
| Important identified risks   | Medication errors                                                                                                      |
| Important potential risks    | Injection-site bleeding in patients with coagulation disorders, including those on concurrent anti-coagulation therapy |
| Important potential risks    | Severe systemic hypersensitivity/Anaphylaxis                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                       | Reactions related to cross-reactivity with endogenous MMPs (including MSS and development/exacerbation   |
|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|                                                                       | Immune mediated reactions                                                                                |
|                                                                       | Skin lesions                                                                                             |
|                                                                       | Injury of the urethra                                                                                    |
|                                                                       | Off label use in patients with ventral curvature deformity                                               |
|                                                                       | Off label use in patients with isolated hourglass deformity                                              |
| Missing information                                                   | Re-treatment with collagenase clostridium histolyticum (Xiapex) Long term safety                         |
| MMP = matrix metalloproteinase; MSS = MSS = musculoskeletal syndrome. | MMP = matrix metalloproteinase; MSS = MSS = musculoskeletal syndrome.                                    |

## Pharmacovigilance plan

Table 15: Ongoing and planned studies in the PhV development plan- Peyronie's disease

<!-- image -->

| Study/Activity Type, Title and category (1-3)                                                                                                                        | Objectives                                                                                                                                                              | Safety concerns addressed           | Status Planned, started, authorised   | Date for submission of interim or final reports   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------|---------------------------------------------------|
| Study AUX-CC-806 (open label study for patients who received placebo in the double blind placebo controlled Phase III studies AUX-CC- 803 and AUX-CC-804) Category 3 | A Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease                                                            | no longer                           | Ongoing                               | 3Q2014                                            |
| Study AUX-CC-810 (long-term, nontreatment 2- 5 year follow up of patients who received AA4500 in AUX-CC-802, AUX-CC-803, and AUX CC 804) Category 3                  | To assess the long-term safety and characterisation of curvature deformity following use of AA4500 in the treatment of adults with Peyronie's disease Medicinal product | Long term safety and immunogenicity | Planned                               | 4Q2018                                            |
| Survey to evaluate effectiveness of additional risk minimisation measures (educational material) Category 3                                                          | Assessment of effectiveness of risk minimisation measures                                                                                                               | N/A                                 | Planned                               | TBD                                               |

The  RMP  was  updated  including  a  PASS  (category  3  non-interventional  PASS)  for  evaluating  the effectiveness  of  the  educational  material  via  survey,  as  mentioned  in  Annex  II  to  the  opinion. Adjustments to the survey may be necessary during development of the protocol. The protocol will be provided within three months after authorisation.

<div style=\"page-break-after: always\"></div>

The PRAC, having considered the data submitted, was of the opinion that the proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

## Risk minimisation measures

Table 16: Summary table of Risk Minimisation Measures- Peyronie's disease

| Safety concern                                                                                                         | Routine risk minimisation measures                           | Additional risk minimisation measures               |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------|
| Important Identified Risks                                                                                             | Important Identified Risks                                   | Important Identified Risks                          |
| Corporal rupture (penile fracture) or other serious injury to the penis                                                | SmPC Sections 4.4 and 4.8 Package Leaflet Section 2          | Physician training/Educational materials            |
| Local reactions                                                                                                        | SmPC Sections 4.8 and 4.9                                    | Physician training/Educational materials            |
| Medication errors                                                                                                      | SmPC Section 4.2 and Package leaflet                         | Physician training/Educational materials authorised |
| Important Potential Risks                                                                                              | Important Potential Risks                                    |                                                     |
| Injection site bleeding in patients with coagulation disorders, including those on concurrent anti-coagulation therapy | SmPC Sections 4.4 Package Leaflet Section 2                  | Physician training/Educational materials            |
| Severe systemic hypersensitivity/ Anaphylaxis                                                                          | SmPC Sections 4.3, 4.4 and 4.8 no longer                     | Physician training/Educational materials            |
| Reactions related to cross-reactivity with endogenous MMPs                                                             | SmPC Section 4.4 product                                     | Physician training/Educational materials            |
| Immune mediated reactions                                                                                              | SmPC Sections 4.3 and 4.4                                    | Physician training/Educational materials            |
| Skin lesions                                                                                                           | N/A                                                          | N/A                                                 |
| Injury of the urethra                                                                                                  | SmPC Section 4.2 and 4.3 Package Leaflet Section 2 Medicinal | Physician training/Educational materials            |
| Off label use in patients with ventral curvature deformity                                                             | SmPC Section 4.3 and 4.4 Package Leaflet Section 2           | Physician training/Educational materials            |
| Off label use in patients with isolated hourglass deformity                                                            | SmPC Section 4.3 and 4.4 Package Leaflet Section 2           | Physician training/Educational materials            |
| Missing information                                                                                                    | Missing information                                          | Missing information                                 |
| Re-treatment with collagenase Clostridium histolyticum                                                                 | Not applicable                                               |                                                     |
| Long term safety                                                                                                       | Not applicable                                               |                                                     |

The PRAC, having considered the data submitted, was of the opinion that the proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication.

The CHMP endorsed this advice without changes.

<div style=\"page-break-after: always\"></div>

## 2.7. Update of the Product information

As a consequence of this new indication, sections 2, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s) [e.g. Excipients guideline, storage conditions, Braille, etc…], which were reviewed by QRD and accepted by the CHMP.

## 2.7.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the MAH show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

3. Benefit-Risk Balance Benefits Beneficial effects The efficacy of Xiapex was evaluated in two randomized, double-blind, placebo-controlled, multi-centred trials in 832 (ITT) adult males with PD. Xiapex 0.58 mg was statistically superior to placebo with respect to the co-primary endpoints (i.e., curvature deformity and patient-reported Peyronie's disease bother) in both clinical studies: In  each  study,  men  treated  with  AA4500  had  a  statistically  significant  (p ≤ 0.0059)  greater  percent reduction in curvature deformity compared with men treated with placebo. A relative reduction of penile curvature deformity (48.8 ° -51.3 ° at baseline) of -37.6% (placebo -21.3%, study 803), resp. -30.5% (placebo -15.2%, study 804) was achieved. Improvement in curvature deformity was apparent after the first treatment cycle (Week 6) with continued improvement noted after each of the three subsequent treatment cycles. The improvement in curvature deformity was maintained through the end of each study (Week 52). Medicinal product no longer authorised

Reduction in penile curvature also translated in a reduction of patients' bother about PD. The baseline bother  score  was  7.4  to  8.2  across  treatment  arms  and  studies.  Translating  the  score  into  bother categories, patients were about moderately bothered at baseline. At the pre-defined time point at the end of the observation period (week 52), Xiapex was statistically superior to placebo in terms of PDQ Bother score reduction (AUX-CC-803: p=0.0451; AUX-CC-804: p=0.0496).

## Uncertainty in the knowledge about the beneficial effects

No efficacy data are available for administration of more than four treatment cycles. Likewise, no data are available on recurrence of penile curvature after more than one year after the first Xiapex injection. Limitation on the data is outlined in the product information and the applicant will provide further data post authorisation from the 5 years long term study AUX-CC-810 as specified in the RMP.

## Risks

## Unfavourable effects

The safety results indicate that the majority of adverse reactions were non-serious, mild or moderate in intensity, confined to the treated area, and resolved within a short period without sequelae. Among subjects who received at least one dose of Xiapex most subjects experienced adverse reactions in the

<div style=\"page-break-after: always\"></div>

treated  extremity,  with  the  most  frequently  reported  adverse  reactions  reported  being:  penile hematoma, penile pain, penile swelling and injection site pain. All treatment-related SAEs were related to events of the penis, corporal rupture (fracture of penis) and penile hematoma. All these events are appropriately reflected in the Product Information.

Due to the highly immunogenic potential of Xiapex the majority of subjects developed antibodies to the protein components of the drug (AUX-I and AUX-II) after the first injection and all subjects had antibodies after the 4th cycle. No adverse reactions consistent with systemic hypersensitivity or anaphylactic response were observed in the Peyronie's study programme. Notwithstanding an anaphylactic reaction was reported in a post-marketing clinical study for the treatment of Dupuytren's contracture in a patient who had previous exposure to Xiapex. It is acknowledged that no increase in the number of adverse events with subsequent injections was observed. Antibody titres were not predictive of the rate, severity, or duration of any of the adverse events. This suggests that Antibodies to both AUX-I and AUX-II did not affect the safety profile of Xiapex.

To mitigate the risks of adverse events related to the penis and potential risks such as anaphylaxis and medication errors during the treatment of Peyronie's disease, a physician training program and subsequent surveys to monitor the implementation of the training plans will be carried out. The training material will cover identified and potential risks as reflected in the RMP and in Annex II. Furthermore these risks are balanced with the appropriate labelling. Uncertainty in the knowledge about the unfavourable effects No long term safety data on immunogenicity or on safety of retreating patients are available in the claimed indication. In this respect the MAH is carrying out a long term safety and immunogenicity study to follow subjects who participated in the phase III studies (double-blind and open-label) for up to 5 years as reflected in the RMP. Benefit-Risk Balance Importance of favourable and unfavourable effects Clinical studies with Xiapex showed statistically significant and clinically relevant results on curvature deformity and patient-reported Peyronie's disease bother in affected patients. Improvement  in  curvature  deformity  was  apparent  after  the  first  treatment  cycle  with  continued improvement noted after each of the three subsequent treatment cycles. The improvement in curvature deformity was maintained through the end of each study. Medicinal product no longer authorised

The majority of adverse reactions were confined to the treated area and all treatment-related SAEs were related to events of the penis, corporal rupture and penile hematoma. All these adverse reactions are appropriately reflected in the Product Information and will be covered by the physician training plan as reflected in the RMP and in Annex II.

Whereas antibody titres observed in patients do not seem to affect the safety profile of Xiapex and no adverse reactions consistent with systemic hypersensitivity or anaphylactic response were observed in the  Peyronie's  study  programme  an  anaphylactic  reaction  was  reported  under  re-exposure  for  the treatment of Dupuytren's contracture which justifies to balance these potential risks with appropriate labelling and the physician training plan.

## Benefit-risk balance

Xiapex shows in the submitted data package statistically significant superiority over placebo in terms of the two co-primary endpoints, i.e. curvature reduction and reduction in the PDQ Bother Scale. During

<div style=\"page-break-after: always\"></div>

Xiapex  trials  observed  AEs  were  mostly  local,  mild  to  moderate  in  intensity  and  resolved  without sequelae. The benefit-risk-balance for Xiapex in the new proposed indication is considered to be positive.

## Discussion on the Benefit-Risk Balance

Xiapex is a novel non-surgical treatment for PD. It is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, and has the potential to be effective in lysing collagen deposits such as those in the plaque, which is composed predominantly of collagen, that cause the curvature deformity and subsequent bother and distress in patients with PD. The injection of Xiapex into the pathologic plaque followed by a penile plaque modelling approximately 24 to 72 hours after injection, allows for the local disruption of the plaque.

The applicant has shown with the submitted study program statistical significant and clinically relevant results. Identified risks such as penile fracture, local reactions and medication errors as well as potential risks like hypersensitivity reactions are considered to be balanced with the current labelling and the educational materials which will ensure the doctors are aware of the important safety information

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends, the variation(s) to the terms of the Marketing Authorisation, concerning the following change(s):

| Variation(s) accepted   | Type                                                                                                                              |         |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------|---------|
| C.I.6.a                 | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one no | Type II |

Update of the SmPC with a new indication in the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Consequently, sections 2, 3, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated. The PL is updated accordingly.

Furthermore, the PI is being brought in line with the latest QRD template version 9.0.

Medicinal product no longer authorised

The variation proposed amendments to the SmPC, Annex II and Package Leaflet.

## Conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the

<div style=\"page-break-after: always\"></div>

RMP.

An updated RMP shall be submitted annually until renewal and every three years once an indefinite licence is granted.

In addition, an updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

## · Additional risk minimisation measures

The MAH shall ensure that all physicians who are expected to prescribe/use Xiapex are appropriately trained in the correct administration of the product and experienced in the diagnosis and management of Dupuytren's contracture and Peyronie's disease.

The MAH, in agreement with the competent authorities in the Member States, shall implement, prior to the launch, an educational programme for physicians aiming to ensure proper injection placement to minimize occurrence of injection-related adverse events and to inform on expected and potential risks associated with the treatment.

The physician educational programme should contain the following key elements:

- Injection technique and dosing interval.
- Proper amount of volumes for both reconstitution and injection differences in the metocarpophalangeal (MP) and proximal interphalangeal (PIP) joints for Dupuytren's contracture and for the Peyronie's disease plaque.
- Recognition and treatment of severe immune-mediated reaction, including anaphylaxis.
- Information on bleeding risk in patients with coagulation disorders including those on concurrent anti-coagulation therapy.
- Information on the potential risk of matrix metalloproteinases (MMP) cross reactivity including the development of musculoskeletal syndrome and exacerbation/initiation of autoimmune disorders.
- Reminder of the need to report adverse events, including medication errors.
- The need to inform the patient about the signs and symptoms associated with the treatment and when to seek attention from the health care provider.
- The summary of product characteristics and the patient information leaflet.

Medicinal product no longer authorised

## · Obligation to conduct post-authorisation measures

- Not applicable

## Additional data exclusivity /market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Update of the SmPC with a new indication in the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Consequently, sections 2, 3, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated. The PL is updated accordingly. Furthermore, the PI was brought in line with the latest QRD template vs. 9.0.

## Summary

Please refer to the scientific discussion Xiapex EMEA/H/C/002048/II/44 for further information.

## Appendix

1. CHMP AR on the novelty of the indication/significant clinical benefit in comparison with existing therapies

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

CHMP assessment report on the significant clinical benefit in comparison with existing therapies in accordance with Article 14(11) of Regulation (EC) No 726/2004

Invented name: Xiapex

International non-proprietary name: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM

Procedure No. EMEA/H/C/2048/II/44

Marketing authorisation holder (MAH): Swedish Orphan Biovitrum AB (publ)

Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 6. Introduction

In  accordance  with  the  provisions  of  Article  14(11)  of  Regulation  (EC)  No  726/2004,  the  Marketing Authorisation  Holder  (MAH)  Swedish  Orphan  Biovitrum  AB  has  applied  for  an  additional  one  year marketing protection period in the framework of the Xiapex 0.9 mg powder and solvent for solution for injection Variation procedure EMEA/H/C/2048/II/44.

The request was based on the MAH's position that Xiapex represents a significant clinical benefit in the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy in comparison with existing therapies.

## 7. Justification of significant clinical benefit as presented by the MAH

7.1. Demonstration of new therapeutic indication The MAH is seeking market authorization for Xiapex, collagenase clostridium histolyticum (AA4500) in the new indication of the treatment of Peyronie's disease. Xiapex obtained first authorization in EU for the treatment of Dupuytren's contracture on 28 February 2011. The MAH considers this application supports a new therapeutic indication which will bring a significant clinical benefit in comparison with existing therapies. In accordance with Article 14(11) of Regulation 726/2004, the MAH therefore seeks approval for an additional year of marketing protection for Xiapex. Peyronie's disease is an idiopathic, connective tissue disorder of the penis and is characterized by the pathological deposition of collagen I and III in the tunica albuginea of the corpus cavernosum (Akkus et al.,  1997, Bivalacqua et al., 2000, Somers et al., 1989). The etiology of PD is not well understood; however, recent research has identified microvascular trauma, abnormal wound healing, and genetic predispositions as potential contributors to development of the condition (Moreland and Nehra, 2002, Ralph et al., 2010). The collagenous plaque replaces the normal elastic fibers of the tunica albuginea and causes penile curvature deformity, which is most evident during erection. The curvature deformity leads to  significant  patient  bother,  distress,  and  sexual  dysfunction  and  can  cause  pain  during  erection. (Hellstrom, 2009, Ralph et al., 2010). Medicinal product no longer authorised

Collagenase Clostridium Histolyticum (AA4500) is a novel non-surgical treatment for Peyronie's disease. Isolated and purified from the fermentation of the bacterium Clostridium histolyticum, it is a lyophilized compound with a fixed-mass ratio (1:1) mixture of two purified collagenolytic enzymes: clostridial type I collagenase (AUX-I) and clostridial type II collagenase (AUX-II). It is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, and has the potential to be effective in lysing collagen deposits such as those in the plaque, which is composed predominantly of collagen, that cause the curvature deformity and subsequent bother and distress in patients with Peyronie's disease. The injection of AA4500 into the pathologic plaque followed by a penile plaque modeling approximately 24 to 72 hours after injection, allows for the local disruption of the plaque.

The efficacy of AA4500 0.58 mg in the treatment of Peyronie's disease, was evaluated in two identical, large, well-controlled, multicenter 12-month Phase 3 studies (AUX-CC-803 and AUX-CC-804). In these studies, a total of 832 subjects with Peyronie's disease were enrolled in the United States and Australia. To further contextualize the results from the double-blind, placebo-controlled study population with those from a European population, the safety and efficacy from the subset of European subjects (N =191) were also evaluated in an open-labeled Phase 3 study.

<div style=\"page-break-after: always\"></div>

To be eligible for these Phase 3 studies, men had to be at least 18 years of age; be in a stable relationship with a female partner/spouse for at least 3 months before screening and be willing to have vaginal intercourse with that partner/spouse; have symptom(s) of Peyronie's disease for at least 12 months before  the  first  dose  of  study  drug  and  have  evidence  of  stable  disease,  as  determined  by  the investigator;  have  penile  curvature  of  at  least  30°  in  the  dorsal,  lateral,  or  dorsal/lateral  plane  at screening.

## 7.2. Details of existing therapies

Several factors should be considered for the therapeutic management of patients with PD, including the extent of patient bother/distress, the duration of disease, presence or absence of pain with erection, the severity of penile deformity, and the adequacy of erectile function (Hellstrom, 2009).

## Conservative Therapies

Non-surgical approaches are considered first-line therapy for PD, as they are indicated for patients in the early stage of the disease who are experiencing progressive deformity and painful erections. The goal of treatment is to mitigate progression and improve symptoms (Ralph et al., 2010). Conservative treatment options  are  multiple  and  diverse  and  include  oral  and  topical  agents,  intralesional  injections, extracorporeal shock wave therapy (ESWT), iontophoresis, and others (Ralph et al., 2010). Although a relatively large number of randomized controlled trials have been published within the last decade, the overall quality of the studies is quite poor. Thus, the clinical safety and efficacy of these approaches have not been convincingly demonstrated to date. Surgical Interventions Surgery is indicated when PD has reached the chronic phase and penile morphology, including plaque size and curvature deformity, has been stable for ≥3 months. The goals of surgery are to correct penile deformity  and  improve  erectile  and  sexual  function.  Therefore,  surgery  is  typically  appropriate  for patients who cannot achieve intercourse owing to the severity of their deformity and/or those patients with refractory ED where placement of an intra-penile prosthesis is required for tumescence. Surgery is typically not indicated for patients whose penile deformity does not prevent intercourse, because of the risk of postoperative ED or other operative complications (Ralph et al., 2010). Standard surgical interventions for PD can be classified into three categories: · tunical shortening · tunical lengthening Medicinal product no longer authorised

- penile prosthesis.

In tunical shortening procedures (Nesbit or modified Nesbit procedures), penile curvature deformity is corrected by plication (ie, suturing across an inward folding of tissue to reduce length) of the tunica albuginea on the convex (longer) side of the penis opposite the point of maximum curvature. Tunical shortening is most appropriate for patients with a less severe penile curvature &lt;70° and adequate penile length to minimize the risk of excessive shortening that may preclude intercourse. Penile shortening is a known complication of this procedure.

Unlike tunical shortening, lengthening procedures involve direct surgical manipulation of the plaque. In plaque  excision,  an  autologous  dermal  graft  is  used  to  repair  the  tunica  albuginea.  More  recent lengthening techniques involve partial removal of the plaque, whereby only a portion of the plaque is excised and then replaced with a tissue graft. In the plaque incision technique, none of the plaque is removed. Instead, a relaxing incision is made in the plaque and filled with an inlay of graft material. Types of graft used include autologous tissue grafts, allografts or xenografts, and synthetic grafts. These newer

<div style=\"page-break-after: always\"></div>

procedures are less likely  to  impair  cavernosal  function  or  cause  postoperative  ED  versus  complete excision (Kovac and Brock, 2007). Tunical lengthening procedures are appropriate for patients with good preoperative  erectile  and  penile  vascular  function,  curvature  greater  than  60-70°,  and/or  complex deformities.

Finally,  the  insertion  of  penile  prostheses  can  allow  patients  with  ED  refractory  to  pharmacologic  or vacuum therapy to engage in sexual intercourse. Insertion of non-inflatable or inflatable prostheses is an effective method for maintaining penile length in patients with PD. However, the prosthesis alone is often not sufficient to achieve complete straightening of the penis. Concomitant use of manual modeling (for inflatable prostheses only) or adjuvant reconstructive procedures (ie, tunical shortening or lengthening) is often required for complete correction of the penile deformity.

## 7.3. Significant clinical benefit based on improved efficacy

Treatment outcomes - Conservative therapies Oral agents studied in small case series and observational studies include off-label use of vitamin E, carnitine, colchicine, pentoxifylline, and para-aminobenzoate (Potaba®). In general, study results have shown limited therapeutic benefit for correcting penile deformities caused by PD. Potaba, shown to have anti-inflammatory and antifibrotic effects, is licensed in Germany (Glenwood GmBH, 2011) and the United Kingdom and considered a first-line therapy for PD (Hellstrom, 2009). In a multicenter, randomized, double-blind, placebo-controlled study, 26/35 versus 20/40 of Potaba- and placebo-treated patients, respectively, achieved clinical success, defined as a ≥30% reduction in penile curvature and/or plaque size (Weidner et al., 2005). Among patients with pre-existing penile deviation, there was no significant difference between the Potaba- and placebo-treated patients. However, among those with a straight penis at study start, 5/5 of Potaba and 2/8 of placebo patients remained stable (Weidner et al., 2005). There were no differences in reduction of erectile pain with Potaba versus placebo or for improvement in erection quality (Weidner et al., 2005). The authors suggest that although Potaba does not reduce existing curvature, it may prevent further progression of the deformity. Topical  agents  have  been  all  but  dismissed  as  potential  therapy  for  PD;  however,  two  concurrent randomized,  double-blind,  studies  involving  the  off-label  use  of  topical  verapamil  (calcium  channel blocker)  demonstrated  significant  curvature  improvement  versus  topical  magnesium  sulfate  (weak calcium  channel  blocker)  and  topical  placebo  (Fitch  et  al.,  2007).  Erectile  pain  erection  quality  was improved in the verapamil treated patients although differences were not statistically significant. Medicinal product no longer authorised

In general, off-label intralesional injections of iloprost, interferon, or verapamil have shown only modest effectiveness for reducing penile curvature or plaque size. However, in an earlier Phase II open-label study of collagenase, a reduction in both curvature and plaque size was seen. Although 28% (7/25) of patients discontinued at some point during the 9-month study, none withdrew owing to injection-related concerns (Jordan, 2008).

## Treatment outcomes - Surgical Interventions

There are no published data from randomized controlled trials of surgical interventions for PD. The vast majority  of  published  studies  are  retrospective  reviews  of  patient  charts  after  follow-up  periods  of wide-ranging durations. In general, the published studies do not clearly define the treatment groups or the objective and/or subjective endpoints of interest. Almost-certain confounders include the skill of the surgeon(s) performing the procedure, baseline demographic and clinical characteristics of the patients, and the use of multiple procedures with different techniques.

<div style=\"page-break-after: always\"></div>

According to the published literature, among patients undergoing tunical shortening surgeries, curvature correction  rates  varied  widely  (42-100%).  Likewise,  48-94%  of  patients  were  able  to  engage  in successful intercourse after surgery. Tunical lengthening procedures are comparably effective; curvature correction  rates  ranged  from  60-100%,  and  46-100%  of  patients  had  successful  intercourse  after surgery.  However,  these  techniques  can  be  associated  with  a  greater  risk  for  postoperative  ED.  In patients with refractory ED secondary to PD, insertion of an inflatable or non-inflatable penile prosthesis -  with  concomitant  adjuvant  procedures  -  is  an  effective  method  for  achieving  complete  penile straightening in 61-100% of patients, enabling them to engage in successful sexual intercourse.

## Treatment outcomes - Collagenase Clostridium Histolyticum (AA4500)

The co-primary endpoints in the two pivotal trials (AUX-CC-803 and AUX-CC-804) were the percent change  from  baseline  in  curvature  deformity  and  the  change  from  baseline  in  the  patient-reported Peyronie's disease bother domain score up to Week 52 (LOCF). After administration of a pharmacological stimulant to induce an erection, the investigator or qualified designee measured the angle of penile deformity  three  times  with  a  goniometer  protractor  device  using  a  standard  method.  All  three measurements had to be within 10° of each other; the most severe of the three findings was recorded.

The PDQ Peyronie's disease bother domain included: bother associated with painful erections; bother associated with appearance of erect penis; bother associated with the impact of Peyronie's disease during intercourse; and impact of Peyronie's disease on intercourse frequency. A reduction in the Peyronie's disease bother score (range 0-16) from baseline represented improvement.

AA4500 0.58 mg was statistically superior to placebo with respect to the co-primary endpoints (curvature deformity and patient-reported Peyronie's disease bother) in the clinical studies:

- In  each  placebo-controlled  study,  men  treated  with  AA4500  had  a  statistically  significant (p≤0.0059) greater percent reduction in curvature deformity compared with men treated with placebo.

Improvement in curvature deformity was apparent after the first treatment cycle (Week 6) with continued  improvement  noted  after  each  of  the  three  subsequent  treatment  cycles.  The improvement in curvature deformity was maintained through the end of each study (Week 52).

- In  each  placebo-controlled  study,  men  treated  with  AA4500  had  a  statistically  significant (p≤0.0496) greater improvement in patient-reported Peyronie's disease bother compared with men treated with placebo.
- Similar findings were observed among EU subjects who received AA4500 in Study AUX-CC-802.
- Among subjects treated with AA4500, there were no clinically meaningful differences in the mean percent improvement from baseline in curvature deformity or in mean reduction from baseline in patient-reported Peyronie's disease bother when considering any of the following subgroups: race; history of diabetes penile trauma, or prior treatment for PD, severity of baseline erectile dysfunction or concomitant phosphodiesterase type 5 inhibitor use.

Medicinal product no longer authorised

## 7.4. Significant clinical benefit based on improved safety

## Safety - Conservative therapies

Overall, conservative therapies are generally well tolerated, although few studies report specific details about the nature and/or frequency of AEs. Oral agents have been associated with gastrointestinal distress (3-6%) (Safarinejad, 2004, Safarinejad, 2009, Safarinejad et al., 2010), and topical applications can produce local skin reactions (5-11%) (Fitch et al., 2007, Riedl et al., 2005) (Error! Reference source not found.). Intralesional therapies are frequently associated with injection-site reactions, including bruising,

<div style=\"page-break-after: always\"></div>

swelling, and ecchymosis (22-66%) (Bennett et al., 2007, Jordan, 2008, Moskovic et al., 2012, Pavone et al., 2012). Many patients can also be lost to follow-up after interlesional injections because of pain and trauma  from  the  first  injection  (Fitch  et  al.,  2007).  Patients  who  receive  interferon  therapy  often experience flu-like symptoms in addition to the local, injection-site reactions (Hellstrom et al., 2006, Inal et al., 2006, Kendirci et al., 2005). Other treatment modalities have been linked to localized bruising, bleeding, and pruritus (Claro et al., 2004, Di Stasi et al., 2004, Gontero et al., 2009, Greenfield et al., 2007).

## Safety - Surgical Interventions

Although research has shown that surgical procedures to treat PD are reasonably safe, surgery will not restore  penile  morphology  to  its  pre-diseased  state.  Thus,  complaints  about persistent  deformity  or unnatural appearance are common, regardless of the technique performed. Postoperative complications include diminished penile sensitivity, penile shortening, and new or worsening ED. Moreover, nearly 20% of patients who undergo surgery for PD may require a secondary procedure owing to residual or recurrent curvature or as a response to more serious complications.

For  the  Nesbit  and  modified  Nesbit  procedures,  reported  complications  include  penile  shortening, recurrence, and ED. Post-procedural AEs associated with tunical plication include paraphimosis, wound infection,  hematoma,  and  palpable  knots.  Other  suture-related  AEs  include  discomfort,  failure,  and granuloma. Common complications include penile shortening, reduced penile sensitivity, and painful erection. Tunical  lengthening  techniques  are  associated  with  a  greater  risk  for  postoperative  ED.  Commonly reported AEs after tunical lengthening surgery include hematoma, palpable knots, and infection. The incidence of reduced penile sensitivity ranges from 2-60%; however, in most studies, rates were ≤15% and normal sensation returned within 6 weeks to 12 months. Recurrence frequently required surgical revision.  For  penile  prostheses,  the  most  frequently  reported  AE  was  reduced  penile  sensitivity  and infection. Complications include mechanical failure and urethral injury. Among the surgical studies included, the reported rates of postoperative residual deformity vary widely and likely depend on a number of factors, including type of procedure, duration of follow-up, definition of residual curvature, and assessment method. For the 15 studies that evaluated residual deformity after penile lengthening procedures, rates ranged from 0% (Rybak et al., 2012) to 40% (Kovac and Brock, 2007) during follow-up periods ranging from 3 months (Horstmann et al., 2011) to 8 years (Simonato et al., 2010). Reported residual deformity rates after penile shortening procedures ranged from 2% (Iacono et al., 2012) to 58% (Paez et al., 2007) during follow-up periods ranging from 3 months (Horstmann et al., 2011) to 7 years (Savoca et al., 2004). Medicinal product no longer authorised

## 7.5. Significant clinical benefit based on major contribution to patient care

Therapy of Peyronie's disease today includes either so called conservative treatment options or surgical intervention. Common to both alternatives is that they are not optimal for the patient. Apart from a lack of robust studies to evaluate their benefits, each option is associated with limitations in terms of efficacy or safety.

Conservative treatment options are multiple and diverse; however, the clinical safety and efficacy of these conservative treatment approaches have not been convincingly demonstrated to date. Although a relatively large number of studies have been published within the last decade, the overall quality of these studies is quite poor.

Long-standing  and  well-established  surgical  approaches  for  PD  generally  provide  good  results  by reducing the extent of penile curvature and enabling patients to engage in successful intercourse with

<div style=\"page-break-after: always\"></div>

their  partner.  However,  surgery  can  be  associated  with  serious  complications  (eg,  infection,  wound dehiscence) and can result in prolonged recovery times. Surgery is further commonly associated with penile shortening, reduced penile sensitivity, and painful erection. It is not a cure, and revision owing to recurrence is more complex than initial surgery leading to increased rates of intra- and post-operative complications.

AA4500 is a novel non-surgical, less invasive, treatment for Peyronie's disease. The injection of AA4500 into the pathologic plaque, which is composed predominantly of collagen, followed by a penile plaque modeling approximately 1 to 3 days after injection, allows for the local disruption of the plaque. Plaque disruption  enables  correction  of  the  offending  curvature  deformity  and  may  preclude  the  resultant morbidity and extensive recovery time associated with invasive surgical procedures.

The efficacy and safety of therapy has been demonstrated in two independent placebo-controlled Phase 3 studies, and the benefits further substantiated in an open-label Phase 3 study. These studies have shown a clinically and statistically significant, sustained reduction in penile curvature as well as reduced Peyronie's  disease  bother  with  AA4500  therapy,  thereby  enabling  patients  to  engage  in  successful intercourse  with  their  partner.  Therapy  was  generally  safe  and  well-tolerated,  with  the  majority  of adverse events localized to the penis and groin. With appropriate training in injection procedures and provision  of  relevant  product  information,  the  risks  associated  with  treatment  can  be  successfully mitigated. AA4500 provides a novel, clinically proven treatment for Peyronie's disease, and fulfils an unmet  need  in  the  EU  by  providing  a  nonsurgical  treatment  for  this  physically  and  psychologically debilitating condition. 8. Assessment of the MAH's justification of significant clinical benefit 1 8.1. Demonstration of new therapeutic indication AA4500  is  a  proteinase  that  can  hydrolyze  the  triple-helical  region  of  collagen  under  physiological conditions, AA4500 may therefore have the potential to be effective in lysing collagen deposits such as those in the plaque that cause the curvature deformity and subsequent bother and distress in patients with Peyronie's disease. Medicinal product no longer authorised

AA4500 is proposed as a novel non-surgical treatment for Peyronie's disease and targets curvature deformity through the injection of collagenase clostridium histolyticum into the pathologic penile plaque, which is composed predominantly of collagen, and allows for the local disruption of the plaque that causes the curvature deformity.

Plaque disruption enables correction of the offending curvature deformity and may preclude the resultant morbidity and extensive recovery time associated with invasive surgical procedures. Thus, the availability of  AA4500 for  use  in  Peyronie's  disease  would  offer  the  treating  urologist  an  additional  nonsurgical treatment option for patients suffering from both the physical and psychological impact of Peyronie's disease and not eligible or not willing to undergo surgical intervention.

1 In accordance with guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in order to benefit from an extended (11-year) marketing protection period

http://ec.europa.eu/health/files/eudralex/vol-2/c/guideline\\_14-11-2007\\_en.pdf

<div style=\"page-break-after: always\"></div>

## 8.2. Details of existing therapies

Overall, the MAH's description of currently available options for PD treatment is well founded by literature reports and is endorsed.

There is a lack of a clear understanding of the aetiopathology and, so far, a cure has not been found. Several factors should be considered for the therapeutic management of patients with PD, including the duration of disease, presence or absence of pain with erection, the severity of penile deformity, and the adequacy of erectile function (Hellstrom, 2009). A variety of treatment options have been used.

Conservative  treatment  options are  multiple and diverse and include oral (colchicine, tamoxifen, pentoxyphylline, vitamin E, potassium para-aminobenzoate) and topical (verapamil) agents, intralesional  injections  (corticosteroids,  iloprost,  interferon,  verapamil),  extracorporeal  shock  wave therapy (ESWT), iontophoresis, and others (Ralph et al., 2010). No pharmacological therapies, except for Potaba in DE and UK, have been formally licensed for the treatment of Peyronie's disease in the EU.

The value of many published reports has been questioned as most were not well controlled, often had a small number of subjects in various phases of stability, had short follow-up phases and with limited reports on objective measures of deformity change. Studies focus on reduction of pain that appears to resolve with time untreated, and reduction of plaque size, which has never been found to correlate with curvature improvement. Following a consensus statement of leading experts (Ralph et al. 2010, The Management of Peyronie's disease: Evidence-based 2010 Guidelines) reduction of erect penile deformity (i.e. curve, narrowing, shortening) is the most critical outcome measure. In the most recently published Guideline on Penile Curvature (syn. IPP, Induratio penis plastic) by the European Association of Urology the authors conclude that due to a.m. methodological problems and often contradictory results, it is difficult to provide recommendations in the everyday, real-life setting based on the studies on conservative treatment for PD. It is reminded that conservative treatment of PD is primarily focused on patients in the early stage of the disease, when symptoms are present and the plaque is not densely fibrotic or calcified. At this stage of the disease 3-13% of patients may show spontaneous remission. Spontaneous remission was also observed as one factor complicating interpretation of the results of phase IIb study AUX-CC-801 where subjects with a minimum disease history of 6 months were included. In order to avoid spontaneous remission as one confounding factor, phase III studies AUX-CC-803 and AUX-CC-804 set the focus on patients at a later stage of the disease (PD symptoms for at least 12 months at study entry). Medicinal product no longer authorised

Surgical interventions are indicated when PD has reached the chronic phase and penile morphology, including plaque size and curvature, has been stable for ≥3 months. The goals of surgery are to correct penile deformity and improve erectile and sexual function. Therefore, surgery is typically only appropriate for patients who cannot achieve intercourse owing to the severity of their deformity and/or those with refractory ED that fails to respond to medical treatment. In addition, patients who have extensive plaque calcification are typically best treated with surgery, as nonsurgical approaches have not been shown to be beneficial in this circumstance. Surgery is typically not indicated for patients whose penile deformity does not prevent intercourse, because of the risk of postoperative ED (Ralph et al., 2010).

In the expert statement (Ralph et al. 2010) it is summarised that surgery remains the gold standard for correcting  erect  penile  deformity  in  the  man  with  stable  disease.  However,  potential  postoperative complications include excessive penile shortening, reduced penile sensitivity, palpable nodules, and ED.

<div style=\"page-break-after: always\"></div>

## 8.3. Significant clinical benefit based on improved efficacy

The efficacy of Xiapex was evaluated in two randomized, double-blind, placebo-controlled, multi-centred trials in 832 (ITT) adult males with Peyronie's disease (Studies 803 and 804). At study entry, patients must have had penile curvature deformity of at least 30 degrees in the stable phase of Peyronie's disease. Patients were excluded if they had a ventral curvature deformity, an isolated hourglass deformity or a calcified plaque that could have interfered with the injection technique. At baseline, the mean duration of PD history of included men (mean age 57-58 years) was 3-5 years. Typically for this stable stage of the disease, pain was not an issue for the vast majority of patients, however, mean penile curvature was pronounced at baseline (48-52° degrees). The curvature deformity often leads to significant bother, distress, and sexual dysfunction among PD patients. Patient Bother was quantified by means of the Peyronie's Disease Bother scale (0-16) and was recorded as 7.4-8.2 across treatment groups at baseline (corresponding to the 'moderately bothered' category). The Bother domain score is a composite of the following patient-reported items: concern about erection pain, erection appearance, and the impact of Peyronie's disease on intercourse and on frequency of intercourse. About every second included subject (46.2-53.9% across treatment groups) presented with a history of erectile dysfunction.

- the change from baseline to Week 52 in the Bother domain score of the PDQ

In these trials, patients were given up to 4 treatment cycles of XIAFLEX or placebo (weeks 0, 6, 12, 18), and were followed in a non-treatment follow-up period (weeks 24 -52). In each treatment cycle, two injections of XIAFLEX or two injections of placebo were administered 1 to 3 days apart. A penile modelling procedure was performed on patients at the study site 1 to 3 days after the second injection of the cycle. The treatment cycle was repeated at approximately six-week intervals for up to three additional times, for a maximum of 8 total injection procedures and 4 total modelling procedures. In addition, patients were instructed to perform penile modelling at home for six weeks after each treatment cycle. Before the first dose of study drug was administered, eligible subjects were stratified by the degree of curvature deformity (30 to 60 degrees, and 61 to 90 degrees) and then randomized into two treatment groups to receive either Xiapex or placebo in a 2:1 ratio. The efficacy population (modified intent-to-treat (mITT) population) comprised a total of 612 intent-to-treat subjects who had both a curvature deformity measurement and a PDQ assessment at baseline, and at one or more subsequent time points in Studies 803 and 804, and had engaged in vaginal intercourse within 3 months prior to each PDQ assessment. Co-Primary endpoints As confirmed by prior CHMP Scientific Advice, the co-primary endpoints were defined as: · the percent change from baseline to Week 52 in penile curvature deformity and; Medicinal product no longer authorised

AA4500 0.58 mg was statistically superior to placebo with respect to the co-primary endpoints (ie, curvature deformity and patient-reported Peyronie's disease bother) in both clinical studies:

In  each  study,  men  treated  with  AA4500  had  a  statistically  significant  (p≤0.0059)  greater  percent reduction in curvature deformity compared with men treated with placebo. A relative reduction of penile curvature deformity (48.8°-51.3° at baseline) of -37.6% (placebo -21.3%, study 803), resp. -30.5% (placebo -15.2%, study 804) was achieved. Hence, at the end of the 1-year observation period a residual curvature of 31.0°-35.1° remained.

Improvement in curvature deformity was apparent after the first treatment cycle (Week 6) with continued improvement noted after each of the three subsequent treatment cycles. The improvement in curvature deformity was maintained through the end of each study (Week 52). No efficacy data are available for administration of more than four treatment cycles. Likewise, no data are available on recurrence of penile curvature after more than one year after the first AA4500 injection.

<div style=\"page-break-after: always\"></div>

Reduction in penile curvature translated in a reduction of patients' bother about PD.

The baseline bother score was 7.4 to 8.2 across treatment arms and studies. Translating the score into bother categories, patients were about moderately bothered at baseline. The PDQ Bother score was assessed at three time points (screening, week 24 and week 52). Hence, increasing reduction of the bother score with increasing number of treatment cycles could not be assessed.

Like already observed for the curvature reduction endpoint, the active and the placebo curves display a similar course with no recurrence of bother between week 24 (assessment of the final injection) and week 52 (end of double-blind treatment period).

At the pre-defined time point at the end of the observation period (week 52), AA4500 was borderline statistically  superior  to  placebo  in  terms  of  PDQ  Bother  score  reduction  (AUX-CC-803:  p=0.0451; AUX-CC-804: p=0.0496).

In the AA4500 treatment arm the PDQ Bother score was 4.2 to 5.0. This translates into the average bother category 'a little bit'.

Secondary endpoints When being asked the global assessment / overall change in symptoms at week 52, overall 66% (study AUX-CC-803) resp. 55% (AUX-CC-804) rated themselves as having improved in a small but important way, having moderately improved or even having much improved and were thus defined as responders. These responders had a mean reduction in curvature of at least 20% and a reduction of the PDQ Bother score of at least one point as compared to baseline. The  observed  reductions  in  curvature  and  PDQ  Bother  score  of  those  rating  themselves  as  having improved (at least in a small but important way) points to the clinical relevance of the therapeutic effect achieved with AA4500 after the four treatment cycles. Other secondary endpoints (e.g. PDQ Physical and Psychological Symptom Score or International Index of  Erectile  Dysfunction  Overall  Satisfaction  (IIED)  did  not  demonstrate  significant  superiority  over placebo when both pivotal studies were separately assessed, however, delivered statistical significance in the pooled analysis of study 803 and 804. The pivotal studies 803 and 804 were conducted in Australia and the US. A further open-label study AUX-CC-802 (including 192/348 EU subjects) was conducted to increase the safety database and to obtain  efficacy  and  safety  results  in  European  subjects.  Study  802  did  not  point  to  any  relevant differences between the US/Australian patient population and Europeans in terms of baseline disease conditions and treatment outcome of AA4500. Medicinal product no longer authorised

## Efficacy conclusion

Overall, it is concluded that the efficacy of AA4500 in adult men in a stable stage of Peyronie's disease was adequately demonstrated for a course of up to four treatment cycles (corresponding to 8 injections) and an observation period of up to one year. The Applicant plans to conduct a 5-year study (AUX-CC-810) to provide data on longer-term efficacy of AA4500.

Efficacy of AA4500 has not been formally compared to existing therapies. This is acceptable since only one pharmacological treatment, i.e. Potaba, has been licensed for the treatment of Peyronie's disease in only two EU countries and scientific support for efficacy of other medicinal products used to treat the condition is very weak. Comparison with surgical procedures would have been difficult due to different surgical techniques, the wide range of reported success rates and would not have allowed blinding of the study. In addition, data from well-designed prospective surgery studies are scarce, providing only low

<div style=\"page-break-after: always\"></div>

level of evidence. Comparison with placebo is therefore appropriate and demonstrated a clear treatment benefit of AA4500.

## 8.4. Significant clinical benefit based on improved safety

The safety database contains 1044 subjects who received 7466 injections of AA4500 0.58 mg for the treatment of Peyronie's disease worldwide. Most adverse events following AA4500 injection were locally to the penis or groin and most commonly include penile hematoma, penile pain, penile swelling, injection site pain and injection site hematoma.

The majority of Peyronie's patients experienced at least one adverse reaction (Global Safety database, 92.5%). Most adverse reactions were locally to the penis or groin and the majority of these events were of mild or moderate severity. Most resolved within 14 days of the injection. The adverse reaction profile was similar after each injection, regardless of the number of injections administered.

The  most  frequently  reported  treatment-related  AEs  in  the  clinical  trials  in  subjects  with  Peyronie's disease (Global Safety database) were penile hematoma (50.2%), penile pain (33.5%), penile swelling (28.9%) and injection site pain (24.1%). Corporal fracture and other serious adverse events related to the penis Treatment-related SAEs included corporal rupture (fracture of penis) in 4 subjects (0.4%). In two of these cases corporal fracture occurred during vigorous sexual intercourse and one subject did not wait the requested 2-week hiatus. One additional subject experienced a corporal fracture that was not a serious AE according to the investigator. Nine subjects (0.9%) reported a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile 'popping' sound or sensation. These subjects were  managed  without  surgical  intervention.  A  diagnosis  of  corporal  rupture  cannot  be  excluded. Treatment-related  SAEs  also  included  penile  hematoma  (n=5).  Severe  penile  hematoma  was  also reported in 39 patients (3.7%). The influence of investigator training on adverse events related to the penis seems to be crucial for the safe  application  of  the  drug.  Investigator  training  in  the  clinical  studies  included  intensive  injection technique instructions via manuals and DVDs, workshops and investigator meetings and it has to be ensured that the training for the education of physicians in clinical practice is adequate. Thus, AA4500 must be administered by a physician appropriately trained in the correct administration of AA4500 and experienced in the treatment of male urological diseases. Immunogenicity Medicinal product no longer authorised

During clinical studies in Peyronie's disease subjects were tested at multiple time points for antibodies to the protein components of AA4500 (AUX-I and AUX-II). After 6 weeks of cycle 1, 73.7% of patients had antibodies against AUC-I and 53.9% had antibodies against AUX-II. After the 4th cycle nearly all subjects had antibodies to both AUX-I and AUX-II. Neutralizing antibodies were detected in 43.8% and 31.3%, respectively, of subjects tested. There was no apparent correlation of antibody frequency, antibody titers, or neutralizing status to adverse reactions.

There  were  no  observed  cases  of  severe  systemic  hypersensitivity  or  anaphylaxis  in  the  clinical development  programme  for  AA4500  in  Peyronie's  disease.  However,  an  anaphylactic  reaction  was reported in a post-marketing clinical study in a patient who had previous exposure to AA4500 for the treatment of Dupuytren's contracture. Thus, physicians must be prepared to address any severe local or systemic allergic reaction. Further data has to be collected post-marketing.

## Long-term safety

<div style=\"page-break-after: always\"></div>

A follow-up programme for the new proposed indication is ongoing. Study AUC-CC-810 is a long term, non-treatment 2-5 year follow up of patients who received AA450 in the AUX-CC-802, AUX-CC-803 and AUX-CC-804 studies. The final results of study AUC-CC-810 are expected in 4Q 2018. The study protocol is presented within the RMP. The Applicant is requested to submit the long-term results for the use of AA4500 as appropriate.

## Safety Conclusion

The safety results indicate that the majority of adverse reactions were non-serious, mild or moderate in intensity, confined to the treated area, and resolved within a short period without sequelae. Among subjects who received at least one dose of AA4500 most subjects experienced adverse reactions in the treated  extremity,  with  the  most  frequently  reported  adverse  reactions  reported  being:  penile hematoma, penile pain, penile swelling and injection site pain.

## 8.5. Significant clinical benefit based on major contribution to patient care

Non-surgical approaches are considered first-line therapy for PD, as they are indicated for patients in the early stage of the disease who are experiencing progressive deformity and painful erections. The goal of treatment is to mitigate progression and improve symptoms (Ralph et al., 2010) Surgery is indicated when curvature impedes adequate sexual penetration or there is an associated ED that fails to respond to medical treatment and should be offered only once the disease has stabilized (Ralph et al. 2010). In the same expert statement it is summarised that surgery is the gold standard for correcting  erect  penile  deformity  in  the  man  with  stable  disease.  However,  potential  postoperative complications include excessive penile shortening, reduced penile sensitivity, palpable nodules, and ED. Clinical  relevant  treatment  effects  and  a  benign  side  effect  profile  could  be  shown  for  AA4500  in well-designed randomised controlled trials in patients with stable Peyronie's disease. Considering risks and limitations of surgery, local collagenase injection therapy can be regarded as a desirable treatment alternative  in  patients  with  non-calcified  plaques  providing  a  major  contribution  to  patient  care particularly in patients with preserved erectile function. A significant clinical benefit based on major contribution to patient care can therefore be concluded. 9. Conclusion Medicinal product no longer authorised

According to the Guideline on Penile Curvature of the European Association of Urology, the surgical correction of curvature should be considered in PD patients at a stable disease state (6 months with no pain  and  stable  deformity,  Ralph  et  al.  2010)  and  erectile  dysfunction  not  responding  to  medical treatment. Risks connected to penile surgery like persistent or recurrent curvature, loss of erect length, diminished rigidity, and decreased sexual sensation are described in the literature.

The submitted data package for AA4500 shows clinical relevant treatment effects and a benign side effect profile particularly in patients with preserved erectile function.

Considering risks and limitations of surgery, local collagenase injection therapy can be regarded as a treatment providing a significant clinical benefit based on major contribution to patient care.

<div style=\"page-break-after: always\"></div>

## 10. Recommendation

The CHMP reviewed the data submitted by the Swedish Orphan Biovitrum AB (publ), taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004 and the 'Guidance on elements required to  support the significant clinical  benefit  in  comparison  with  existing  therapies  of  a  new  therapeutic indication in order to benefit from an extended (11-year) marketing protection period', and consider by consensus that the new therapeutic indication brings a significant clinical benefit in comparison with existing therapies.

<!-- image -->